SK128193A3 - Carboxylic acids derivatives, medicaments containing these compounds and method of their production - Google Patents

Carboxylic acids derivatives, medicaments containing these compounds and method of their production Download PDF

Info

Publication number
SK128193A3
SK128193A3 SK1281-93A SK128193A SK128193A3 SK 128193 A3 SK128193 A3 SK 128193A3 SK 128193 A SK128193 A SK 128193A SK 128193 A3 SK128193 A3 SK 128193A3
Authority
SK
Slovakia
Prior art keywords
group
phenyl
alkyl
carbon atoms
atom
Prior art date
Application number
SK1281-93A
Other languages
Slovak (sk)
Inventor
Frank Himmelsbach
Gunter Linz
Volkhard Austel
Helmut Pieper
Thomas Muller
Johannes Weisenberger
Brian Guth
Original Assignee
Thomae Gmbh Dr K
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomae Gmbh Dr K filed Critical Thomae Gmbh Dr K
Publication of SK128193A3 publication Critical patent/SK128193A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/38Halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention relates to carboxylic acid derivatives of the general formula A - B - C - D - E - COORa, (I> in which A to E and Ra are defined as in Claim 1, in particular compounds of the formula (II), <IMAGE> to their tautomers, their stereoisomers, including their mixtures, and to their salts, in particular to their physiologically tolerated salts with inorganic or organic acids or bases, which have valuable pharmacological properties, preferably aggregation-inhibiting effects, to drugs (medicaments, pharmaceuticals) containing these compounds, and to processes for their preparation.

Description

Oblasť technikyTechnical field

Vynález sa týka derivátov karboxylových kyselín, liečiv, ktoré tieto zlúčeniny obsahujú a spôsobov ich výroby.The present invention relates to carboxylic acid derivatives, to medicaments containing them, and to processes for their preparation.

Doterajší stav technikyBACKGROUND OF THE INVENTION

V európskych zverejnených spisoch 0478328 a 0478363 boli opísané fenylalanylderiváty ako antagonisti fibrinogénových receptorov.In European published publications 0478328 and 0478363, phenylalanyl derivatives have been described as antagonists of fibrinogen receptors.

Podstata vynálezuSUMMARY OF THE INVENTION

Teraz bolo nájdené, že nové deriváty karboxylových kyselín všeobecného vzorca IIt has now been found that the novel carboxylic acid derivatives of formula (I)

A - B - C - D - E - COORa (I) vykazujú taktiež cenné farmakologické ’ vlastnosti, najmä účinnosť potlačovania agregácie, pričom sa nové zlúčeniny od zlúčenín opísaných vo vyššie uvedenom zverejnenom spise líšia najmä zvyškom B.A-B-C-D-E-COOR and (I) also exhibit valuable pharmacological properties, in particular aggregation suppression efficiency, wherein the novel compounds differ from the compounds described in the above-mentioned published publication in particular in the remainder of B.

Podstatou predloženého vynálezu sú spolu s novými derivátmi karboxylových kyselín vyššie uvedeného všeobecného vzorca I, ich tautoméry, ich stereoizoméry vrátane ich zmesí a ich solí, najmä fyziologicky prijateľné soli s anorganickými alebo organickými kyselinami alebo bázami, liečivá, obsahujúce tieto zlúčeniny a ich použitie ako aj spôsoby ich výroby.The present invention, together with the novel carboxylic acid derivatives of the above general formula I, their tautomers, their stereoisomers, including mixtures thereof and their salts, in particular the physiologically acceptable salts with inorganic or organic acids or bases, medicaments containing these compounds and their use as well as production methods.

Vo vyššie uvedenom všeobecnom vzorci I znamenáIn the above general formula I means

- 2 R atóm vodíka, alkylovú skupinu s 1 až 5 atómami uhlíka, alkenylovú skupinu s 3 až 5 atómami uhlíka, fenylalkylovú skupinu s 1 až 3 atómami uhlíka v alkylovej časti, cykloalkylovú skupinu s 5 až 7 atómami uhlíka alebo R^-CO-O-(R2CH)-skupinu, kde predstavuje alkylovú skupinu s 1 až 5 atómami uhlíka, cykloalkylovú skupinu s 5 až 7 atómami uhlíka, fenylalkylovú skupinu s 1 až 3 atómami uhlíka v alkylovej časti, alkoxyskupinu s 1 až 5 atómami uhlíka, cykloalkoxyskupinu s 5 až 7 atómami uhlíka alebo fenylovú skupinu a- R 2 is hydrogen, C 1 -C 5 alkyl, C 3 -C 5 alkenyl, C 1 -C 3 phenylalkyl, C 5 -C 7 cycloalkyl or R 1 -CO- O- (R 2 CH) -C 1 -C 5 -alkyl, C 5 -C 7 -cycloalkyl, C 1 -C 3 -phenylalkyl, C 1 -C 5 -alkoxy, (C 5 -C 7) cycloalkoxy or phenyl; and

R2 predstavuje atóm vodíka, alkylovú skupinu s 1 až 4 atómami uhlíka, cykloalkylovú skupinu s 5 až 7 atómami uhlíka alebo fenylovú skupinu,R 2 represents a hydrogen atom, a C 1 -C 4 alkyl group, a C 5 -C 7 cycloalkyl group or a phenyl group,

A znamená cez atóm uhlíka zvyšku A so zvyškom B spojenú aminoalkylovú skupinu s 1 až 5 atómami uhlíka alebo 5-, 6alebo 7-člennú azacykloalkylovú skupinu, pričom spojenie azacykloalkylovej skupiny so zvyškom B je vykonané cez atóm uhlíka azacykloalkylskupiny ako aj atóm vodíka aminoskupiny v uvedených aminoalkylových skupinách a atóm vodíka na atóme dusíka uvedených azacykloalkylových skupín môže byť nahradený zvyškom a ďalej môžu byť atómy uhlíka azacykloalkylovej skupiny substituované jednou až tromi alkylovými skupinami vždy s 1 až 3 atómami uhlíka, alkylamino-, kyano-, R^O- alebo R3O-CO-skupinou, kde predstavuje alkylovú skupinu s 1 až 3 atómami uhlíka, fenylalkylovú skupinu s 1 až 3 atómami uhlíka v alkylovej časti, alkanoylskupinu s 1 až 3 atómami uhlíka v alkylovej časti, trifluóracetylskupinu, alkoxykarbonylovú skupinu s celkom 2 až 6 atómami uhlíka, fenylalkoxykarbonylovú skupinu s 1 až 3 atómami uhlíka v alkoxylovej časti, alkenyloxykarbonylovú skupinu s celkom 4 až 6 atómami uhlíka alebo R^-CO-O-(R2CH)-O-CO-skupinu, kde R^ a R2 majú užA represents a C 1 -C 5 aminoalkyl or a 5-, 6 or 7-membered azacycloalkyl radical via the carbon atom of radical A with the radical B, wherein the coupling of the azacycloalkyl radical with the radical B is effected via the carbon atom of the azacycloalkyl group and the hydrogen atom of the amino group the aminoalkyl groups and the hydrogen atom on the nitrogen atom of said azacycloalkyl groups may be replaced by a residue and furthermore, the carbon atoms of the azacycloalkyl group may be substituted by one to three alkyl groups of 1 to 3 carbon atoms, alkylamino, cyano, R RO- or R R3O- CO-C 1 -C 3 -alkyl, C 1 -C 3 -phenylalkyl, C 1 -C 3 -alkanoyl, trifluoroacetyl, C 2 -C 6 -alkoxycarbonyl, C 1 -C 3 phenylalkoxycarbonyl; an alkoxy moiety, an alkenyloxycarbonyl group having a total of 4 to 6 carbon atoms, or an R 1 -CO-O- (R 2 CH) -O-CO-group, where R 1 and R 2 have already

- 3 skôr definovaný význam a- 3 as defined above, and

Rg predstavuje atóm vodíka, alkylovú alebo fenylalkylovú skupinu vždy s 1 až 3 atómami uhlíka v alkylovej časti, ako aj v takto vytvorenej 6- alebo 7-člennej azacykloalkylovej skupine jedna jednotka >CH- v polohe 4, vztiahnuté na dusíkový atóm kruhu môže byť nahradená atómom N alebo v takto vytvorenej 5- až 7-člennej azacykloalkylskupine -CH2~CH< jednotka môže byť nahradená -CH=C< jednotkou a v takto vytvo renom pipeŕazinyl- alebo homopiperazinylkruhu môže byť metylénová skupina, ktorá susedí s atómom dusíka v polohe 4 byť nahradená karbonylskupinou, chinuklidinylovú alebo pyridylskupinu,Rg represents a hydrogen atom, an alkyl or phenylalkyl group having from 1 to 3 carbon atoms in the alkyl moiety, as well as in the 6- or 7-membered azacycloalkyl group thus formed, one unit> CH- in the 4-position relative to the ring nitrogen atom the N atom or the 5- to 7-membered azacycloalkyl group -CH2-CH <unit thus formed may be replaced by a -CH = C <unit and the thus formed piperazinyl- or homopiperazinyl ring may be a methylene group adjacent to the nitrogen atom in the 4-position. replaced by carbonyl, quinuclidinyl or pyridyl,

B znamená prípadne atómom fluóru, chlóru alebo brómu, trifluórmetylovou skupinou, alkylovou, alkoxylovou, alkylsulfenylovou, alkylsulfinylovou alebo alkylsulfonylovou skupinou vždy s 1 až 3 atómami uhlíka v alkylovej alebo alkoxylovej časti mono- alebo disubstituovanú fenylénovú skupinu, kde substituenty sú rovnaké alebo rozdielne a v ktorých ďalej môžu byť 1 alebo 2 nesubstituované metinové skupiny vždy nahradené N-atómom alebo piperidinylénovú skupinu,B is optionally a fluorine, chlorine or bromine atom, a trifluoromethyl group, an alkyl, alkoxy, alkylsulfenyl, alkylsulfinyl or alkylsulfonyl group each having 1 to 3 carbon atoms in the alkyl or alkoxy moiety of a mono- or disubstituted phenylene group wherein the substituents are the same or different and furthermore, 1 or 2 unsubstituted meth groups may in each case be replaced by an N-atom or a piperidinylene group,

C znamená karbonyl-, -CH2CH2-, -CH=CH-, -CH2-, -CH2O-,C is carbonyl-, -CH 2 CH 2 -, -CH = CH-, -CH 2 -, -CH 2 O-,

-och2-, -conr4-, -conr4-ch2-, -nr4co-, -nr4co-nr4-,-och 2 -, -con 4 -, -con 4 -ch 2 -, -nr 4 co-, -nr 4 co-nr 4 -,

-CH2NR4-, -NR4CH2-, -SO2NR4-, -S02NR4-CH2- alebo-CH 2 NR 4 -, -NR 4 CH 2 -, -SO 2 NR 4 -, -SO 2 NR 4 -CH 2 - or

-NR4SO2-skupinu, kde-NR 4 SO 2 -group where

R4 predstavuje atóm vodíka, alkylovú alebo fenylalkylovú skupinu vždy s 1 až 3 atómami uhlíka v alkylovej časti alebo tiež, ak C predstavuje cez karbonylovú skupinu na zvyšok B naviazanú skupinu -CONR4~, R4 predstavuje metylénovú alebo 1, 2-etylénskupinu, ktoré sú vždy naviazané na atóm uhlíka v polohe orto atómu uhlíka zvyšku B k polohe pripojenia zvyšku -conr44R 4 represents a hydrogen atom, an alkyl or phenylalkyl group having from 1 to 3 carbon atoms in the alkyl part, or also if C represents a -CONR 4 - group attached via a carbonyl group to the radical B, R 4 represents a methylene or 1,2-ethylene group, which are always attached to a carbon atom in the ortho position of the carbon atom of residue B to the position of attachment of the residue -conr 4 4

D znamená prípadne atómom fluóru, chlóru alebo brómu, trifluórmetylovou skupinou, alkylovou, alkoxylovou, alkylsulfenylovou, alkylsulfinylovou alebo alkylsulfonylskupinou vždy s 1 až 3 atómami uhlíka v alkylovej a alkoxylovej časti mono alebo disubstituovanú fenylénovú skupinu, kde substituenty sú rovnaké alebo rozdielne a kde ďalej 1 alebo 2 nesubstituované metinové skupiny môžu byť nahradené vždy N-atómom, cykloalkylénovú skupinu s 5 až 7 atómami uhlíka, v ktorej jedna alebo dve >CH- jednotky môžu byť nahradené N-atómom, pričom naviac v takto vytvorenom aza- alebo diazacyklohexylénovom kruhu môže byť metylénová skupina, susediaca s atómom dusíka nahradená karbonylovou skupinou a väzba na zvyšky C a E tiež môže byť vykonaná cez atóm dusíka azaalebo diazacyklohexylénového kruhu aD is optionally fluorine, chlorine or bromine, trifluoromethyl, alkyl, alkoxy, alkylsulfenyl, alkylsulfinyl or alkylsulfonyl having from 1 to 3 carbon atoms in the alkyl and alkoxy moiety of a mono or disubstituted phenylene group, wherein the substituents are the same or different and where or 2 unsubstituted meth groups may in each case be replaced by an N-atom, a cycloalkylene group of 5 to 7 carbon atoms, in which one or two CH- units may be replaced by an N-atom, and in addition the aza- or diazacyclohexylene ring thus formed the methylene group adjacent to the nitrogen atom replaced by a carbonyl group and the bond to the C and E radicals can also be carried out via the nitrogen atom and the diazacyclohexylene ring; and

E znamená väzbu, alkylénoxyskupinu s 1 až 3 atómami uhlíka v alkylovej časti, pričom atóm kyslíka je naviazaný na zvyšok D, priamu alkylénovú skupinu s 1 až 5 atómami uhlíka, ktoré môžu byť substituované 1 alebo 2 alkylovými skupinami, hydroxylovou, alkoxylovou, R^NH-, R^N(alkyl)- alebo R^N(fenylalkyl)-skupinou alebo alkenylénovovú skupinu s 2 až 5 atómami uhlíka, ktorá môže byť substituovaná jednou alebo dvoma alkylovými skupinami, pričom alkylová časť fenylalkylovej skupiny môže obsahovať 1 až 3 atómy uhlíka a ostatné alkylové, alkylénové a alkoxylové časti vždy 1 až 8 atómov uhlíka, kdeE represents a bond, an alkyleneoxy group having 1 to 3 carbon atoms in the alkyl moiety, wherein the oxygen atom is attached to the radical D, a direct alkylene group having 1 to 5 carbon atoms which may be substituted by 1 or 2 alkyl groups, hydroxyl, alkoxy, R R; NH-, R ^N (alkyl) - or R ^N (phenylalkyl) - or an alkenylene group having 2 to 5 carbon atoms, which may be substituted by one or two alkyl groups, the alkyl portion of the phenylalkyl group may contain 1 to 3 atoms carbon and other alkyl, alkylene and alkoxy moieties each having from 1 to 8 carbon atoms, wherein

Rg znamená atóm vodíka, alkylovú skupinu s 1 až 8 atómami uhlíka, alkoxykarbonylovú skupinu s celkom 2 až 5 atómami uhlíka, fenylalkoxykarbonylovú skupinu alebo alkylovú skupinu s 1 až 8 atómami uhlíka, cykloalkyl-, fenylalkyl alebo fenylovou skupinou substituovanú karbonyl- alebo sulfonylskupinu, v ktorých alkylová a alkoxylová časť v uvedených fenylalkylových a fenylalkoxyskupinách môže obsahovať vždy 1 až 3 atómy uhlíka a cykloalkylová časť 3 až 7 atómov uhlíka, pričom v definícii zvyšku R$ skôr uvedené fenylové jadrá niôžu byť naviac mono- alebo disubstituované atómom fluóru, chlóru alebo brómu, trifluórmetylskupinou, alkylovou, alkoxylovou, alkylsulf enylovou , alkylsulfinylovou alebo alkylsulfonylovou skupinou vždy s 1 až 3 atómami uhlíka v alkylovej a alkoxylovej časti a substituenty môžu byť rovnaké alebo rozdielne, pričom, keďR 8 is hydrogen, C 1 -C 8 alkyl, C 2 -C 5 alkoxycarbonyl, phenylalkoxycarbonyl or C 1 -C 8 alkyl, cycloalkyl, phenylalkyl or phenyl-substituted carbonyl or sulfonyl; wherein the alkyl and alkoxy moieties in said phenylalkyl and phenylalkoxy groups may each contain 1 to 3 carbon atoms and a cycloalkyl moiety of 3 to 7 carbon atoms, wherein in the definition of the radical R 8 the phenyl rings mentioned above may additionally be mono- or disubstituted with fluorine, chlorine or bromine , trifluoromethyl, alkyl, alkoxy, alkylsulphenyl, alkylsulphinyl or alkylsulphonyl each having 1 to 3 carbon atoms in the alkyl and alkoxy moiety and the substituents may be the same or different, provided that when

i) A-B-skupina znamená v polohe 4 Rfc-NH-CHj-skupinou substi* tuovanú fenylovú skupinu, v ktorej R^ predstavuje benzyloxykarbonylovú skupinu, RaOOC-E-D-C-skupina nemôže predstavovať 3-karboxy-fenylaminokarbonylovú skupinu (viď. EP-A-0372486 a J. Med. Chem. 35, 4393 až 4407 (1992)), alebo, keď ii) A-B-skupina znamená v polohe 4 R^-Nlí-CI^-skupinou substituovanú fenylovú skupinu, v ktorej R^ predstavuje atóm vodíka alebo acetylovú skupinu, Ra-OOC-E-D-Cŕ-skupina nemôže predstavovať v polohe 4 karbometylovou, metoxykarbonylmetylovou, 2-karboxyetylovou, 2-metoxykarbonyletylovou aleboi) AB-group represents at the 4-position an Rf-NH-CH 3 -substituted phenyl group in which R 1 represents a benzyloxycarbonyl group, R and OOC-EDC group cannot represent a 3-carboxy-phenylaminocarbonyl group (see EP- A-0372486 and J. Med. Chem., 35, 4393-4407 (1992)), or when (ii) the AB-group represents in the 4-position an R 1 -N 1 -C 1 -group substituted phenyl group wherein R 1 is a hydrogen atom or an acetyl group, the R and -OOC-ED-C 1 - group cannot be in the 4-position by carbomethyl, methoxycarbonylmethyl, 2-carboxyethyl, 2-methoxycarbonylethyl or

2-etoxykarbonyletylovou skupinou substituovanú fenylkarbonylovú skupinu (viď. EP-A-0044541, JP-A-5813553, JP-A5939866, JP-A-5846051 a Chem. Pharm. Bull. 33, 5059 až 5061 (1985)), alebo, keď iii) A-B-skupina znamená v polohe 4 NH2-CH2-CH2-skupinou substituovanú fenylovú skupinu, RaOOC-E-D-C-skupina nemôže znamenať 4-etoxykarbonylfenylkarbonylovú skupinu (viď. DE-A-3718638) alebo, keď iv) A-B-skupina znamená 4-aminofenylovú, 3-aminometylfenylovú, 4-aminometyl-3-metoxyfenylovú alebo 3-aminometyl-4-meto- 6 xyfenylskupinu, RaOOC-E-D-C-skupina nemôže znamenať 4-etoxykarbonylmetoxy-2,3-dichlórfenylkarbonylskupinu (viď J. Med. Chem. 27, 1579 až 1587 (1984) a Diuretics: Chem. Pharmacol. , Clin. Appl., Proc. Int. Conf. Diuretics, 1., 21 až 29 (1984) alebo, keďA phenylcarbonyl substituted 2-ethoxycarbonylethyl group (see EP-A-0044541, JP-A-5813553, JP-A5939866, JP-A-5846051 and Chem. Pharm. Bull. 33, 5059-5061 (1985)), or, when iii) the AB group represents a 4-substituted phenyl group at the 4-position of the NH 2 -CH 2 -CH 2 -group, the R and OOC-EDC group cannot be a 4-ethoxycarbonylphenylcarbonyl group (see DE-A-3718638) or means 4-aminophenyl, 3-aminomethylphenyl, 4-aminomethyl-3-methoxyphenyl or 3-aminomethyl-4-methoxy-6-xyphenyl, R and OOC-EDC cannot be 4-ethoxycarbonylmethoxy-2,3-dichlorophenylcarbonyl (see J) Chem., 27, 1579-1587 (1984) and Diuretics: Chem Pharmacol., Clin. Appl., Proc. Int. Conf. Diuretics, 1, 21-29 (1984), or when

v) A-B-skupina predstavuje v polohe 4 NH2-CH2- alebo (CH^)^CO-CO-NH-CH^-skupinou substituovanú fenylovú skupinu, RaOOC-E-D-C-skupina nemôže predstavovať 4-karboxy-fenylmetoxyskupinu (viď. Int. J. Pept. Protein Res. 18, 451 až 458 (1981)), alebo, keď vi) A-B-skupina predstavuje v polohe 4 NH2-CH2-skupinou substituovanú fenylovú skupinu, RaOOC-E-D-C-skupina nemôže predstavovať 4-karboxy-fenylaminosulfonylskupinu (viď Chem. Pharm.- Bull (Tokio) 7, 734 až 739 (1959) a J. Chem. Phys. 32, 691 až 697 (1960)) alebo, keď vii) A-B-skupina predstavuje 4-(2-pyridyl)-fenylovú alebov) the AB-group is at the 4-position of NH 2 -CH 2 - or (CH 2) 4 CO-CO-NH-CH 3 -substituted phenyl, the R and OOC-EDC group cannot be 4-carboxyphenylmethoxy (cf. Int. J. Pept. Protein Res., 18, 451-458 (1981)), or when vi) the AB group represents a 4-substituted phenyl group at the 4-position of the NH 2 -CH 2 group, the R and OOC-EDC group cannot be 4 -carboxy-phenylaminosulfonyl (see Chem. Pharm.-Bull (Tokyo) 7, 734-739 (1959) and J. Chem. Phys. 32, 691-697 (1960)), or when vii) the AB-group is 4- (2-pyridyl) phenyl or

4-(3-pyridyl)fenylovú skupinu, RaOOC-E-D-C-skupina nemôže predstavovať 4-karboxyfenylkarbonylamino-skupinu, 4-benzyloxykarbonylfenylkarbonylamino-skupinu alebo 2-(4-karboxy-fenyl)etylskupinu (viď. J. Med. Chem. 11, 295 (1968) a US-A-2837522) alebo, keď viii) A-B-skupina predstavuje 3-(4-pyridyl)fenylovú skupinu, RaOOC-E-D-C-skupina nemôže predstavovať 2-(karboxymetyl)fenylkarbonylaminoskupinu (viď Farmaco 44, 721 až 729 (1989)).4- (3-pyridyl) phenyl, R and OOC-EDC cannot be 4-carboxyphenylcarbonylamino, 4-benzyloxycarbonylphenylcarbonylamino or 2- (4-carboxyphenyl) ethyl (see J. Med. Chem. Chem. 11, 295 (1968) and US-A-2837522) or, when viii) the AB group represents a 3- (4-pyridyl) phenyl group, the R and OOC-EDC group cannot represent a 2- (carboxymethyl) phenylcarbonylamino group (see Farmaco 44, 721-729 (1989)).

Výhodné zlúčeniny vyššie uvedeného všeobecného vzorca I sú však tie, v ktorýchHowever, preferred compounds of formula (I) above are those in which:

R znamená atóm vodíka, alkylovú skupinu s 1 až 5 atómami uhlíka, fenylalkylovú skupinu s 1 až 3 atómami uhlíka v alkylovej časti alebo cykloalkylovú skupinu s 5 až 7 atómami uhlíka,R represents a hydrogen atom, an alkyl group having 1 to 5 carbon atoms, a phenylalkyl group having 1 to 3 carbon atoms in the alkyl moiety or a cycloalkyl group having 5 to 7 carbon atoms,

A znamená cez atóm uhlíka zvyšku A so zvyškom B spojenú aminoalkylovú skupinu s 2 až 5 atómami uhlíka alebo piperidinylovú skupinu, kde spojenie piperidinylovej skupiny so zvyškom B je vykonané cez atóm uhlíka piperidinylovej skupiny a atóm vodíka aminoskupiny vo vyššie uvedených aminoalkylových skupinách a atóm vodíka na atóme dusíka uvedených piperidinylových skupinách môže byť nahradený zvyškom R^ a ďalej môžu byť atómy uhlíka piperidinylovej skupiny substituované metylovou, kyanovou, karboxylovou, metoxykarbonylovou alebo aminokarbonylovou skupinou, kde predstavuje alkylovú skupinu s 1 až 3 atómami uhlíka, benzylovú skupinu, alkoxykarbonylovú skupinu s celkom 2 až 6 atómami uhlíka, benzyloxykarbonylovú skupinu alebo CH^-CO-O-(CH2)-0-C0-skupinu, ako aj v jednej takto vytvorenej piperidinylovej skupine >CH- jednotka v polohe 4 môže byť nahradená atómom dusíka alebo v takto vytvorenej piperidinylovej skupine -CH2-CH< jednotka môže byť nahradená -CH=CH jednotkou, chinuklidinylovú alebo pyridylskupinu,A represents a C5-C5 aminoalkyl or piperidinyl group linked via the carbon atom of the A residue of the residue B, wherein the coupling of the piperidinyl group to the B group is carried out via the carbon atom of the piperidinyl group and the hydrogen atom of the amino group in the above aminoalkyl groups; the nitrogen atom of said piperidinyl groups may be replaced by the radical R @ 1 and furthermore, the carbon atoms of the piperidinyl group may be substituted by a methyl, cyano, carboxyl, methoxycarbonyl or aminocarbonyl group wherein C1-3 alkyl, benzyl, alkoxycarbonyl having a total of 2 up to 6 carbon atoms, benzyloxycarbonyl or CH 2 -CO-O- (CH 2 ) -O-CO-group, as well as in the piperidinyl group> CH- thus formed in the 4-position may be replaced by a nitrogen atom or in the thus formed piperidinyl -CH 2 -CH? and may be replaced by a -CH = CH unit, a quinuclidinyl or a pyridyl group,

B znamená prípadne atómom fluóru, chlóru alebo brómu, alkylovou, alkoxylovou, alkylsulfenylovou, alkylsulfinylovou alebo alkylsulfonylovou skupinou vždy s 1 až 2 atómami uhlíka v alkylovej a alkoxylovej časti substituovanú fenylénovú skupinu, pyridinylénovú alebo piperidinylénovú skupinu,B is optionally a fluorine, chlorine or bromine atom, an alkyl, alkoxy, alkylsulfenyl, alkylsulfinyl or alkylsulfonyl group having from 1 to 2 carbon atoms in the alkyl and alkoxy moiety substituted by a phenylene, pyridinylene or piperidinylene group,

C znamená -CO-, -CH2CH2-, -CH=CH-, -CH2-, -CH2O-, -OCH2-,C is -CO-, -CH 2 CH 2 -, -CH = CH-, -CH 2 -, -CH 2 O-, -OCH 2 -,

- 8 -conr4-, -nr4co-, -nr4co-nr4-, -ch2nr4-, -nr4ch2-, -so2nr4alebo -NR4S02-skupinu, kde- 8 -conr 4 -, -nr 4 co-, -nr 4 co-nr 4 -, -ch 2 nr 4 -, -nr 4 ch 2 -, -so 2 nr 4 or -NR 4 S0 2 -group, where

R4 predstavuje atóm vodíka, alkylovú alebo fenylalkylovú skupinu vždy s 1 až 2 atómami uhlíka v alkylovej časti alebo tiež, ak C predstavuje cez karbonylovú skupinu na zvyšok B naviazanú skupinu -CONR4-, R4 predstavuje metylénovú alebo 1, 2-etylénskupinu, ktoré sú vždy naviazané na atóm uhlíka zvyšku B v polohe orto k miestu pripojenia zvyšku -CONR4D znamená prípadne atómom chlóru alebo brómu, alkylovou alebo alkoxylovou skupinou s 1 alebo 2 atómami uhlíka substituovanú fenylénovú skupinu alebo cyklohexylénovú skupinu, pričom v cyklohexylénovej skupine jedna alebo dve >CH- jednotky môžu byť nahradené N-atómom, pričom naviac v takto vytvorenom piperidinylénovom alebo piperazinylénovom kruhu môže byť metylénová skupina, susediaca s atómom dusíka nahradená karbonylovou skupinou a väzba na zvyšky C a E tiež môže byť vykonaná cez atóm dusíka piperidinylénového alebo piperazinylénového kruhu aR 4 represents a hydrogen atom, an alkyl or phenylalkyl radical having from 1 to 2 carbon atoms in the alkyl moiety or also when C represents a -CONR 4 - bonded via the carbonyl group to the radical B, R 4 represents a methylene or 1,2-ethylene group, which are each attached to a carbon atom of B in the ortho position to the point of attachment of the moiety CONR 4 where D is chlorine, bromine, alkyl or alkoxy having 1 or 2 carbon atoms substituted phenylene or cyclohexylene, in which one or cyclohexylene two> CH- units may be replaced by an N-atom, and in addition to the piperidinylene or piperazinylene ring thus formed, the methylene group adjacent to the nitrogen atom may be replaced by a carbonyl group and the bond to residues C and E may also be via the piperidinylene or piperazinylene circle and

E znamená väzbu, metylénoxyskupinu, kde je atóm kyslíka naviazaný na zvyšok D, 1,2-etenylovú skupinu alebo priamu alkylénovú skupinu s 1 až 5 atómami uhlíka, ktorá môže byť substituovaná alkylovou skupinou s 1 až 7 atómami uhlíka alebo R^NH-skupinou, kde znamená atóm vodíka, alkylovú skupinu s 1 až 7 atómami uhlíka alebo benzylovou skupinou substituovanú karbonylovú skupinu alebo alkylovou skupinou s 1 až 5 atómami uhlíka alebo benzylovou skupinou substituovanú sulfonylovú skupinu, pričom, keď iii) A-B-skupina znamená v polohe 4 NH2-CH2~CH2-skupinou substituovanú fenylovú skupinu, RaOOC-E-D-C-skupina nemôže znamenať 4-etoxykarbonylfenylkarbonylovú skupinu, alebo, keď vii) A-B-skupina predstavuje 4-(2-pyridyl)-fenylovú aleboE represents a bond, a methyleneoxy group wherein the oxygen atom is bonded to the radical D, a 1,2-ethenyl group or a straight alkylene group having 1 to 5 carbon atoms which may be substituted by an alkyl group having 1 to 7 carbon atoms or an R ^NH group wherein is hydrogen, alkyl having 1 to 7 carbon atoms or a benzyl group, a substituted carbonyl group, or an alkyl having 1 to 5 carbon atoms or a benzyl group, a substituted sulfonyl group, wherein, if iii) the AB-group is in the 4-NH 2 --CH2 CH2 group joining substituted phenyl, R a OOC-EDC-group can not represent 4-etoxykarbonylfenylkarbonylovú group, or, when vii) the AB-group is 4- (2-pyridyl) -phenyl, or

4-(3-pyridyl)-fenylovú skupinu, RaOOC-E-D-C-skupina nemôže predstavovať 4-karboxyfenylkarbonylamino-skupinu, 4-benzyloxykarbonylfenylkarbonylamino-skupinu alebo 2-(4-karboxy-fenyl)etylskupinu alebo, keď viii) A-B-skupina predstavuje 3-(4-pyridyl)fenylovú skupinu, RaOOC-E-D-C-skupina nemôže predstavovať 2-(karboxymetyl)fenylkarbonylaminoskupinu, ich tautoméry, ich stereoizoméry vrátane ich zmesí a ich soli.4- (3-pyridyl) -phenyl, R and OOC-EDC cannot be 4-carboxyphenylcarbonylamino, 4-benzyloxycarbonylphenylcarbonylamino or 2- (4-carboxyphenyl) ethyl or when viii) AB-group R 3 and OOC-EDC cannot represent 2- (carboxymethyl) phenylcarbonylamino, their tautomers, their stereoisomers, including mixtures thereof, and their salts.

Zvlášť výhodné sú tie zlúčeniny vyššie uvedeného všeobecného vzorca I, kdeParticularly preferred are those compounds of formula (I) above wherein

Ra znamená atóm vodíka, alkylovú skupinu s 1 až 4 atómami uhlíka, 2-fenyletylovú skupinu alebo cyklohexylovú skupinu, And R is H, alkyl of 1 to 4 carbon atoms, 2-phenylethyl or cyclohexyl,

A znamená cez atóm uhlíka zvyšku A so zvyškom B spojenú aminoalkylovú skupinu s 3 až 5 atómami uhlíka alebo piperidinylovú skupinu, kde spojenie piperidinylovej skupiny so zvyškom B je vykonané cez atóm uhlíka piperidinylovej skupiny a atóm vodíka aminoskupiny vo vyššie uvedených aminoalkylových skupinách a atóm vodíka na atóme dusíka uvedených piperidinylových skupinách môže byť nahradený zvyškom R^ a ďalej môžu byť atómy uhlíka piperidinylovej skupiny substituované metylovou, kyanovou, karboxylovou, metoxykarbonylovou alebo aminokarbonylovou skupinou, kde predstavuje alkylovú skupinu s 1 až 3 atómami uhlíka, benzylovú skupinu, alkoxykarbonylovú skupinu s celkom 2 až 5 atómami uhlíka alebo CH^-CO-O-(CH2)-O-CO-skupinu, a v takto vytvorenej piperidinylovej skupine >CH- jednotka v polohe 4 môže byť nahradená atómom dusíka alebo v takto vytvorenej piperidinylovej skupine -CH2-CH< jednotka môže byť nahradená -CH=C< jednotkou, chinuklidinylovú alebo 4-pyridylovú skupinu,A is a C 3 -C 5 aminoalkyl group or a piperidinyl group linked via the carbon atom of the residue A of the residue B, wherein the coupling of the piperidinyl group to the B group is carried out via the carbon atom of the piperidinyl group and the hydrogen atom of the amino group in the above aminoalkyl groups; the nitrogen atom of said piperidinyl groups may be replaced by the radical R @ 1 and furthermore, the carbon atoms of the piperidinyl group may be substituted by a methyl, cyano, carboxyl, methoxycarbonyl or aminocarbonyl group wherein C1-3 alkyl, benzyl, alkoxycarbonyl having a total of 2 up to 5 carbon atoms or a CH 2 -CO-O- (CH 2 ) -O-CO-group, and in the piperidinyl group> CH- thus formed, the unit at the 4-position may be replaced by a nitrogen atom or in the piperidinyl -CH 2 - thus formed CH <unit may be replaced by -CH = C <unit, c a hinuclidinyl or 4-pyridyl group,

B znamená prípadne metylovou alebo metoxylovou substituovanú fenylénovú skupinu, 2,5-pyridinylénovú alebo 1,4-piperidinylénovú skupinu,B represents an optionally methyl or methoxy substituted phenylene, 2,5-pyridinylene or 1,4-piperidinylene group,

C znamená -CO-, -CH2CH2-, -CH=CH-, -CH2-, -CH20-, -OCH2-, -CONR4-, -NR4CO-, -NR4CO-NR4- alebo -CH2NR4~skupinu alebo -SO2NR4-, kde SO2 skupina je spojená so zvyškom B a kdeC is -CO-, -CH 2 CH 2 -, -CH = CH-, -CH 2 -, -CH 2 O-, -OCH 2 -, -CONR 4 -, -NR 4 CO-, -NR 4 CO-NR 4 - or - A CH 2 NR 4 - group or -SO 2 NR 4 -, wherein the SO 2 group is linked to the residue B and wherein

R4- predstavuje atóm vodíka, metylovú aleboR 4 - represents a hydrogen atom, a methyl atom or a methyl group;

2-fenyletylovú skupinu alebo tiež, ak C predstavuje -CONR4-skupinu naviazanú na zvyšok B cez karbonylovú skupinu, predstavuje R4 metylénovú alebo 1, 2-etylénskupinu, ktoré sú vždy naviazané na atóm uhlíka zvyšku B v polohe orto k miestu pripojenia zvyšku -CONR4-,2-phenylethyl or, if C is -CONR4-linked to residue B via a carbonyl group, R4 is methylene or 1,2-ethylene, which are in each case attached to the carbon atom of residue B in the ortho position to the point of attachment of -CONR4 -.

D predstavuje fenylénovú skupinu alebo skupinu, pričom v cyklohexylénovej skupine >CH- jednotky môžu byť nahradené N-atómom, zvyšky C a E môže tiež byť vykonaná cez atóm dusíka piperidinylénového alebo piperazinylénového kruhu a cyklohexylénovú jedna alebo dve pričom väzba naD represents a phenylene group or a group wherein in the cyclohexylene group> CH- units can be replaced by an N-atom, the C and E radicals can also be carried out via the nitrogen atom of the piperidinylene or piperazinylene ring and the cyclohexylene one or two;

E znamená väzbu, metylénoxyskupinu, kde je atóm kyslíka naviazaný na zvyšok D, priamu alkylénovú skupinu s 1 až 5 atómami uhlíka, ktorá môže byť substituovaná R^NH-skupinou, kde znamená .atóm vodíka, alkylovú skupinu s 1 až 5 atómami uhlíka, substituovanú karbonylovú skupinu alebo alkylovou skupinou s 1 až 4 atómami uhlíka alebo benzylovou skupinou substituovanú sulfonylovú skupinu, ich tautoméry, ich stereoizoméry vrátane ich zmesí a ich soli.E represents a bond, a methyleneoxy group where the oxygen atom is bonded to the radical D, a straight chain alkylene group having 1 to 5 carbon atoms, which may be substituted by a R ^NH group wherein hydrogen atom is an alkyl group having 1 to 5 carbon atoms, substituted carbonyl or C 1 -C 4 alkyl or benzyl substituted sulfonyl, tautomers, stereoisomers thereof, including mixtures thereof, and salts thereof.

Najvýhodnejšie sú tie zlúčeniny všeobecného vzorca I, kdeMost preferred are those compounds of formula I wherein

Ra znamená atóm vodíka, alkylovú skupinu s 1 až 4 atómami uhlíka alebo cyklohexylovú skupinu,R a represents a hydrogen atom, a C 1 -C 4 alkyl group or a cyclohexyl group,

A znamená cez atóm uhlíka zvyšku A so zvyškom B spojenú piperidinylovú skupinu alebo 3,4-dehydropiperidinylovú skupinu, kde vždy atóm vodíka na atóme dusíka môže byť nahradený zvyškom R^ aA represents a piperidinyl group or a 3,4-dehydropiperidinyl group linked via the carbon atom of the radical A to the radical B, in which the hydrogen atom on the nitrogen atom can in each case be replaced by the radical R @ a;

R^ predstavuje alkoxykarbonylovú skupinu s celkom 2 až 5 atómami uhlíka, prípadne v polohe 1 zvyškom R^ substituovanú 4-piperazinylo vú skupinu, kde R^ má skôr definovaný význam alebo chinuklidinylovú skupinu,R 1 represents an alkoxycarbonyl group having a total of 2 to 5 carbon atoms, optionally in the 1-position of R 1 substituted by a 4-piperazinyl group, wherein R 1 has the previously defined meaning or a quinuclidinyl group,

B predstavuje fenylénovú skupinu,B represents a phenylene group,

C predstavuje -CONR^-skupinu, kdeC is -CONR 4 -, wherein

R4 predstavuje atóm vodíka, metylovú alebo tiež, ak C predstavuje cez karbonylovú skupinu na zvyšok B naviazanú CONR^-skupinu, predstavuje R^ metylénovú alebo 1,2-etylénskupinu, ktoré sú vždy naviazané na atóm uhlíka zvyšku B v polohe orto k miestu pripojenia zvyšku -CONR^-,R4 represents a hydrogen atom, a methyl atom or also, if C represents a CONR4-linked radical through the carbonyl group to the B radical, R6 represents a methylene or 1,2-ethylene radical, which are always attached to the carbon atom of the B radical ortho to the point of attachment residue -CONR ^ -,

D predstavuje 1,4-fenylénovú skupinu alebo 1,4-cyklohexylénovú skupinu aD is 1,4-phenylene or 1,4-cyclohexylene; and

E predstavuje väzbu, 1,2-etylénovú skupinu, ktorá môže byť substituovaná R^NH-skupinou, kdeE represents a bond, a 1,2-ethylene group which may be substituted with an R 1 NH-group, wherein

R$ znamená alkylovú skupinu s 1 až 5 atómami uhlíka, substituovanú karbonylovú skupinu alebo alkylovou skupinou s 1 až 4 atómami uhlíka substituovanú sulfonylovú skupinu, ich tautoméry·, ich stereoizoméry vrátane ich zmesí a ich soli, najmä však nasledujúce zlúčeninyR 8 represents a C 1 -C 5 alkyl group, a substituted carbonyl group or a C 1 -C 4 alkyl group substituted a sulfonyl group, their tautomers, their stereoisomers, including mixtures thereof, and salts thereof, in particular the following compounds

4-[4-[[trans-4-[2-(metoxykarbonyl)etyl]cyklohexyl]aminokarbonyl]fenyl]piperidín,4- [4 - [[trans-4- [2- (methoxycarbonyl) ethyl] cyclohexyl] aminocarbonyl] phenyl] piperidine,

4- [4-[[4-[2-(n-butánsulfonylamino)-2-(metoxykarbonyl)etyl]fenyl]aminokarbonyl]fenyl]piperidín,4- [4 - [[4- [2- (n-butanesulfonylamino) -2- (methoxycarbonyl) ethyl] phenyl] aminocarbonyl] phenyl] piperidine,

4-[4-[[trans-4-(2-karboxy-etyl)cyklohexyl]aminokarbonyl]fenyl]piperidín,4- [4 - [[trans-4- (2-carboxy-ethyl) -cyclohexyl] aminocarbonyl] phenyl] piperidine,

4- [4- [ [4-[2-(n-butánsulfonylamino)-2-karboxyetyl]fenyl]aminokarbonyl]fenyl]piperidín,4- [4 - [[4- [2- (n-butanesulfonylamino) -2-carboxyethyl] phenyl] aminocarbonyl] phenyl] piperidine,

4-[3-[[4-[2-(n-butánsulfonylamino)-2-karboxyetyl]fenyl]aminokarbonyl]fenyl]piperidín a4- [3 - [[4- [2- (n-butanesulfonylamino) -2-carboxyethyl] phenyl] aminocarbonyl] phenyl] piperidine and

4-[3-[[4-[2-(n-butánsulfonylamino)-2-(metoxykarbonyl)etyl]fenyl]aminokarbonyl]fenyl]piperidín, ich tautoméry, ich stereoizoméry vrátane ich zmesí a ich soli.4- [3 - [[4- [2- (n-butanesulfonylamino) -2- (methoxycarbonyl) ethyl] phenyl] aminocarbonyl] phenyl] piperidine, their tautomers, their stereoisomers, including mixtures thereof, and their salts.

Podlá vynálezu sa získajú nové zlúčeniny všeobecnéhoAccording to the invention, new compounds of general formula are obtained

- 13 vzorca I napríklad nasledujúcim spôsobom:- 13 of formula I, for example, as follows:

á) na výrobu zlúčenín všeobecného vzorca I, kde Ra predstavuje atóm vodíka:(a) for the preparation of compounds of the formula I in which R a represents a hydrogen atom:

Hydrolýzou, pyrolýzou alebo hydrogenolýzou zlúčeniny všeobecného vzorca IIHydrolysis, pyrolysis or hydrogenolysis of a compound of formula II

A-B-C-D-E- COORa’ (II) kdeABCDE-COOR and (II) wherein

A až E majú vyššie definovaný význam a R&’ s výnimkou atómu vodíka má významy uvedené už pre R&.A to E are as defined above and R &apos; except for the hydrogen atom has the meanings already given for R & apos ; .

Hydrogenolýza sa účelne vykonáva buď za prítomnosti kyseliny ako je kyselina chlorovodíková, kyselina sírová, kyselina fosforečná, kyselina octová, kyselina octová/kyselina chlorovodíková, kyselina trichlóroctová alebo kyselina trifluóroctová alebo za prítomnosti bázy ako je hydroxid lítny, hydroxid sodný alebo hydroxid draselný vo vhodnom rozpúšťadle ako je voda, metanol, voda/metanol, etanol, voda/etanol, voda/izopropanol, voda/terahydrofurán alebo voda/dioxán pri teplotách medzi -10 °C a 120 °C, napríklad pri teplotách medzi teplotou miestnosti a teplotou varu reakčnej zmesi. Pri spracovaní s organickou kyselinou ako je kyselina trichlóroctová alebo kyselina trifluóroctová, môžu byť prípadne prítomné alkoholické hydroxyskupiny súčasne prevedené na zodpovedajúcu acyloxyskupinu ako je trifluóracetoxyskupina.The hydrogenolysis is conveniently carried out either in the presence of an acid such as hydrochloric acid, sulfuric acid, phosphoric acid, acetic acid, acetic acid / hydrochloric acid, trichloroacetic acid or trifluoroacetic acid or in the presence of a base such as lithium hydroxide, sodium hydroxide or potassium hydroxide in a suitable solvent such as water, methanol, water / methanol, ethanol, water / ethanol, water / isopropanol, water / terahydrofuran or water / dioxane at temperatures between -10 ° C and 120 ° C, for example at temperatures between room temperature and the boiling point of the reaction mixture . When treated with an organic acid such as trichloroacetic acid or trifluoroacetic acid, the optionally present alcoholic hydroxy groups may be simultaneously converted to the corresponding acyloxy group, such as trifluoroacetoxy.

Pri kyslej hydrolýze môžu byť podlá použitých podmienok v zlúčenine vzorca I prípadne tiež prítomné hydrolyticky odštiepitelné skupiny ako je acetylová, trifluóracetylová, benzoylová, terc.butyloxykarbonylová alebo benzyloxykarbonylová skupina súčasne odštiepené.In acid hydrolysis, hydrolytically cleavable groups such as acetyl, trifluoroacetyl, benzoyl, tert-butyloxycarbonyl or benzyloxycarbonyl groups can optionally also be present simultaneously in the compound of formula I.

Ak napríklad zlúčenina vzorca II obsahuje terc.butyloxykarbonylovú skupinu, môže byť terc.butylová skupina odštiepená aj spracovaním s kyselinou ako je kyselina trifluóroctová, kyselina chlorovodíková, kyselina mravčia, kyselina p-toluénsulfónová, kyselina sírová, kyselina fosforečná alebo kyselina polyfosforečná, prípadne v inertnom rozpúšťadle ako je metylénchlorid, chloroform, benzén, toluén, tetrahydrofurán alebo dioxán, výhodne pri teplotách medzi -10 °C a 120 °C, napríklad pri teplotách medzi 0 °C až 60 °C alebo tiež termicky prípadne v inertnom rozpúšťadle ako je metylénchlorid, chloroform, benzén, toluén, tetrahydrofurán alebo dioxán a prípadne za prítomnosti katalytického množstva kyseliny ako je kyselina p-toluénsulfónová, kyselina sírová, kyselina fosforečná alebo kyselina polyfosforečná, výhodne pri teplote varu použitého rozpúšťadla, napríklad pri teplotách medzi 40 °C a 100 °C.For example, if the compound of formula II contains a tert-butyloxycarbonyl group, the tert-butyl group may also be cleaved by treatment with an acid such as trifluoroacetic acid, hydrochloric acid, formic acid, p-toluenesulfonic acid, sulfuric acid, phosphoric acid or polyphosphoric acid, optionally a solvent such as methylene chloride, chloroform, benzene, toluene, tetrahydrofuran or dioxane, preferably at temperatures between -10 ° C and 120 ° C, for example at temperatures between 0 ° C and 60 ° C or also thermally or in an inert solvent such as methylene chloride, chloroform, benzene, toluene, tetrahydrofuran or dioxane and optionally in the presence of a catalytic amount of an acid such as p-toluenesulfonic acid, sulfuric acid, phosphoric acid or polyphosphoric acid, preferably at the boiling point of the solvent used, for example at temperatures between 40 ° C and 100 ° C .

Ak napríklad obsahuje zlúčenina vzorca II benzyloxykarbonylovú skupinu, môže byť benzyloxyskupina odštiepená aj hydrogenolyticky za prítomnosti hydrogenačného katalyzátora ako je paládium na uhlí vo vhodnom rozpúšťadle ako je metanol, etanol, etanol/voda, ľadová kyselina octová, etylester kyseliny octovej, dioxán alebo dimetylformamid, výhodne pri teplotách medzi 0 °C a 50 “C, napríklad' pri teplote miestnosti a pri tlaku vodíka od 0,1 do 1 MPa. Pri hydrogenolýze môžu byť súčasne redukované aj iné zvyšky, napríklad nitroskupina na aminoskupinu alebo benzyloxyskupina na hydroxyskupinu a benzylaminoskupina na aminoskupinu. Okrem toho môžu byť súčasne hydrogenované C=C-dvojité väzby na väzby j ednoduché.For example, if the compound of formula II contains a benzyloxycarbonyl group, the benzyloxy group may also be cleaved hydrogenolytically in the presence of a hydrogenation catalyst such as palladium on carbon in a suitable solvent such as methanol, ethanol, ethanol / water, glacial acetic acid, ethyl acetate, dioxane or dimethylformamide. at temperatures between 0 ° C and 50 ° C, for example at room temperature and at a hydrogen pressure of from 1 to 10 bar. In the case of hydrogenolysis, other radicals can also be reduced at the same time, for example nitro to amino or benzyloxy to hydroxy and benzylamino to amino. In addition, C = C-double bonds to the bonds can be hydrogenated simultaneously.

b) Na výrobu zlúčenín všeobecného vzorca I, kde A je substituovaný zvyškom R^:(b) For the preparation of compounds of formula I wherein A is substituted with the radical R @ 1:

A1 - B - C - D - E - COORa (III) kdeA 1 - B - C - D - E - COOR and (III) where

B až E a Ra majú už skôr definovaný význam aB to E and R a are as previously defined and

Aj znamená cez atóm uhlíka so zvyškom B spojenú aminoalky15 lovú skupinu s 1 až 5 atómami uhlíka alebo cez atóm uhlíka so zvyškom B spojenú 5-, 6- alebo 7-člennú azacykloalkylovú skupinu, kde atómy uhlíka azacykloalkylovej skupiny môžu byť substituovanú jednou až tromi alkylovými skupinami vždy s 1 až 3 atómami uhlíka, aminokarbonylovou, kyanovou, R^Oalebo R^O-CO-skupinou, kde R3 má už vyššie uvedený význam, sa táto zlúčenina nechá reagovať so zlúčeninou všeobecného vzorca IVAlso, via a carbon atom having a B moiety linked to an aminoalkyl group 15, a 1 to 5 carbon atom or via a carbon atom having a B moiety attached to a 5-, 6- or 7-membered azacycloalkyl group, wherein the carbon atoms of the azacycloalkyl group may be substituted with one to three alkyl groups. groups of 1 to 3 carbon atoms, aminocarbonyl, cyano, R ^O or R ^O-CO-, in which R má is as defined above, this compound is reacted with a compound of the formula IV

Rb - z1 (iv) kde má už skôr definovaný význam a Z-£ predstavuje nukleofilnú odštiepitelnú skupinu ako je atóm halogénu napríklad atóm chlóru, brómu alebo jódu alebo tiež, ak je Z^ naviazaný na karbonylovú skupinu, hydroxyskupinu, alkanoyloxyskupinu alebo alkoxykarbonyloxyskupinu alebo tiež Z-£ znamená spolu so susedným atómom vodíka zvyšku Rb atóm kyslíka.R b - z 1 (iv) wherein it is as previously defined and Z -? Represents a nucleophilic leaving group such as a halogen atom, for example a chlorine, bromine or iodine atom or also when Z 2 is attached to a carbonyl, hydroxy, alkanoyloxy or alkoxycarbonyloxy group or Z-? together with the adjacent hydrogen atom of R b represents an oxygen atom.

Reakcia sa výhodne vykonáva vo vhodnom rozpúšťadle prípadne za prítomnosti bázy alebo prípadne za prítomnosti kyselinu aktivujúceho činidla alebo za prítomnosti redukčného činidla pri teplotách medzi -30 °C a 150 “C.The reaction is preferably carried out in a suitable solvent, optionally in the presence of a base or optionally in the presence of an acid activating agent or in the presence of a reducing agent at temperatures between -30 ° C and 150 ° C.

Ak Z-£ znamená nukleofilnú odštiepitelnú skupinu, môže sa reakcia výhodne vykonávať v rozpúšťadle alebo v zmesi rozpúšťadiel ako je voda, tetrahydrofurán, tetrahydrofurán/voda, dioxán, dioxán/voda, metylénchlorid, chloroform, etylacetát alebo dimetylformamid, výhodne za prítomnosti bázy ako je uhličitan sodný, uhličitan draselný alebo hydroxid sodný alebo za prítomnosti terciárnej organickej bázy ako je trietylamín, N-etyl-diizopropylamín, N-metyl-morfolín alebo pyridín, ktoré súčasne môžu slúžiť ako rozpúšťadlo, prípadne za prítomnosti látky, urýchľujúcej reakciu ako je jodid draselný pri teplotách medzi -10 °C a 80 °C.When Z = 6 is a nucleophilic leaving group, the reaction may preferably be carried out in a solvent or solvent mixture such as water, tetrahydrofuran, tetrahydrofuran / water, dioxane, dioxane / water, methylene chloride, chloroform, ethyl acetate or dimethylformamide, preferably in the presence of a base such as sodium carbonate, potassium carbonate or sodium hydroxide, or in the presence of a tertiary organic base such as triethylamine, N-ethyl-diisopropylamine, N-methylmorpholine or pyridine, which may simultaneously serve as a solvent, optionally in the presence of a reaction accelerator such as potassium iodide at temperatures between -10 ° C and 80 ° C.

Ak Z-£ znamená hydroxyskupinu, vykonáva sa reakcia vý- 16 hodne v rozpúšťadle alebo v zmesi rozpúšťadiel ako je metylénchlorid, dimetylformamid, benzén, toluén, chlórbenzén, tetrahydrofurán, benzén/tetrahydrofurán alebo dioxán, prípadne za prítomnosti kyseliny ako je kyselina chlorovodíková alebo za prítomnosti činidla, ktoré odoberá vodu, napríklad za prítomnosti izobutylesteru kyseliny chlórmravčej, tionylchloridu, trimetylchlórsilánu, kyseliny chlorovodíkovej, kyseliny sírovej, kyseliny metánsulfónovej, kyseliny p-toluénsulfónovej, chloridu fosforitého, oxidu fosforečného, N,N’-dicyklohexylkarbodiimidu, N,N’-dicyklohexylkarbodiimidu/N-hydroxysukcínimidu, 2-(lH-benztriazolyl)-1,1,3,3tetrametyl-uróniových solí, N,N’-karbonyldiimidazolu, N,N’tionyldiimidazolu alebo trifenylfosfín/chloridu uhličitého, prípadne za prítomnosti dimetylaminopyridínu alebo l-hydroxy-benzotriazolu, výhodne pri teplotách medzi 0 QC a 150 °C, výhodne najmä pri teplotách medzi 0 °C a 50 °C.When Z = 6 is hydroxy, the reaction is preferably carried out in a solvent or solvent mixture such as methylene chloride, dimethylformamide, benzene, toluene, chlorobenzene, tetrahydrofuran, benzene / tetrahydrofuran or dioxane, optionally in the presence of an acid such as hydrochloric acid or in the presence of a water-removing agent, for example in the presence of isobutyl chloroformate, thionyl chloride, trimethylchlorosilane, hydrochloric acid, sulfuric acid, methanesulfonic acid, p-toluenesulfonic acid, phosphorus trichloride, phosphorus pentoxide, N, N'-dicyclohexylcarbodiimide, dicyclohexylcarbodiimide / N-hydroxysuccinimide, 2- (1H-benzotriazolyl) -1,1,3,3-tetramethyluronium salts, N, N'-carbonyldiimidazole, N, N'-thionyldiimidazole or triphenylphosphine / carbon tetrachloride, optionally in the presence of dimethylaminopyridine or 1- hydroxybenzotriazole, preferably at temperatures between 0 C and Q 150, preferably but ä at temperatures between 0 ° C and 50 ° C.

Ak Z-£ znamená spolu so susedným atómom vodíka zvyšku atóm kyslíka, vykoná sa redukčná alkylácia výhodne vo vhodnom rozpúšťadle ako je metanol, etanol, tetrahydrofurán, dioxán, acetonitril alebo ich zmesi s vodou za prítomnosti vhodného redukčného činidla ako je kyselina mravčia alebo vhodného komplexného hydridu kovu, výhodne však za prítomnosti kyánborohydridu sodného alebo vodíkom za prítomnosti hydrogenačného katalyzátora ako je paládium/uhlie pri teplotách medzi 0 °C a 50 ’C, výhodne však pri teplote miestnosti .When Z- £ together with the adjacent hydrogen atom of the residue is an oxygen atom, the reductive alkylation is preferably carried out in a suitable solvent such as methanol, ethanol, tetrahydrofuran, dioxane, acetonitrile or mixtures thereof with water in the presence of a suitable reducing agent such as formic acid or a suitable complex metal hydride, preferably in the presence of sodium cyanoborohydride or hydrogen in the presence of a hydrogenation catalyst such as palladium / carbon at temperatures between 0 ° C and 50 ° C, preferably at room temperature.

c) Na výrobu zlúčenín všeobecného vzorca I, kde Ra s výnimkou vodíka má vyššie definovaný význam:(c) For the preparation of compounds of the formula I, in which R and with the exception of hydrogen have the meaning defined above:

sa nechá reagovať zlúčenina všeobecného vzorca Vthe compound of formula V is reacted

A-B-C-D-E- COOH (V) kdeA - B - C - D - E - COOH (V) where

A až E majú už definovaný význam, so zlúčeninou všeobecného vzorca VI kdeA to E are as defined above, with a compound of formula VI wherein

R ’ s výnimkou vodíka majú významy uvedené vyššie pre Ra a Z2 predstavuje nukleofilnú odštiepiteľnú skupinu ako je atóm halogénu, napríklad atóm chlóru alebo brómu alebo na sulfonylovej skupine substituovaná sulfonyloxyskupina, napríklad metánsulfonyloxy skupina, metoxysulfonyloxy skupina, toluénsulfonyloxyskupina alebo hydroxyskupinu.R 1 except hydrogen has the meanings given above for R 1 and Z 2 is a nucleophilic leaving group such as a halogen atom, for example a chlorine or bromine atom, or a sulfonyloxy substituted on a sulfonyl group, for example a methanesulfonyloxy group, methoxysulfonyloxy group, toluenesulfonyloxy or hydroxy group.

Reakcia sa, ak Z2 predstavuje atóm halogénu alebo na sulfonylovej skupine substituovanú sulfonyloxyskupinu, vykonáva výhodne v rozpúšťadle ako je tetrahydrofurán, dioxán, metylénchlorid, chloroform, etylacetát, dimetylsulfoxid alebo dimetylformamid, výhodne za prítomnosti bázy ako je uhličitan sodný, uhličitan draselný alebo hydroxid sodný alebo za prítomnosti terciárnej organickej bázy ako je trietylamín, N-etyl-diizopropylamín alebo N-metylmorfolín, ktoré môžu súčasne slúžiť ako rozpúšťadlo, prípadne za prítomnosti látky, urýchľujúcej reakciu, ako je jodid draselný pri teplotách; medzi -30 ’C a 100 ’C, výhodne však pri teplotách medzi -10 ’C a 80 °C. ‘The reaction, when Z 2 represents a halogen atom or a sulphonyl group substituted by a sulphonyloxy group, is preferably carried out in a solvent such as tetrahydrofuran, dioxane, methylene chloride, chloroform, ethyl acetate, dimethylsulfoxide or dimethylformamide, preferably in the presence of a base such as sodium carbonate, potassium carbonate or sodium hydroxide; in the presence of a tertiary organic base such as triethylamine, N-ethyl-diisopropylamine or N-methylmorpholine, which may simultaneously serve as a solvent, optionally in the presence of a reaction accelerator such as potassium iodide at temperatures; between -30 ° C and 100 ° C, but preferably at temperatures between -10 ° C and 80 ° C. '

Ak Z2 znamená hydroxyskupinu, vykonáva sa reakcia výhodne sa použitia zlúčeniny VI ako rozpúšťadla za prítomnosti tionylchloridu alebo kyseliny ako je kyselina chlorovodíková alebo kyselina sírová, pri teplotách medzi -10 ’C a 100 ’C, výhodne pri teplotách medzi 0 ’C a 50 'C.When Z2 is hydroxy, the reaction is preferably carried out using a compound VI as a solvent in the presence of thionyl chloride or an acid such as hydrochloric acid or sulfuric acid at temperatures between -10 ° C and 100 ° C, preferably at temperatures between 0 ° C and 50 ° C.

d) Na výrobu zlúčenín všeobecného vzorca I, kde C znamenád) For the preparation of compounds of formula I wherein C is

-CH2-NH-skupinu:-CH2-NH-group:

sa redukuje zlúčenina všeobecného vzorca VIIreducing the compound of formula VII

A-B-CH = N- D- E- COORA-B-CH = N-D-E-COOR

G.G.

kdewhere

A, B, D, E a Ra majú už skôr definovaný význam.A, B, D, E and R and are as previously defined.

(VII)(VII)

Redukcia sa výhodne vykonáva vo vhodnom rozpúšťadle ako je metanol, metanol/voda, metanol/amoniak, metanol/voda/amoniak, metanol/kyselina chlorovodíková, metanol/éterická kyselina chlorovodíková, etanol, etylacetát, éter, tetrahydrof urán, dioxán, dimetylformamid alebo ľadová kyselina octová za prítomnosti katalytický aktivovaného vodika, napríklad vodíka za prítomnosti Raney-niklu, platiny alebo paládia/uhlie alebo za prítomnosti hydridu kovu ako je bórhydrid sodný, nátriumkyánbórhydrid alebo bórhydrid lítny pri teplotách medzi -20 eC a 100 “C, výhodne pri teplotách medzi 0 °C a 60 °C.The reduction is preferably carried out in a suitable solvent such as methanol, methanol / water, methanol / ammonia, methanol / water / ammonia, methanol / hydrochloric acid, methanol / ethereal hydrochloric acid, ethanol, ethyl acetate, ether, tetrahydrofuran, dioxane, dimethylformamide or ice. acetic acid in the presence of catalytically activated hydrogen, for example hydrogen in the presence of Raney nickel, platinum or palladium / charcoal, or in the presence of a metal hydride such as sodium borohydride, sodium cyanoborohydride or lithium borohydride at temperatures between -20 C and e 100 "C, preferably at temperatures between 0 ° C and 60 ° C.

e) Na výrobu zlúčenín všeobecného vzorca I, kde C predstavuj e -CO-NR4-skupinu:e) For the preparation of compounds of the formula I in which C represents an -CO-NR4-group:

nechá sa reagovať zlúčenina všeobecného vzorca VIIIreacting a compound of formula VIII

A2 - B - COOH (VIII) kdeA 2 - B - COOH (VIII) where

B má už skôr definovaný význam aB has the previously defined meaning of a

A2 predstavuje na atóme dusíka alkyl-, aralkyl-, alkanoyl-, trifluóracetyl- alebo alkoxykarbonylovým zvyškom substituovanú skupinu Á, s amínom všeobecného vzorca IXA 2 represents an alkyl-, aralkyl-, alkanoyl-, trifluoroacetyl- or alkoxycarbonyl-substituted A group with an amine of the general formula IX on the nitrogen atom

R4 - NH - D - E - COORa’ (IX) kdeR 4 - NH - D - E - COOR a '(IX) where

D, E a R4 majú už skôr definovaný význam aD, E and R 4 are as previously defined and

R ’ s výnimkou atómu vodíka má významy už skôr uvedené preR ', except for a hydrogen atom, has the meanings previously given for

Reakcia sa výhodne vykonáva v rozpúšťadle alebo v zmesi rozpúšťadiel ako je metylénchlorid, dimetylformamid, dimetylsulfoxid, benzén, toluén, chlórbenzén, tetrahydrofurán, benzén/tetrahydrofurán alebo dioxán, prípadne ža prítomnosti činidla, odoberajúceho vodu, napríklad za prítomnosti izobu19 tylesteru kyseliny chlórmravčej, tionylchloridu, trimetylchlórsilánu, kyseliny chlorovodíkovej, kyseliny sírovej, kyseliny metánsulfónovej, kyseliny p-toluénsulfónovej, chloridu fosforitého, oxidu fosforečného, N,N’-dicyklohexylkarbodiimidu, N,N’-dicyklohexylkarbodiimidu/N-hydroxysukcínimidu, 2-(lH-benztriazolyl)-1,1,3,3-tetrametyluróniových solí,The reaction is preferably carried out in a solvent or solvent mixture such as methylene chloride, dimethylformamide, dimethylsulfoxide, benzene, toluene, chlorobenzene, tetrahydrofuran, benzene / tetrahydrofuran or dioxane, optionally in the presence of a water scavenger, for example in the presence of isobutyl chloride, trimethylchlorosilane, hydrochloric acid, sulfuric acid, methanesulfonic acid, p-toluenesulfonic acid, phosphorus trichloride, phosphorus pentoxide, N, N'-dicyclohexylcarbodiimide, N, N'-dicyclohexylcarbodiimide / N-hydroxysuccinimide, 2- (1H) -benzol 1,3,3-tetramethyluronium salts,

N,N’-karbonyldiimidazolu, N,N’-tionyldiimidazolu alebo trifenylfosfínu/chloridu uhličitého, prípadne za prítomnosti dimetylaminopyridínu alebo 1-hydroxybenzotriazolu a/alebo bázy ako je trietylamín, N-etyl-diizopropylamín alebo N-metyl-morfolín, výhodne pri teplotách medzi -10 C a 150 °C, výhodnejšie pri teplotách medzi 0 °C a 50 °C.N, N'-carbonyldiimidazole, N, N'-thionylldiimidazole or triphenylphosphine / carbon tetrachloride, optionally in the presence of dimethylaminopyridine or 1-hydroxybenzotriazole and / or a base such as triethylamine, N-ethyl-diisopropylamine or N-methylmorpholine, preferably at temperatures between -10 ° C and 150 ° C, more preferably at temperatures between 0 ° C and 50 ° C.

f) Na výrobu zlúčenín všeobecného vzorca I, kde C predstavuje -NR4CO-skupinu:f) For the preparation of compounds of formula I wherein C represents an -NR 4 CO group:

Nechá sa reagovať zlúčenina všeobecného vzorca XThe compound of formula X is reacted

A2 - B - NH-R4 (X) kdeA 2 - B - NH - R 4 (X) wherein

R4 a B majú už vyššie definovaný význam aR4 and B are as defined above and

A2 predstavuje na atóme dusíka alkyl-, a-ralkyl-, alkanoyl-, trifluóracetyl- alebo alkoxykarbonylovým zvyškom substituovanú skupinu A, s karboxylovou kyselinou všeobecného vzorca XIA 2 represents an alkyl-, α-alkyl-, alkanoyl-, trifluoroacetyl- or alkoxycarbonyl-substituted A group with a carboxylic acid of the general formula XI on the nitrogen atom

HOOC - D - E - COORa’ (XI) kdeHOOC - D - E - COOR and (XI) where

D a E majú vyššie definovaný význam aD and E are as defined above and

Ra’ s výnimkou atómu vodíka má významy uvedené vyššie pre RR a ', with the exception of the hydrogen atom, has the meanings given above for R a';

Reakcia sa výhodne vykonáva v rozpúšťadle alebo v zmesi rozpúšťadiel ako je metylénchlorid, dimetylformamid, dimetylsulfoxid, benzén, toluén, chlórbenzén, tetrahydrofurán, benzén/tetrahydrofurán alebo dioxán prípadne za prítomnosti činidla, odoberajúceho vodu, napríklad za prítomnosti izobutylesteru kyseliny chlórmravčej, tionylchloridu, trimetylchlórsilánu, kyseliny chlorovodíkovej, kyseliny sírovej, kyseliny metánsulfónovej, kyseliny p-toluéňsulfónovej, chloridu fosforitého, oxidu fosforečného, N,N’-dicyklohexylkarbodiimidu, N,N’-dicyklohexylkarbodiimidu/N-hydroxysukcínimidu, 2-(lH-benztriazolyl)-1,1,3,3-tetrametyluróniových solí,The reaction is preferably carried out in a solvent or solvent mixture such as methylene chloride, dimethylformamide, dimethylsulfoxide, benzene, toluene, chlorobenzene, tetrahydrofuran, benzene / tetrahydrofuran or dioxane, optionally in the presence of a water scavenger, for example, isobutyl chloroformate hydrochloric acid, sulfuric acid, methanesulfonic acid, p-toluenesulfonic acid, phosphorus trichloride, phosphorus pentoxide, N, N'-dicyclohexylcarbodiimide, N, N'-dicyclohexylcarbodiimide / N-hydroxysuccinimide, 2- (1H-benztriazolyl) -1,1, 3,3-tetramethyluronium salts,

N,N’-karbonyldiimidazolu, N,N’-tionyldiimidazolu alebo trifenylfosfínu/chloridu uhličitého, prípadne za prítomnosti dimetylaminopyridínu alebo 1-hydroxybenzotriazolu a/alebo bázy ako je trietylamín, N-etyl-diizopropylamín alebo N-metyl-morfolín, výhodne pri teplotách medzi -10 °C a 150 ’C, výhodnejšie pri teplotách medzi 0 ’C a 50 ’C.N, N'-carbonyldiimidazole, N, N'-thionylldiimidazole or triphenylphosphine / carbon tetrachloride, optionally in the presence of dimethylaminopyridine or 1-hydroxybenzotriazole and / or a base such as triethylamine, N-ethyl-diisopropylamine or N-methylmorpholine, preferably at temperatures between -10 ° C and 150 ° C, more preferably at temperatures between 0 ° C and 50 ° C.

g) Na výrobu zlúčenín všeobecného vzorca I, kde A predstavuje cez atóm uhlíka so zvyškom B spojenú aminoalkylovú skupinu s 1 až 5 atómami uhlíka:(g) For the preparation of compounds of the formula I in which A represents a C 1 -C 5 aminoalkyl group linked via a carbon atom of the radical B:

Redukuje sa zlúčenina všeobecného vzorca XIIThe compound of formula XII is reduced

A3 - B - C - D - E - COORa (XII) kdeA 3 - B - C - D - E - COOR and (XII) where

B až E a R& má vyššie uvedený význam aB to E and R & apos ;

A3 predstavuje kyanoskupinu alebo kyanoalkylovú skupinu s 1 až 4 atómami uhlíka v alkylovej časti.A 3 represents cyano or C 1 -C 4 -alkyl cyanoalkyl.

Redukcia sa výhodne vykonáva vo vhodnom rozpúšťadle ako je metanol, metanol/voda, metanol/voda/amoniak, etanol, éter, tetrahydrofurán, dioxán alebo dimetylformamid, prípadne sa prídavku kyseliny ako je kyselina chlorovodíková za prítomnosti katalytický aktivovaného vodíka, napríklad vodíka za prítomnosti Raney-niklu, platiny alebo paládia/uhlie alebo za prítomnosti hydridu kovu ako nátriumbórhydridu, lítiumbórhydridu alebo lítiumalumíniumhydridu pri teplotách medzi 0 ’C a 100 ’C, výhodne pri teplotách medzi 20 ’C a 80 “C.The reduction is preferably carried out in a suitable solvent such as methanol, methanol / water, methanol / water / ammonia, ethanol, ether, tetrahydrofuran, dioxane or dimethylformamide, optionally by addition of an acid such as hydrochloric acid in the presence of catalytically activated hydrogen, e.g. - nickel, platinum or palladium / coal or in the presence of a metal hydride such as sodium borohydride, lithium borohydride or lithium aluminum hydride at temperatures between 0 ° C and 100 ° C, preferably at temperatures between 20 ° C and 80 ° C.

Ak sa získa zlúčenina všeobecného vzorca I, kde predstavuje atóm vodíka, môže byť táto prevedená pomocou al~ kylácie na zodpovedajúcu zlúčeninu všeobecného vzorca I, kde R4 predstavuje prípadne fenylovou skupinou substituovanú alkylovú skupinu s 1 alebo 2 atómami uhlíka.When a compound of formula (I) wherein a hydrogen atom is obtained, it may be converted by alkylation to the corresponding compound of formula (I) wherein R4 represents an optionally substituted alkyl group having 1 or 2 carbon atoms.

Následne vykonaná alkylácia sa výhodne vykonáva zodpovedajúcim halogenidom ako je metyljodid, etylbromid, benzylchlorid alebo fenyletylbromid, výhodne v rozpúšťadle ako je metylénchlorid, tetrahydrofurán, dioxán, dimetylsulfoxid alebo dimetylformamid, prípadne za prítomnosti bázy ako je uhličitan sodný, uhličitan draselný alebo hydroxid sodný alebo za prítomnosti terciárnej organickej bázy, ako je N-etyl-diizopropylamín alebo N-metyl-morfolín, ktoré súčasne môžu slúžiť ako rozpúšťadlo, pri teplotách medzi -30 °C a 100 “C, výhodne však pri teplotách medzi -10 °C a 80 “C.The subsequent alkylation is preferably carried out with a corresponding halide such as methyl iodide, ethyl bromide, benzyl chloride or phenylethyl bromide, preferably in a solvent such as methylene chloride, tetrahydrofuran, dioxane, dimethylsulfoxide or dimethylformamide, optionally in the presence of a base such as sodium carbonate, potassium carbonate or a tertiary organic base, such as N-ethyl-diisopropylamine or N-methyl-morpholine, which can simultaneously serve as a solvent at temperatures between -30 ° C and 100 ° C, preferably at temperatures between -10 ° C and 80 ° C .

Pri uvedených reakciách môžu byť prípadne prítomné reaktívne skupiny ako hydroxylové, karboxylové, amínové, alkylamínové alebo iminiskupiny počas reakcie chránené obvyklými chrániacimi skupinami, ktoré môžu byť po reakcii opäť odštiepené.In the above reactions, reactive groups such as hydroxyl, carboxyl, amino, alkylamine or imino groups may optionally be present during the reaction, protected by conventional protecting groups, which may be cleaved again after the reaction.

Napríklad prichádzajú do úvahy ako chrániace skupiny hydroxyskupiny trimetylsilylová, acetylová, benzoylová, terc.butyltritylová, benzylová alebo tetrahydropyranylskupina, ako chrániace skupiny karboxylovej skupiny trimetysilylová, metylová, etylová, terc.butylová, benzylová alebo tetrahydropyranylskupina a ako chrániaca skupina pre amínovú, alkylamínovú alebo imínovú skupinu, acetylová, trifluóracetylová, benzoylová, etoxykarbonylová, terc.butoxykarbonylová benzyloxykarbonylová, benzylová, metoxybenzylová alebo 2, 4-dimetoxybenzylskupina a pre aminoskupinu naviac ftalylová skupina.For example, trimethylsilyl, acetyl, benzoyl, tert-butyltrityl, benzyl or tetrahydropyranyl protecting groups as hydroxyl protecting groups, trimethylsilyl, methyl, ethyl, tert-butyl, benzyl or tetrahydropyranyl or imidinyl amino protecting groups, and as protecting groups for imino, an acetyl, trifluoroacetyl, benzoyl, ethoxycarbonyl, tert-butoxycarbonyl benzyloxycarbonyl, benzyl, methoxybenzyl or 2,4-dimethoxybenzyl group and, in addition to the amino group, a phthalyl group.

Prípadne následne vykonávané odštiepenie chrániacej skupiny sa napríklad vykonáva hydrolyticky vo vodnom rozpúš22 ťadle, napríklad vo vode, izopropanole/vode, tetrahydrofuráne/ vode alebo dioxáne/vode, za prítomnosti kyseliny ako je kyselina trifluóroctová, kyselina chlorovodíková alebo kyselina sírová alebo za prítomnosti bázy alkalického kovu ako je hydroxid lítny, hydroxid sodný alebo hydroxid draselný alebo pomocou éterového štiepenia, napríklad za prítomnosti jódtrimetylsilánu, pri teplotách medzi 0 °C a 100 °C, výhodne pri teplotách medzi 10 ’C a 50 °C.The optional deprotection subsequently carried out is carried out, for example, hydrolytically in an aqueous solvent, for example water, isopropanol / water, tetrahydrofuran / water or dioxane / water, in the presence of an acid such as trifluoroacetic acid, hydrochloric acid or sulfuric acid or alkali metal base. such as lithium hydroxide, sodium hydroxide or potassium hydroxide or via ether cleavage, for example in the presence of iodotrimethylsilane, at temperatures between 0 ° C and 100 ° C, preferably at temperatures between 10 ° C and 50 ° C.

Odštiepenie benzylového, metoxybenzylového alebo benzyloxykarbonylového zvyšku sa vykonáva napríklad hydrogenolyticky, napríklad vodíkom za prítomnosti katalyzátora ako je paládium/uhlie v rozpúšťadle ako je metanol, etanol, etylacetát, dimetylformamid, dimetylformamid/acetón alebo ľadová kyselina octová, prípadne za prídavku kyseliny ako je kyselina chlorovodíková, pri teplotách medzi 0 °C a 50 ’C, výhodne však pri teplotách medzi 0 °C a 50 °C, výhodne však pri teplote miestnosti a pri tlaku vodíka 0,1 až 0,7 MPa, výhodne 0,3 až 0,5 MPa. Pri hydrogenolytickom odštiepení benzyl-skupín môžu súčasne byť prípadne v zlúčenine všeobecného vzorca II prítomné C=C-dvojité väzby hydrogenované. Napríklad môže byť týmto spôsobom prevedená N-benzyldehydropiperidylová skupina na piperidylovú skupinu.The cleavage of the benzyl, methoxybenzyl or benzyloxycarbonyl radical is carried out, for example, by hydrogenolysis, for example with hydrogen in the presence of a catalyst such as palladium / carbon in a solvent such as methanol, ethanol, ethyl acetate, dimethylformamide, dimethylformamide / acetone or glacial acetic acid. at temperatures between 0 ° C and 50 ° C, preferably at temperatures between 0 ° C and 50 ° C, preferably at room temperature and at a hydrogen pressure of 0.1 to 0.7 MPa, preferably 0.3 to 0, 5 MPa. In the hydrogenolytic cleavage of the benzyl groups, the C = C-double bonds optionally present in the compound of the formula II can be hydrogenated simultaneously. For example, an N-benzyldehydropiperidyl group can be converted to a piperidyl group in this manner.

Odštiepenie metoxybenzylovej skupiny sa môže tiež previesť za prítomnosti oxidačného činidla ako je dusičnan céričitoamónny v rozpúšťadle ako je metylénchlorid, acetonitril alebo acetonitril/vóda pri teplotách medzi 0 °C a 50 ’C, výhodne pri teplote miestnosti.Cleavage of the methoxybenzyl group can also be carried out in the presence of an oxidizing agent such as cerium ammonium nitrate in a solvent such as methylene chloride, acetonitrile or acetonitrile / water at temperatures between 0 ° C and 50 ° C, preferably at room temperature.

Odštiepenie 2,4-dimetoxybenzylového zvyšku sa vykonáva napríklad v kyseline trifluóroctovej za prítomnosti anizolu.The cleavage of the 2,4-dimethoxybenzyl residue is carried out, for example, in trifluoroacetic acid in the presence of anisole.

Odštiepenie terc.butylového alebo terc.butyloxykarbonylového zvyšku sa výhodne vykonáva spracovaním s kyselinou ako je kyselina trifluóroctová alebo kyselina chlorovodíková, prípadne za použitia rozpúšťadla ako je metylénchlorid, dioxán, éter alebo dioxán/éter.The cleavage of the tert-butyl or tert-butyloxycarbonyl residue is preferably carried out by treatment with an acid such as trifluoroacetic acid or hydrochloric acid, optionally using a solvent such as methylene chloride, dioxane, ether or dioxane / ether.

Odštiepenie ftalylového zvyšku sa výhodne vykonáva za prítomnosti hydrazínu alebo primárneho amínu ako je metylamín, etylamín alebo n-butylamín v rozpúšťadle ako je metanol, etanol, izopropanol, toluén/voda alebo dioxán pri teplotách medzi 20 °C a 50 °C.The cleavage of the phthalyl residue is preferably carried out in the presence of hydrazine or a primary amine such as methylamine, ethylamine or n-butylamine in a solvent such as methanol, ethanol, isopropanol, toluene / water or dioxane at temperatures between 20 ° C and 50 ° C.

Odštiepenie alyloxykarbonylového zvyšku sa vykonáva spracovaním s katalytickým množstvom tetrakis-(trifenylfosfin)paládia (0) výhodne v rozpúšťadle ako je tetrahydrofurán a za prítomnosti prebytku akceptora alylskupín ako je morfolín alebo 1,3-dimedón pri teplotách medzi 0 °C a 100 °C, výhodne pri teplote miestnosti a pod inertným plynom alebo spracovaním s katalytickým množstvom tris-(trifenylfosfin)ródium(I)chloridu v rozpúšťadle ako je vodný etanol a prípadne za prítomnosti bázy ako je 1,4-diazabicyklo[2.2.2]oktán pri teplotách medzi 20 “C a 70 °C.Cleavage of the allyloxycarbonyl moiety is accomplished by treatment with a catalytic amount of tetrakis (triphenylphosphine) palladium (0) preferably in a solvent such as tetrahydrofuran and in the presence of an excess of allyl acceptor such as morpholine or 1,3-dimedone at temperatures between 0 ° C and 100 ° C. preferably at room temperature and under an inert gas or treatment with a catalytic amount of tris- (triphenylphosphine) rhodium (I) chloride in a solvent such as aqueous ethanol and optionally in the presence of a base such as 1,4-diazabicyclo [2.2.2] octane at temperatures between 20 ° C and 70 ° C.

Ďalej môžu byť získané zlúčeniny všeobecného vzorca I, ako už bolo uvedené, môžu byť rozdelené na svoje enantioméry a/alebo diastereoméry. Tak napríklad môžu' byť cis/trans-zmesi rozdelené na svoje cis- a trans-izoméry a chirálne zlúčeniny na svoje enantioméry.Furthermore, the compounds of the formula I can be obtained, as mentioned above, separated into their enantiomers and / or diastereomers. For example, cis / trans mixtures can be separated into their cis and trans isomers and chiral compounds into their enantiomers.

Tak je možné napríklad získané cis-/trans-zmesi rozdeliť na ich cis- a trans-izoméry, získané zlúčeniny všeobecného vzorca I, ktoré sú vo forme racemátov, môžu byť rozdelené osebe známymi metódami (viď. Allinger N.L. a Eliel E.L. v Topics in Stereochemistry, zv. 6, Viley Interscience, 1971) na svoje optické antipódy a zlúčeniny všeobecného vzorca I s aspoň 2 stereogénnymi centrami na základe svojich fyzikálne-chemických odlišností byť rozdelené osebe známymi metódami, napríklad chromatografiou a/alebo frakčnou kryštalizáciou, na ich diastereoméry, ktoré, ak sa vyskytujú v racemickej forme, môžu potom byť, ako je uvedené vyššie, rozdelené na svoje enantioméry.Thus, for example, the cis / trans mixtures obtained can be separated into their cis and trans isomers, the obtained compounds of the formula I which are in the form of racemates can be resolved by methods known per se (see Allinger NL and Eliel EL in Topics in Stereochemistry, Vol. 6, Viley Interscience, 1971), to their optical antipodes and compounds of formula I with at least 2 stereogenic centers due to their physicochemical differences, be separated into their diastereomers by known methods, for example chromatography and / or fractional crystallization, which, when present in racemic form, can then be resolved, as mentioned above, into their enantiomers.

Delenie enantiomérov sa výhodne vykonáva na stĺpci na chirálnych fázach alebo rekryštalizáciou z opticky aktívneho rozpúšťadla alebo reakciou s opticky aktívnou substanciou, tvoriacou s racemickou zlúčeninou soli alebo deriváty ako napríklad estery alebo amidy, zvlášť s kyselinami a ich aktívnymi derivátmi alebo alkoholmi a rozdelením týmto spôsobom získaných diastereomérnych solí vo forme zmesí alebo derivátov, napríklad na základe rôznych rozpustnosti, pričom môžu byť z čistých racemických solí alebo derivátov uvoľnené antipódy pôsobením vhodného činidla. Zvlášť použiteľnými, opticky aktívnymi kyselinami sú napríklad D- a L-formy kyseliny vinnej alebo kyseliny dibenzoylvinnej, di-o-tolylvinnej kyseliny, kyseliny jablčnej, kyseliny mandľovej, kyseliny gáforsulfónovej, kyseliny glutamínovej, kyseliny asparagovej alebo kyseliny chinínovej. Ako opticky aktívny alkohol prichádza napríklad do úvahy (+)- alebo (-)-mentol a ako opticky aktívny acylový zvyšok v amidoch napríklad (+)- alebo (-)-metyloxykarbonyl.The separation of the enantiomers is preferably carried out on a column on chiral phases or by recrystallization from an optically active solvent or by reaction with an optically active substance, forming salts or derivatives such as esters or amides, in particular with acids and their active derivatives or alcohols, with the racemic compound. diastereomeric salts in the form of mixtures or derivatives, for example due to different solubilities, whereby antipodes can be released from the pure racemic salts or derivatives by treatment with a suitable agent. Particularly useful optically active acids are, for example, the D- and L-forms of tartaric acid or dibenzoyltartaric acid, di-o-tolyltartaric acid, malic acid, mandelic acid, camphorsulfonic acid, glutamic acid, aspartic acid or quinic acid. Suitable optically active alcohol is, for example, (+) - or (-) - menthol and, as optically active acyl residue in amides, for example, (+) - or (-) - methyloxycarbonyl.

Ďalej môžu získané zlúčeniny vzorca I byť prevedené na svoje soli, najmä pre farmaceutické použitie na svoje fyziologicky prijateľné soli s anorganickými, alebo organickými kyselinami. Ako kyseliny tu prichádzajú do úvahy napríklad kyselina chlorovodíková, kyselina bromovodíková, kyselina sírová, kyselina fosforečná, kyselina octová, kyselina fumarová, kyselina jantárová, kyselina mliečna, kyselina citrónová, kyselina vinná alebo kyselina maleínová.Furthermore, the compounds of the formula I obtained can be converted into their salts, in particular for pharmaceutical use, into their physiologically acceptable salts with inorganic or organic acids. Suitable acids here are, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, acetic acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric acid or maleic acid.

Okrem toho sa nechajú takto získané nové zlúčeniny vzorca I, ak obsahujú karboxylovú skupinu, prípadne nakoniec previesť na svoje adičné soli s anorganickými alebo organickými bázami, najmä pre farmaceutické použitie na svoje fyziologicky prijateľné adičné soli. Ako bázy tu prichádzajú napríklad do úvahy hydroxid sodný, hydroxid draselný, amoniak, cyklohexylamín, etanolamín, dietanolamín a trietanolamín.In addition, the novel compounds of the formula I thus obtained, if they contain a carboxyl group, can optionally be converted into their addition salts with inorganic or organic bases, in particular for pharmaceutical use, into their physiologically acceptable addition salts. Suitable bases here are, for example, sodium hydroxide, potassium hydroxide, ammonia, cyclohexylamine, ethanolamine, diethanolamine and triethanolamine.

Zlúčeniny používané ako východiskové látky sú čiastočne známe z literatúry alebo je možné ich získať spôsobmi známymi z literatúry (viď. napríklad I až XXIV).The compounds used as starting materials are partly known from the literature or can be obtained by methods known in the literature (see, for example, I to XXIV).

Ako už bolo uvedené vykazujú tieto nové deriváty karboxylových kyselín všeobecného vzorca I a ich soli, najmä ich fyziologicky prijateľné soli s anorganickými alebo organickými kyselinami alebo bázami, cenné vlastnosti. Nové zlúčeniny všeobecného vzorca I, kde A predstavuje prípadne na dusíku substituovanú aminoalkylovú aza- alebo diazacykloalkylovú skupinu alebo pyridylovú alebo chinuklidinylovú skupinu alebo prípadne in vivo na aminoalkylovú, aza- alebo diazacykloalkylskupinu prevoditeľnú skupinu, napríklad na atóme dusíka alkoxykarbonylovou, alkenyloxykarbonylovou, aralkoxykarbonylovou, alkylkarbonylovou, trifluórmetylkarbonylovou, alkanoyloxymetoxykarbonylovou, cykloalkanoyloxymetoxykarbonylovou alebo aralkanoyloxymetoxykarbonylskupinou substituovanú aminoskupinu, aza- alebo diazacýkloalkylskupinu obsahujúcu -COORa na karboxyskupinu alebo skupinu prevoditeľnú in vivo na karboxylovú skupinu, napríklad alkoxylovú, alkenyloxylovú, fenylalkoxylovú, cykloalkyloxylovú, alkanoyloxyalkoxylovú, cykloalkanoyloxyalkoxylovú, fenylalkanoyloxyalkoxylovú, benzoyloxýalkoxylovú, alkoxykarbonyloxyalkoxylovú alebo cykloalkyloxykarbonylalkoxykarbonylovú skupinu, vykazujú cenné farmakologické vlastnosti vedia účinnosti potláčajúcej zápaly a odbúravanie kostí najmä antitrombotickú, antiagregačnú a nádory prípadne metastázy potláčajúcu účinnosť.As already mentioned, these novel carboxylic acid derivatives of the formula I and their salts, in particular their physiologically acceptable salts with inorganic or organic acids or bases, have valuable properties. Novel compounds of formula I wherein A represents an optionally substituted aminoalkyl aza- or diazacycloalkyl group or a pyridyl or quinuclidinyl group or, optionally, in vivo, a convertible group, for example a nitrogen atom, alkoxycarbonyl, alkenyloxycarbonyl, alkenyloxycarbonyl, alkenyloxycarbonyl, trifluormethylcarbonyl, alkanoyloxymetoxykarbonylovou, cykloalkanoyloxymetoxykarbonylovou aralkanoyloxymetoxykarbonylskupinou or substituted amino, aza, or -COOR comprising -diazacycloalkyl and carboxyl, convertible in vivo into a carboxy group, e.g. alkoxy, alkenyloxy, phenylalkoxy, cycloalkyloxy, alkanoyloxyalkoxylovú, cykloalkanoyloxyalkoxylovú, fenylalkanoyloxyalkoxylovú, benzoyloxýalkoxylovú, alkoxykarbonyloxyalkoxylovú group or cykloalkyloxykarbonylalkoxykarbonylovú show valuable the pharmacological properties are known to be effective in suppressing inflammation and bone breakdown, in particular antithrombotic, antiplatelet and tumor-suppressing metastases.

Zlúčeniny všeobecného vzorca I boli skúmané na svoju biologickú účinnosť napríklad následovne:The compounds of formula I have been investigated for their biological activity, for example, as follows:

oabout

1. Kompetitívna väzba H-BIBU 52/testovanej substancie na ľudské trombocytyCompetitive binding of H-BIBU 52 / test substance to human platelets

OABOUT

Suspenzia ľudských trombocytov v plazme ša zmieša s H BIBU 52 /=(3S,5S)-5-[(4’-amidino-4-bifenylyl)oxymetyl]-3- 26 [(karboxyl)metyl]-2-pyrolidinón-[3- Η-4-bifenylyl]/, ktorý nahrádza z literatúry známe ligandy -fibrinogén (viď.Plasma suspension of human platelets is mixed with H BIBU 52 / = (3S, 5S) -5 - [(4'-amidino-4-biphenylyl) oxymethyl] -3-26 [(carboxyl) methyl] -2-pyrrolidinone- [ 3- (4-biphenylyl)], which replaces the known ligands-fibrinogen (cf.

nemecká patentová prihláška P 42 14 245.8 rovnakej prihlasovatelky z 30.04.1992, interná značka: Čase 5/1093-FL) a inkubuje sa s rôznymi koncentráciami testovanej substancie. Voľný a naviazaný ligand sa oddelí odstredením a stanoví sa kvantitatívne scintilačným počtom. Z nameraných hodnôt sa stanoví potlačenie H-BIBU 52-väzby testovanou substanciou.German patent application P 42 14 245.8 of the same applicant from April 30, 1992, internal reference: Time 5/1093-FL) and incubated with different concentrations of the test substance. Free and bound ligand is collected by centrifugation and quantitated by scintillation counting. Suppression of H-BIBU 52-binding by the test substance is determined from the measured values.

Za týmto účelom sa z antikubitálnej žily darcu odoberie krv a antikoaguluje sa citrátom sodným (konečná koncentrácia 13 mM). Krv sa odstreďuje 10 minút pri 170 x g a odoberie sa supernatant na doštičky bohatej plazmy (PRP). Zvyšná krv sa na získanie plazmy ešte raz rýchlo odstredí. PRP sa zriedi 1:10 autolognou plazmou. 750 μΐ s 50 μΐ fyziologického chloridu sodného, 100 μΐ roztoku testovanej substancie, 50 μΐ 4C-sacharózy (3,700 Bq) a 50 μΐ ^H-BIBU 52 (konečná koncentrácia: 5 nM) sa inkubuje 20 minút pri teplote miestnosti. Na meranie nešpecifickej väzby sa namiesto testovanej substancie použije 5 μΐ BIBU 52 (konečná koncentrácia: 30μΜ). Vzorky sa odstreďujú 20 sekúnd pri 10000 x g a supernatant sa odoberie. 100 μΐ supernatantu sa použije na meranie voľného ligandu. Peleta sa rozpustí v 500 μΐ 0,2 N NaOH, 450 μΐ sa zmieša s 2 ml scintilátora a 25 μΐ 5 N HC1 a merá sa. Zvyšná plazma v pelete sa stanoví z obsahu ^4C, naviazaný ligand z ^H-merania. Po odčítaní nešpecifickej väzby sa vynesie koncentrácia testovanej substancie proti aktivite pelety a stanoví sa koncentrácia pre 50% potlačenie väzby.To this end, blood is drawn from the donor anticubital vein and anticoagulated with sodium citrate (final concentration 13 mM). The blood is centrifuged at 170 xg for 10 minutes and platelet-rich plasma (PRP) supernatant is collected. The remaining blood is rapidly centrifuged once more to obtain plasma. PRP is diluted 1:10 with autologous plasma. Incubate 750 μΐ with 50 μΐ physiological sodium chloride, 100 μΐ test substance solution, 50 μΐ 4 C-sucrose (3,700 Bq) and 50 μΐ ^ H-BIBU 52 (final concentration: 5 nM) for 20 minutes at room temperature. 5 μΐ BIBU 52 (final concentration: 30μΜ) is used instead of the test substance to measure non-specific binding. The samples are centrifuged for 20 seconds at 10,000 xg and the supernatant is collected. 100 μΐ of the supernatant is used to measure the free ligand. Dissolve the pellet in 500 μΐ 0,2 N NaOH, mix 450 μΐ with 2 ml scintillator and 25 μΐ 5 N HCl and measure. The residual plasma in the pellet is determined from a 44 C content, bound ligand from a HH-measurement. After subtraction of non-specific binding, the concentration of test substance against the pellet activity is plotted and the concentration for 50% binding suppression is determined.

2. Antitrombotická účinnosť2. Antithrombotic efficacy

Metodikamethodics

Agregácia trombocytov sa merá podľa metódy von Borna a Crossa (J. Physiol. 170, 397 (1964)) v plazme bohatej na doštičky získané od zdravých pokusných osôb. Na potlačenie zrážania sa krv zriedi 1:10 citrátom sodným 3,14 % (objemovýPlatelet aggregation is measured according to the method of von Born and Cross (J. Physiol. 170, 397 (1964)) in platelet-rich plasma obtained from healthy test subjects. To suppress clotting, blood is diluted 1:10 with sodium citrate 3.14% (v / v)

II

- 27 pomer).- 27 ratio).

Kolagénom vyvolaná agregáciaCollagen-induced aggregation

Registruje sa a fotometrický merá priebeh poklesu optickej hustoty po prídavku substancie, vyvolávajúcu agregáciu. Z uhla sklonu krivky hustoty sa stanoví rýchlosť agregácie. Bod na krivke, v ktorom sa vyskytuje najväčšia priechodnosť svetla, slúži na výpočet optical density.It records and measures photometric the decrease in optical density after the addition of the aggregation-inducing substance. The aggregation rate is determined from the angle of inclination of the density curve. The point on the curve at which the greatest light transmission occurs is to calculate the optical density.

Koncentrácia kolagénu sa volí čo možno najmenšia, ale predsa taká, že sa získa ireverzibilné prebiehajúca reakčná krivka. Použije sa obchodne dostupný kolagén od firmy Hormonchemie, Mníchov. Pred prídavkom kolagénu sa plazma inkubuje vždy 10 minút so substanciou pri 37 “C.The collagen concentration is chosen to be as small as possible, but such that an irreversibly running reaction curve is obtained. Commercially available collagen from Hormonchemie, Munich is used. Prior to the addition of collagen, the plasma is incubated with the substance at 37 ° C for 10 minutes.

Z kriviek koncentrácia-účinnosť sa vypočíta EC^q, ktorá opisuje koncentráciu, pri ktorej je zmeňa optical density potlačená z polovice maxima.From the concentration-efficiency curves, EC 50 is calculated, which describes the concentration at which the change in optical density is suppressed by half the maximum.

Nasledujúca tabuľka uvádza nájdené výsledky.The following table shows the results found.

Substancia (príklad č.) substance (example #) ú» V . kompetitívna väzba H-BIBU 52/ potlačenie ú »V. competitive binding of H-BIBU 52 / suppression 1 testovanej substancie na ľudských trombocytoch IC50 [nM]1 test substance on human platelets IC 50 [nM] agregácie doštičiek EC^q [nM] platelet aggregation EC ^ q [nM] 2 2 1100 1100 840 840 2.1 2.1 > 100000 > 100000 3300 3300 2.2 2.2 4500 4500 3300 3300 3 3 190 190 260 260 3.1 3.1 1400 1400 2400 2400 3.3 3.3 17 17 260 260 3.4 3.4 2000 2000 5800 5800 3.6 3.6 14 14 120 120 5 5 2900 2900 5600 5600

- 28 Potlačenie agregácie trombocytov po orálnom podaní skúšobnej substancie sa vykonáva ex vivo na opiciach Rhesus.Suppression of platelet aggregation following oral administration of test substance is performed ex vivo in Rhesus monkeys.

Priamo po orálnom podaní v Natrosolé suspendovanej skúšobnej substancie sa zvieratám odoberie vzorka krvi z kubitálnej žily. V definovaných časoch po podaní substancie sa odoberaj ú nové vzorky krvi a skúšaj ú ako j e ďalej uvedené.A blood sample is taken from the cubital vein directly after oral administration in the Natrosol suspended suspension substance. At defined times after administration of the substance, new blood samples are taken and tested as described below.

Krv zriedená 3,14% citrátom sodným v objemovom pomere 1:10 sa odstreďuje 15 minút pri 200 g. Supernatant na doštičky bohatej plazmy sa opatrne odoberie. Zo sedimentu bohatého na erytrocyty sa odstredením pri 4000 g po 10 minút získa ako supernatant na doštičky chudobná plazma.Blood diluted with 3.14% sodium citrate 1:10 is centrifuged at 200 g for 15 minutes. The plasma-rich platelet supernatant is carefully collected. From the erythrocyte-rich sediment, centrifugation at 4000 g for 10 minutes yields platelet-poor plasma as a supernatant.

Kolagénom (Hormonchemie, Mníchov, 2 pg/ml konečná koncentrácia v plazme chudobnej na doštičky) vyvolaná agregácia trombocytov sa fotometrický podľa metódy von Borna a Crossa (J. Physiol. 170, 397 (1964) zmerá v týchto vzorkách. Po kolagénovej stimulácii zmeraná najväčšia svetelná priepustnosť plazmy- chudobnej na doštičky sa porovnáva s referenčnou hodnotou na stanovenie potlačenia agregácie v rôznych časoch odberu krvi po podaní substancie vzhľadom’ k referenčnej hodnote .Collagen (Hormonchemie, Munich, 2 µg / ml final platelet-poor plasma concentration) induced platelet aggregation is measured photometrically according to the method of von Born and Cross (J. Physiol. 170, 397 (1964) in these samples. After collagen stimulation, the largest measured The light transmittance of the platelet-poor plasma is compared to a reference value to determine aggregation suppression at different times of blood collection after substance administration relative to the reference value.

Zlúčeniny z príkladu 2 a 5(2) potláčajú kolagénom indukovanú agregáciu trombocytov ex vivo po orálnom podaní 1 mg/kg po dobu dlhšiu než 2 hodiny.The compounds of Examples 2 and 5 (2) suppress collagen-induced platelet aggregation ex vivo after oral administration of 1 mg / kg for more than 2 hours.

Zlúčeniny podľa vynálezu sú dobre znášateľné, pretože napríklad pri intravenóznom podaní 30 mg/kg každej z 3 myší u zlúčenín z príkladu 2 a 3 neuhynulo žiadne zviera.The compounds of the invention are well tolerated because, for example, when the intravenous administration of 30 mg / kg of each of the 3 mice to the compounds of Examples 2 and 3, no animal died.

Na základe ich potláčajúceho pôsobenia na vzájomné pôsobenie bunka-bunka prípadne bunka-matrica, sú nové deriváty karboxylových kyselín všeobecného vzorca I a ich fyziologicky prijateľné soli vhodné na liečenie prípadne zmierňovanie chorôb, pri ktorých vznikajú väčšie alebo menšie bun29 kové agregáty alebo hrajú úlohu interakcie bunka-matrica, prípadne pri liečení alebo prevencii venóznych alebo cerebrovaskulárnych chorôb, pľúcnych embólií, srdcového infarktu, artériosklerózy, osteoporózy, metastazovania tumorov a terapii geneticky podmienených alebo aj získaných porúch interakcie buniek medzi sebou alebo s pevnými štruktúrami. Ďalej sú tieto zlúčeniny vhodné aj na podpornú terapiu pri trombolýze fibrinolytiky alebo pri cievnych intervenciách ako je transluminálna angioplastika alebo aj pri terapii šokových stavov, psoriázy, diabetu a zápalov.Because of their suppressing effect on cell-cell or cell-matrix interactions, the novel carboxylic acid derivatives of formula I and their physiologically acceptable salts are suitable for the treatment or alleviation of diseases in which larger or smaller cell aggregates are formed or play a role in cell interaction. - matrix, optionally in the treatment or prevention of venous or cerebrovascular diseases, pulmonary embolism, heart attack, arteriosclerosis, osteoporosis, tumor metastasis and therapy of genetically-related or also acquired cell interaction disorders with one another or with solid structures. Furthermore, the compounds are also useful in supportive therapy in thrombolysis of fibrinolytics or in vascular interventions such as transluminal angioplasty or in the treatment of shock conditions, psoriasis, diabetes and inflammation.

Na liečenie prípadne prevenciu uvedených chorôb sa používajú dávky medzi 0,1 gg a 30 mg/kg telesnej hmotnosti, výhodne 1 gg až 15 mg/kg telesnej hmotnosti, pri až 4 podaniach denne. Za týmto účelom je možné spracovať podľa vynálezu vyrobené zlúčeniny vzorca I, prípadne v kombinácii s inými účinnými substanciami ako sú antagonisti troraboxanových receptorov a látky, potláčajúce syntézu trómboxanu alebo ich kombinácie, antagonisti serotonínu, antagonisti receptorov, alkylnitráty ako je glycerínnitrát, látky, potláčajúce fosfordiesterázu, prostacyklín a jeho analóga, fibrinolytiká ako tPA, prourokináza, urokináza, streptokináza alebo antikoagulancia ako je heparín, dermatánsulfát, aktivovaný protein C, antagonisti vitamínu A, hirudín, inhibítory trombínu alebo iné aktivované faktory zrážania, spolu s jedným alebo viacerými inertnými obvyklými nosičmi a/alebo riedidlami, napríklad s kukuričným škrobom, mliečnym cukrom, trstinovým cukrom, mikrokryštalickou celulózou, stearátom horečnatým, polyvinylpyrolidónom, kyselinou citrónovou, kyselinou vinnou, vodou, vodou/etanolom, vodou/glycerínom, vodou/sorbitom, vodou/polyetylénglykolom, propylénglykolom, stearylalkoholom, karboxymetylcelulózou alebo substanciami, obsahujúcimi tuk, ako je stužený tuk alebo ich vhodnými zmesami, na bežné galenické prípravky ako sú tablety, dražé, kapsle, prášky, suspenzie, roztoky, spreje alebo čipky.Dosages between 0.1 gg and 30 mg / kg body weight, preferably 1 gg to 15 mg / kg body weight, are used for the treatment or prevention of said diseases, for up to 4 administrations per day. For this purpose, the compounds of the formula I prepared according to the invention can be processed, optionally in combination with other active substances such as troraboxane receptor antagonists and thromboxane synthesis inhibiting agents or combinations thereof, serotonin antagonists, receptor antagonists, alkyl nitrates such as glycerinnitrate , prostacyclin and an analogue thereof, fibrinolytics such as tPA, prourokinase, urokinase, streptokinase or anticoagulants such as heparin, dermatan sulfate, activated protein C, vitamin A antagonists, hirudin, thrombin inhibitors or other activated clotting factors, together with one or more inert excipients and usually / or diluents, for example with corn starch, milk sugar, cane sugar, microcrystalline cellulose, magnesium stearate, polyvinylpyrrolidone, citric acid, tartaric acid, water, water / ethanol, water / glycerin, water / with rbitus, water / polyethylene glycol, propylene glycol, stearyl alcohol, carboxymethylcellulose or fat containing substances such as hardened fat or suitable mixtures thereof, for conventional galenic preparations such as tablets, dragees, capsules, powders, suspensions, solutions, sprays or lace.

Nasledujúce príklady slúžia na bližšie vysvetlenie vynálezu.The following examples serve to explain the invention in more detail.

Príklady uskutočnenia vynálezuDETAILED DESCRIPTION OF THE INVENTION

Výroba východiskových zlúčenínProduction of starting compounds

PríkladIexample

4-(4-karboxyfenyl)piperidín-hydrochlorid4- (4-carboxyphenyl) piperidine hydrochloride

K roztoku 63,0 g l-acetyl-4-fenyl-piperidínu v 1000 ml metylénchloridu sa za dobrého miešania prikvapká pri -10 °C až -20 ’C 157,4 g oxalylchloridu. Potom sa pridá 46,7 g chloridu hlinitého. Mieša sa 1 hodinu pri -10 °C a pridá sa ďalších 82,7 g chloridu hlinitého. Po ďalších 2 hodinách sa chladiaci kúpe! odstráni a mieša sa 24 hodín pri teplote miestnosti. Reakčný roztok sa opatrne vmieša do asi 4 1 ladu/vody a vodná fáza sa dvakrát extrahuje metylénchloridom. Spojené organické fázy sa premyjú vodou, sušia sa nad síranom sodným a rozpúšťadlo sa odstráni za zníženého tlaku. Zvyšok sa rozpustí za silného miešania v 2,5 1 2 N hydroxidu sodného. K tmavému vodnému roztoku sa pridá ľad a okyslí sa koncentrovanou kyselinou chlorovodíkovou. Zrazenina sa odsaje na nuči, premyje sa vodou a zohrieva v 2 1 6 N kyseliny chlorovodíkovej 5 hodín pod refluxom. Rozpúšťadlo sa odstráni za zníženého tlaku. Zvyšná tuhá látka sa rozotrie s malým množstvom vody a odsaje na nuči.To a solution of 63.0 g of 1-acetyl-4-phenyl-piperidine in 1000 ml of methylene chloride, 157.4 g of oxalyl chloride is added dropwise at -10 ° C to -20 ° C with good stirring. 46.7 g of aluminum chloride are then added. Stir 1 hour at -10 ° C and add another 82.7 g of aluminum chloride. After another 2 hours the cooling bath! is removed and stirred at room temperature for 24 hours. The reaction solution is carefully mixed into about 4 L of ice / water and the aqueous phase is extracted twice with methylene chloride. The combined organic phases were washed with water, dried over sodium sulfate and the solvent was removed under reduced pressure. The residue was dissolved with vigorous stirring in 2.5 L of 2 N sodium hydroxide. Ice was added to the dark aqueous solution and acidified with concentrated hydrochloric acid. The precipitate is suction filtered, washed with water and heated in refluxing 2 L of 6 N hydrochloric acid for 5 hours. The solvent was removed under reduced pressure. The residual solid is triturated with a small amount of water and suction filtered.

Výťažok: 40,5 g (54 % teórie)Yield: 40.5 g (54% of theory)

Teplota topenia: 300 °CMelting point: 300 ° C

R^-hodnota: 0,07 (silikagél, metylénchlorid/metanol/konc. amoniak =4:1:0,25)Rf value: 0.07 (silica gel, methylene chloride / methanol / conc. Ammonia = 4: 1: 0.25)

Príklad IIExample II

1-terc.butyloxykarbonyl-4-(4-karboxyfenyl)piperidín1-tert-butyloxycarbonyl-4- (4-carboxyphenyl) piperidine

K 16,4 g hydroxidu sodného v 300 ml vody sa opatrne pridá 47,5 g 4-(4-karboxyfenyl)piperidín-hydrochloridu. Suspenzia sa zriedi 500 ml dioxánu a 250 ml vody. Potom sa po častiach pridá 54,6 g di-terc.butylesteru kyseliny pyrouhličitej. Mieša sa 16 hodín pri teplote miestnosti. Zrazenina sa odsaje na nuči a filtrát sa čiastočne odparí za zníženého tlaku. Zrazenina a zvyšný vodný filtrát sa spoja a zriedia 1 1 vody. Vodná fáza sa upraví na pH 2 nasýteným roztokom hydrogénsíranu draselného a dvakrát sa extrahuje etylacetátom. Spojené etylacetátové fázy sa premyjú nasýteným roztokom chloridu sodného, sušia nad síranom sodným a rozpúšťadlo sa odstráni za zníženého tlaku. Kryštalický surový produkt sa rozotrie s malým množstvom etylacetátu, odsaje sa na nuči a suší sa.To 16.4 g of sodium hydroxide in 300 ml of water was carefully added 47.5 g of 4- (4-carboxyphenyl) piperidine hydrochloride. The suspension is diluted with 500 ml dioxane and 250 ml water. Then 54.6 g of di-tert-butyl pyrocarbonate are added portionwise. Stir for 16 hours at room temperature. The precipitate is suction filtered and the filtrate is partially evaporated under reduced pressure. The precipitate and the remaining aqueous filtrate were combined and diluted with 1 L of water. The aqueous phase is adjusted to pH 2 with saturated potassium hydrogen sulphate solution and extracted twice with ethyl acetate. The combined ethyl acetate phases are washed with saturated sodium chloride solution, dried over sodium sulfate and the solvent is removed under reduced pressure. The crystalline crude product is triturated with a small amount of ethyl acetate, suction filtered and dried.

Výťažok: 54,0 g (90 % teórie)Yield: 54.0 g (90% of theory)

Teplota topenia: 172 až 174 °CMelting point: 172-174 ° C

Rj:-hodnota: 0,73 silikagél, etylacetát/cyklohexán = 4:1)Rj: -value: 0.73 silica gel, ethyl acetate / cyclohexane = 4: 1)

Príklad IIIExample III

3-(4-aminofenyl)-2-(n-butánsulfonylamino)propiónová kyselina ako metylester g metylesteru kyseliny 2-(n-butánsulfonylamino)-3(4-nitrofenyl)propiónovej sa spracováva v 200 ml etylacetátu za prítomnosti 2 g 10% paládia na uhlí 1,5 hodiny pri teplote miestnosti vodíkom pri tlaku 0,5 MPa. Katalyzátor sa odfiltruje, odparí a zvyšok sa použije bez ďalšieho čistenia. Výťažok: 17,8 g (100 % teórie)3- (4-aminophenyl) -2- (n-butanesulfonylamino) propionic acid as methyl ester g of 2- (n-butanesulfonylamino) -3 (4-nitrophenyl) propionic acid methyl ester is treated in 200 ml of ethyl acetate in the presence of 2 g of 10% palladium on carbon for 1.5 hours at room temperature with hydrogen at 0.5 MPa. The catalyst was filtered off, evaporated and the residue was used without further purification. Yield: 17.8 g (100% of theory)

Rf-hodnota: 0,43 (silikagél, cyklohexán/etylacetát = 1:1)Rf value: 0.43 (silica gel, cyclohexane / ethyl acetate = 1: 1)

Analogicky sa získa nasledujúca zlúčenina:The following compound is obtained analogously:

1) metylester kyseliny 3-(4-aminofenyl)propiónovej1) 3- (4-aminophenyl) propionic acid methyl ester

Vychádza sa z metylesteru kyseliny 4-nitroškoricovej a hydrogenuje sa pri 50 °C.Starting from methyl 4-nitro-cinnamate and hydrogenating at 50 ° C.

R^-hodnota: 0,76 (silikagél, cyklohexán/etylacetát = 1:3)Rf value: 0.76 (silica gel, cyclohexane / ethyl acetate = 1: 3)

Príklad IV metylester kyseliny 2-(n-butánsulfonylamino)-3-(4-nitrofenyl)propiónovejExample IV 2- (n-Butanesulfonylamino) -3- (4-nitrophenyl) propionic acid methyl ester

25,9 g hydrochloridu metylesteru kyseliny 2-amino-3-(4nitrofenyl)propiónovej sa suspenduje v 100 ml metylénchloridu a zmieša sa s 32 g N-etyl-diizopropylamínu, pričom sa rozpustí zrazenina. K roztoku sa pri 8 až 15 C pridá 17,1 g n-butánsulfonylchloridu v 20 ml metylénchloridu. Po 16-hodinovom miešaní pri teplote miestnosti sa za chladenia ľadom pridá 10 g N-etyl-diizopropylamínu a ešte raz sa prikvapká 8 g n-butánsulfonylchloridu a mieša sa ďalšie dve hodiny pri teplote miestnosti. Zmieša sa s ľadovou vodou, organická fáza sa postupne premyje vodou, 1 N kyselinou chlorovodíkovou a vodou a odparí sa. Zvyšok sa prečistí cez silikagél (elučné činidlo-metylénchlorid).25.9 g of 2-amino-3- (4-nitrophenyl) propionic acid methyl ester hydrochloride are suspended in 100 ml of methylene chloride and mixed with 32 g of N-ethyl-diisopropylamine to dissolve the precipitate. 17.1 g of n-butanesulfonyl chloride in 20 ml of methylene chloride are added to the solution at 8 to 15 ° C. After stirring at room temperature for 16 hours, 10 g of N-ethyl-diisopropylamine was added under ice-cooling, and 8 g of n-butanesulfonyl chloride was added dropwise again and stirred for another two hours at room temperature. It is mixed with ice water, the organic phase is washed successively with water, 1 N hydrochloric acid and water and evaporated. The residue was purified over silica gel (eluent-methylene chloride).

Výťažok: 19,4 g (57 % teórie)Yield: 19.4 g (57% of theory)

Teplota topenia: 100 až 102 °CMelting point: 100-102 ° C

Rjj-hodnota: 0,38 (silikagél, cyklohexán/etylacetát = 6:4)Rf value: 0.38 (silica gel, cyclohexane / ethyl acetate = 6: 4)

Príklad VExample V

Hydrochlorid metylesteru 2-amino-3-(4-nitrofenyl)propiónovej kyseliny g 4-nitrofenylamínu sa suspenduje v 250 ml metanolu a zmieša sa a 10 ml metanolickej kyseliny chlorovodíkovej, pričom sa rozpustí tuhý produkt. Nechá sa stáť 60 hodín pri teplote miestnosti a odparí sa vo vákuu. Produkt sa použije bez ďalšieho čistenia.2-Amino-3- (4-nitrophenyl) propionic acid methyl ester hydrochloride g 4-Nitrophenylamine is suspended in 250 ml of methanol and mixed with 10 ml of methanolic hydrochloric acid to dissolve the solid product. It was allowed to stand at room temperature for 60 hours and evaporated in vacuo. The product was used without further purification.

Výťažok: 25,9 g (99 % teórie)Yield: 25.9 g (99% of theory)

Teplota topenia: 206 až 208 °C (rozklad)Melting point: 206 to 208 ° C (decomposition)

R^-hodnota: 0,67 (reverzná fáza-doštička RP8, metanol/5% roztok chloridu sodného - 6:4)Rf value: 0.67 (reverse phase-plate RP8, methanol / 5% sodium chloride solution - 6: 4)

Analogicky sa získa nasledujúca zlúčenina:The following compound is obtained analogously:

Hydrochlorid metylesteru 3-(trans-4-aminocyklohexyl)propiónovej3- (trans-4-Amino-cyclohexyl) -propionic acid methyl ester hydrochloride

Teplota topenia: nad 200 °CMelting point: above 200 ° C

Príklad VIExample VI

Hydrochlorid kyseliny 3-(trans-4-aminocyklohexyl)propiónovej g kyseliny 3-(trans-4-acetamino-cyklohexyl)propiónovej sa zohrieva v 200 ml 6 N kyseliny chlorovodíkovej 16 hodín pod refluxom. Odparí sa vo vákuu do sucha a viackrát sa odparí po prídavku toluénu a metanolu. Zvyšok sa priamo použije ďalej.3- (trans-4-aminocyclohexyl) propionic acid hydrochloride g of 3- (trans-4-acetaminocyclohexyl) propionic acid is heated in 200 ml of 6 N hydrochloric acid under reflux for 16 hours. It is evaporated to dryness in vacuo and evaporated several times after addition of toluene and methanol. The residue is used directly.

Výťažok: 26 g (100 % teórie)Yield: 26 g (100% of theory)

Príklad VIIExample VII

Kyselina 3-(trans-4-acetamino-cyklohexyl)propiónová3- (trans-4-acetaminocyclohexyl) propionic acid

112,7 g kyseliny 3-(4-acetamino-fenyl)propiónovej a 10 g oxidu platičitého sa v 350 ml ľadovej kyseliny octovej pri 60 °C spracuje s vodíkom pri tlaku 0,5 MPa. Po 1,5 hodine a 7 hodinách sa vždy oxid platičitý vymení za nový. Celková doba reakcie je 10 hodín. Odparí sa vo vákuu do sucha a zvyšok sa kryštalizuje z 1800 ml acetónu. Primárny kryštalizát sa ešte rekryštalizuje z 50 ml 80% kyseliny octovej.112.7 g of 3- (4-acetaminophenyl) propionic acid and 10 g of platinum oxide are treated with hydrogen at 0.5 MPa in 350 ml of glacial acetic acid at 60 ° C. After 1.5 hours and 7 hours, the platinum oxide is always replaced with a new one. The total reaction time is 10 hours. It is evaporated to dryness in vacuo and the residue is crystallized from 1800 ml of acetone. The primary crystallizate is still recrystallized from 50 ml of 80% acetic acid.

Výťažok: 26 g (22,4 % teórie)Yield: 26 g (22.4% of theory)

Teplota topenia: 200 až 201 “CMelting point: 200 to 201 ° C

R^-hodnota: 0,30 (silikagél, metylénchlorid/etylacetát/ľadová kyselina octová = 4:1:0,4)Rf value: 0.30 (silica gel, methylene chloride / ethyl acetate / glacial acetic acid = 4: 1: 0.4)

Z acetónových materských luhov sa po odparení a po rekryštalizácii zo 100 ml vody získa 53,6 g (46 % teórie) cis-3-(4-acetamino-cyklohexyl)propiónovej.53.6 g (46% of theory) of cis-3- (4-acetaminocyclohexyl) propionic acid are obtained from the acetone mother liquors after evaporation and after recrystallization from 100 ml of water.

Príklad VIIIExample VIII

- 34 Hydrochlorid l-benzyl-4-(3-karboxy-fenyl)-3,4-dehydro-piperidínu g l-benzyl-4-(3-brómfenyl)-3,4-dehydro-piperidínu sa rozpustí v 300 ml tetrahydrofuránu. Ochladí sa na teplotu pod -65 °C a pri tejto teplote sa počas 30 minút prikvapká 47,6 ml 1,6 molárneho roztoku n-butyllítia v hexáne. Mieša sa ďalej ešte jednu hodinu a potom sa pomalým prúdom zavádza oxid uhličitý sušený cez koncentrovanú kyselinu sírovú. Teplota sa pritom udržuje najskôr 1 hodinu pod -65 °C, potom sa pomaly zvýši na teplotu miestnosti a reakčná zmes sa nechá stáť pri tejt.o teplote 60 hodín. Odparí sa do sucha zvyšok sa vyberie do 500 ml etylacetátu a extrahuje sa vodou. Vodné fázy sa odparia vo vákuu, ochladia na ľadovom kúpeli a pH sa upraví 2 N kyselinou chlorovodíkovou na hodnotu 1. Vylúčené kryštály sa odfiltrujú a premyjú sa vodou.- 34 1-Benzyl-4- (3-carboxy-phenyl) -3,4-dehydro-piperidine hydrochloride g 1-Benzyl-4- (3-bromophenyl) -3,4-dehydro-piperidine is dissolved in 300 ml of tetrahydrofuran . It is cooled to below -65 ° C and 47.6 ml of a 1.6 molar solution of n-butyllithium in hexane is added dropwise over 30 minutes. Stirring is continued for an additional hour and then carbon dioxide dried through concentrated sulfuric acid is introduced in a slow stream. The temperature is kept below -65 ° C for 1 hour, then slowly raised to room temperature and the reaction mixture is allowed to stand at this temperature for 60 hours. It is evaporated to dryness and the residue is taken up in 500 ml of ethyl acetate and extracted with water. The aqueous phases are evaporated in vacuo, cooled in an ice bath, and the pH is adjusted to 1 with 2N hydrochloric acid. The precipitated crystals are filtered off and washed with water.

Výťažok: 9 g (40 % teórie)Yield: 9 g (40% of theory)

Teplota topenia: pri 185 °C (rozklad).Melting point: 185 DEG C. (decomposition).

R.f-hodnota: 0,50 (doštička RP8 s reverznou fázou, metanol/R.f-value: 0.50 (reversed phase RP8 plate, methanol /

5% roztok chloridu sodného = 6:4)5% sodium chloride solution = 6: 4)

Príklad IX l-benzyl-4-(3-brómfenyl)-3,4-dehydro-piperidínExample IX 1-Benzyl-4- (3-bromophenyl) -3,4-dehydro-piperidine

29,6 g l-benzyl-4-(3-brómfenyl)-4-hydroxy-piperidínu,29.6 g of 1-benzyl-4- (3-bromophenyl) -4-hydroxy-piperidine,

32,5 g hydrátu kyseliny p-toulénsulfónovej a 300 ml toluénu sa zohrieva 2 hodiny na odlučovači vody. Po ochladení sa zriedi metylénchloridom, pridá sa ľadová voda a zalkalizuje sa 30% hydroxidom sodným. Vodná fáza sa ešte raz extrahuje metylénchloridom a spojené organické fázy sa odparia. Výťažok: 25,2 g (90 % teórie)32.5 g of p-toluenesulfonic acid hydrate and 300 ml of toluene were heated in a water separator for 2 hours. After cooling, dilute with methylene chloride, add ice water and basify with 30% sodium hydroxide. The aqueous phase is extracted once more with methylene chloride and the combined organic phases are evaporated. Yield: 25.2 g (90% of theory)

R^-hodnota: 0,69 (silikagél, metylénchlorid/metanol = 100:2)Rf value: 0.69 (silica gel, methylene chloride / methanol = 100: 2)

Príklad X l-benzyl-4-(3-brómfenyl)-4-hydroxy-piperidínExample X 1-Benzyl-4- (3-bromophenyl) -4-hydroxy-piperidine

- 35 K roztoku 35,7 g 1,3-dibrómbenzénu v 200 ml éteru sa počas 25 minút prikvapká pri teplote pod 0 ’C 93,1 ml 1,6molárneho roztoku n-butyllítia v hexáne. Ďalej sa mieša 40 minút a potom sa pri teplote pod 10 prikvapká roztok 28,2 g čerstvo destilovaného l-benzyl-4-piperidónu v 40 ml éteru. Ešte 30 minút sa mieša pri tejto teplote a potom 1 hodinu pri teplote miestnosti. Zmieša sa s 500 ml nasýteného roztoku chloridu sodného, vodná fáza sa ešte dvakrát extrahuje etylacetátom, organické fázy sa odparia vo vákuu a zvyšok sa čistí stĺpcovou chromatografiou na silikagéli (elučné činidlo: metylénchlorid/metanol = 100:2).- 35 To a solution of 35.7 g of 1,3-dibromobenzene in 200 ml of ether is added dropwise over 25 minutes at a temperature below 0 ° C 93.1 ml of a 1.6 molar solution of n-butyllithium in hexane. After stirring for 40 minutes, a solution of 28.2 g of freshly distilled 1-benzyl-4-piperidone in 40 ml of ether is added dropwise at a temperature below 10. It was stirred at this temperature for 30 minutes and then at room temperature for 1 hour. It is mixed with 500 ml of saturated sodium chloride solution, the aqueous phase is extracted twice more with ethyl acetate, the organic phases are evaporated in vacuo and the residue is purified by silica gel column chromatography (eluent: methylene chloride / methanol = 100: 2).

Výťažok: 29,6- g (56 % teórie)Yield: 29.6 g (56% of theory)

R^-hodnota: 0,34 (silikagél, metylénchlorid/metanol = 100:2)Rf value: 0.34 (silica gel, methylene chloride / methanol = 100: 2)

Príklad XIExample XI

Kyselina 3-(4-acetaminofenyl)propiónová3- (4-Acetaminophenyl) propionic acid

155 g 3-(4-acetaminofenyl)propiónovej kyseliny vo forme metylesteru sa rozpustí v 1000 ml metanolu, zohreje sa na 50 ’C a zmieša sa so 700 ml hydroxidu sodného. Nechá sa ochladiť na teplotu miestnosti a ešte sa mieša 3 hodiny. 0chladí sa na ľadovom kúpeli, pridá sa 750 ml 2 N kyseliny chlorovodíkovej a mieša sa jednu hodinu za chladenia ľadom. Zrazenina sa odfiltruje a premyje malým množstvom ľadovej vody.155 g of 3- (4-acetaminophenyl) propionic acid methyl ester are dissolved in 1000 ml of methanol, heated to 50 ° C and mixed with 700 ml of sodium hydroxide. It was allowed to cool to room temperature and stirred for 3 hours. Cool in an ice bath, add 750 ml of 2 N hydrochloric acid and stir for one hour with ice cooling. The precipitate was filtered off and washed with a little ice water.

Výťažok: 112,7 g (77,6 % teórie)Yield: 112.7 g (77.6% of theory)

Teplota topenia: 144 až 147 ’CMelting point: 144-147 ° C

R^-hodnota: 0,25 (silikagél, metylénchlorid/etylacetát/ľadová kyselina octová = 8:1:0,4)Rf value: 0.25 (silica gel, methylene chloride / ethyl acetate / glacial acetic acid = 8: 1: 0.4)

Príklad XIIExample XII

Metylester kyseliny 3-(4-acetaminofenyl)propiónovej3- (4-Acetaminophenyl) propionic acid methyl ester

138,4 g metylesteru kyseliny 3-(4-aminofenyl)propiónovej sa rozpustí v 100 ml metylénchloridu a pridá sa 119 ml trietylamínu. Zmes sa ochladí na teplotu pod 0 ’C a po kvapkách sa počas 35 minút pri 0 °C až 10 °C zmieša s 58 ml acetylchloridu v 200 ml metylénchloridu. Mieša sa ďalej jednu hodinu pri 0 °C, zmieša sa s 300 ml vody, organická fáza sa ešte dvakrát extrahuje vodou a odparí vo vákuu.138.4 g of methyl 3- (4-aminophenyl) propionate are dissolved in 100 ml of methylene chloride and 119 ml of triethylamine are added. The mixture is cooled to below 0 ° C and treated dropwise with 58 ml of acetyl chloride in 200 ml of methylene chloride over 35 minutes at 0 ° C to 10 ° C. Stirring is continued for one hour at 0 [deg.] C., 300 ml of water are added, the organic phase is extracted twice more with water and evaporated in vacuo.

Výťažok: 155,5 g (91 % teórie)Yield: 155.5 g (91% of theory)

Teplota topenia: 118 až 120 °CMelting point: 118-120 ° C

Rf-hodnota: 0,50 (silikagél, cyklohexán/etylacetát = 1:3)Rf value: 0.50 (silica gel, cyclohexane / ethyl acetate = 1: 3)

Príklad XIIIExample XIII

4-[4-[[4-[2-(metoxykarbonyl)etyl]fenyl]aminometyl]fenyl]-1trifluóracetyl-piperidín4- [4 - [[4- [2- (methoxycarbonyl) ethyl] phenyl] aminomethyl] phenyl] piperidin--1trifluóracetyl

6,9 g 4-(4-formylfenyl)-l-trifluóracetyl-piperidínu a 4,33 g 3-(4-aminofenyl)propiónovej kyseliny vo forme metylesteru sa zohrieva v 5 ml toluénu 5 hodín pod refluxom na odlučovači vody. Odparí sa vo vákuu a produkt sa použije bez ďalšieho čistenia.6.9 g of 4- (4-formylphenyl) -1-trifluoroacetyl-piperidine and 4.33 g of 3- (4-aminophenyl) propionic acid methyl ester were heated in 5 ml of toluene under reflux on a water separator for 5 hours. Evaporate in vacuo and use the product without further purification.

Výťažok: 10,8 g (100 % teórie)Yield: 10.8 g (100% of theory)

R^-hodnota: 0,43 (silikagél, cyklohexán/etylacetát = 2:1)Rf value: 0.43 (silica gel, cyclohexane / ethyl acetate = 2: 1)

Príklad XIVExample XIV

4-(4-formylfenyl)-l-trifluóracetyl-piperidín4- (4-formylphenyl) -L-trifluoroacetyl-piperidine

K roztoku 8,3 g (4-fenyl-l-trifluóracetyl-piperidínu v 30 ml metylénchloridu sa pri teplote pod 0 °C prikvapká 7,8 ml chloridu titaničitého. Po 10 minútach sa v priebehu 40 minút prikvapká 3,5 ml dichlórmetylmetyléteru, pričom sa teplota udržuje pod 0 °C. Nechá sa stáť 16 hodín pri teplote miestnosti, naleje sa na ľadovú vodu a vodná fáza sa extrahuje viackrát metylénchloridom. Organické fázy sa odparia vo vákuu a zvyšok sa prečistí chromatograficky na stĺpci silikagélu (elučné činidlo: cyklohexán/etylacetát =2:1). Výťažok: 6,9 g (75 % teórie)To a solution of 8.3 g of (4-phenyl-1-trifluoroacetyl-piperidine in 30 ml of methylene chloride) was added dropwise 7.8 ml of titanium tetrachloride at a temperature below 0 DEG C. After 10 minutes, 3.5 ml of dichloromethyl methyl ether was added dropwise over 40 minutes. while keeping the temperature below 0 ° C, allowed to stand at room temperature for 16 hours, poured onto ice water and the aqueous phase extracted several times with methylene chloride. (ethyl acetate = 2: 1) Yield: 6.9 g (75% of theory).

Teplota topenia: 76 až 77 °CMp 76-77 ° C

- 37 R^-hodnota: 0,42 (silikagél, cyklohexán/etylacetát = 2:1)- 37 Rf value: 0.42 (silica gel, cyclohexane / ethyl acetate = 2: 1)

Príklad XVExample XV

4-fenyl-1-trifluóracetyl-piperidín g 4-fenyl-piperidínu sa rozpustí v 250 ml metylénchloridu, zmieša s 29,8 ml N-etyl-diizopropylamínu a ochladí na 0 °C. K roztoku sa prikvapká 24,1 ml anhydridu kyseliny trifluóroctovej tak, že teplota neprekročí 10 °C. Mieša sa ešte 30 minút pri 0 °C, nechá sa vystúpiť na teplotu miestnosti , pridá, sa 100 ml vody a organická fáza sa ešte dvakrát premyje vodou. Metylénchloridová fáza sa odparí a zvyšok sa použije bez ďalšieho čistenia.4-Phenyl-1-trifluoroacetyl-piperidine 4-Phenyl-piperidine (g) is dissolved in 250 ml of methylene chloride, treated with 29.8 ml of N-ethyl-diisopropylamine and cooled to 0 ° C. 24.1 ml of trifluoroacetic anhydride are added dropwise such that the temperature does not exceed 10 ° C. Stirring is continued for 30 minutes at 0 ° C, allowed to come to room temperature, 100 ml of water are added and the organic phase is washed twice more with water. The methylene chloride phase was evaporated and the residue was used without further purification.

Výťažok: 40 g (100 % teórie)Yield: 40 g (100% of theory)

R^-hodnota: 0,90 (silikagél, cyklohexán/etylacetát = 1:1)Rf value: 0.90 (silica gel, cyclohexane / ethyl acetate = 1: 1)

P r í k 1 a d XVIExample XVI

4-(4-aminofenyl)-l-trifluóracetyl-piperidín4- (4-aminophenyl) piperidin-trifluoroacetyl

a) 4-fenyl-l-trifluóracetyl-piperidín(a) 4-phenyl-1-trifluoroacetyl-piperidine

K roztoku 125 g (0,775 mol) 4-fenyl-piperidínu a 149 ml (0,775 mol) Ν,Ν-diizopropyl-etylamínu v 1300 ml dichlórmetánu sa pridá pri -5 °C za miešania počas 2 hodín po kvapkáchTo a solution of 125 g (0.775 mol) of 4-phenyl-piperidine and 149 ml (0.775 mol) of Ν, Ν-diisopropylethylamine in 1300 ml of dichloromethane is added dropwise at -5 ° C with stirring for 2 hours

120,5 ml (0,775 mol) anhydridu kyseliny trifluóroctovej. Potom sa mieša ďalšiu hodinu za chladenia ľadom, nechá sa stáť cez noc pri teplote miestnosti a potom sa zriedi 400 ml vody. Dichlórmetánová fáza sa oddelí, 2x premyje vždy 400 ml vody, suší sa nad síranom sodným a odparí za vákua do sucha. Výťažok: 193 g (97 % teórie) žlté kryštály120.5 ml (0.775 mol) of trifluoroacetic anhydride. It is then stirred for an additional hour under ice-cooling, allowed to stand overnight at room temperature and then diluted with 400 ml of water. The dichloromethane phase is separated, washed twice with 400 ml of water each time, dried over sodium sulphate and evaporated to dryness in vacuo. Yield: 193 g (97% of theory) of yellow crystals

R^-hodnota: 0,88 (silikagél, cyklohexán/etylacetát = 1:1)Rf value: 0.88 (silica gel, cyclohexane / ethyl acetate = 1: 1)

b) 4-(4-nitrofenyl)-l-trifluóracetyl-piperidín g (0,311 mol) pod a) získaného surového 4-fenyl-ltrifluóracetyl-piperidínu sa rozpustí v zmesi 400 ml ľadovej kyseliny octovej a 200 ml acetánhydridu. Tento roztok sa ochladí na ľadovom kúpeli na 10 °C a za miešania sa zmieša s 1,6 g dusitanu sodného a potom po kvapkách 51,9 ml (0,311 mol) dymovej kyseliny dusičnej. Nechá sa stáť cez noc pri teplote miestnosti a potom sa naleje na 100 ml vody, ktorá obsahuje 200 g ľadu. Pomocou 8 N hydroxidu sodného sa počasb) 4- (4-nitrophenyl) -1-trifluoroacetyl-piperidine g (0.311 mol) under a) of the obtained crude 4-phenyl-1-trifluoroacetyl-piperidine was dissolved in a mixture of 400 ml of glacial acetic acid and 200 ml of acetic anhydride. This solution is cooled to 10 ° C in an ice bath and treated with stirring with 1.6 g of sodium nitrite and then dropwise with 51.9 ml (0.311 mol) of fuming nitric acid. It is allowed to stand overnight at room temperature and then poured onto 100 ml of water containing 200 g of ice. Use 8 N sodium hydroxide for a period of 2 hours

4,5 hodiny za chladenia upraví pH na hodnotu 8 a síce tak, že teplota nepresiahne 20 °C. Extrahuje sa celkom 2000 ml dichlórmetánu, premyjú sa dichlórmetánové extrakty 100 ml 0,1 N hydroxidu sodného a potom 2x vodou, sušia sa nad síranom sodným a odparia sa za vákuu do sucha. Zvyšok sa kryštalizuje z etylacetátu/cyklohexánu.The pH is adjusted to 8 with cooling so that the temperature does not exceed 20 ° C with cooling for 4.5 hours. It is extracted with a total of 2000 ml of dichloromethane, washed with dichloromethane extracts with 100 ml of 0.1 N sodium hydroxide and then twice with water, dried over sodium sulphate and evaporated to dryness in vacuo. The residue was crystallized from ethyl acetate / cyclohexane.

Výťažok: 54,5 g (58 % teórie) žlté kryštályYield: 54.5 g (58% of theory) of yellow crystals

Teplota topenia: 100 až 102 °CMelting point: 100-102 ° C

c) 4-(4-aminofenyl)-l-trifluóracetyl-piperidínc) 4- (4-aminophenyl) -1-trifluoroacetyl-piperidine

Zlúčenina vyrobená pod b) sa rozpustí v 700 ml etylacetátu a po prídavku 7 g paládia na uhlí (10%) sa hydrogenuje pri teplote miestnosti a tlaku vodíka 0,3 MPa. Katalyzátor sa odfiltruje a etylacetátový roztok sa odparí vo vákuu do sucha.The compound prepared under b) is dissolved in 700 ml of ethyl acetate and, after addition of 7 g of palladium on carbon (10%), hydrogenated at room temperature and a hydrogen pressure of 0.3 MPa. The catalyst was filtered off and the ethyl acetate solution was evaporated to dryness in vacuo.

Výťažok: 39,7 g (kvantitatívny)Yield: 39.7 g (quantitative)

R^-hodnota: 0,25 (silikagél, cyklohexán/etylacetát = 1:1)Rf value: 0.25 (silica gel, cyclohexane / ethyl acetate = 1: 1)

Príklad XVIIExample XVII

1-terc.butyloxykarbonyl-4-[4-[[4-[2-(metoxykarbonyl)etyl]piperidino]metyl]fenyl]piperidín1-tert-butyloxycarbonyl-4- [4 - [[4- [2- (methoxycarbonyl) ethyl] piperidino] methyl] phenyl] piperidine

a) 1-terc.butyloxykarbonyl-4-(4-hydroxymetylfenyl)piperidína) 1-tert-Butyloxycarbonyl-4- (4-hydroxymethylphenyl) piperidine

K roztoku 5 g (0,0164 mol) 1-terc.butyloxykarbonyl-4(4-karbonylfenyl)piperidínu a 1,66 g (0,0164 mol) = 2,28 ml trietylamínu v 100 ml tetrahydrofuránu sa prikvapká za miešania pri 5 °C roztok 1,78 g (0,0164 mol) = 1,57 ml etylesteru kyseliny chlórmravčej v 10 ml tetrahydrofuránu a mieša sa pri tejto teplote ďalšiu hodinu. Vylúčený hydrochlorid trietylamínu sa odsaje a premyje tetrahydrofuránom. Spojené tetrahydrofuránové fázy sa nakvapkajú za miešania a pri 10 až 15 °C do roztoku 1,55 g (0,0141 mol) nátriumbórhydridu. Po miešaní cez noc pri teplote miestnosti sa odparí za vákua do sucha. Zvyšok sa rozdelí medzi etylacetát a IN roztok hydroxidu sodného. Etylacetátové fázy sa premyjú vodou, sušia nad síranom sodným a odparia za vákua do sucha. Zvyšok sa kryštalizuje z petroléteru.To a solution of 5 g (0.0164 mol) of 1-tert-butyloxycarbonyl-4- (4-carbonylphenyl) piperidine and 1.66 g (0.0164 mol) = 2.28 ml of triethylamine in 100 ml of tetrahydrofuran is added dropwise with stirring at 5 ml. ° C solution of 1.78 g (0.0164 mol) = 1.57 ml of ethyl chloroformate in 10 ml of tetrahydrofuran and stirred at this temperature for an additional hour. The resulting triethylamine hydrochloride is filtered off with suction and washed with tetrahydrofuran. The combined tetrahydrofuran phases were added dropwise with stirring and at 10-15 ° C to a solution of 1.55 g (0.0141 mol) of sodium borohydride. After stirring overnight at room temperature, it is evaporated to dryness in vacuo. The residue was partitioned between ethyl acetate and 1N sodium hydroxide solution. The ethyl acetate phases are washed with water, dried over sodium sulphate and evaporated to dryness in vacuo. The residue was crystallized from petroleum ether.

Výťažok: 4,05 g (84,7 % teórie)Yield: 4.05 g (84.7% of theory)

Teplota topenia: 78 až 80 °C.Melting point: 78 to 80 ° C.

b) 1-terc.butyloxykarbonyl-4-(4-chlórmetylfenyl)piperidínb) 1-tert-butyloxycarbonyl-4- (4-chloromethylphenyl) piperidine

Roztok 3,95 g (0,0136 mol) zlúčeniny a) a 2,74 g (0,0271 mol) = 3,8 ml trietylamínu v 80 ml dichlórmetánu sa pomaly a za miešania zmieša s 3,1 g (0,0271 mol) = 2,1 ml mesylchloridu. Po skončení pridávania sa nechá stáť cez noc a potom sa číry roztok odparí do sucha. Zvyšok sa chromatograf uj e cez silikagél, pričom ako elučné činidlo slúži dichlórmetán.A solution of 3.95 g (0.0136 mol) of (a) and 2.74 g (0.0271 mol) = 3.8 ml of triethylamine in 80 ml of dichloromethane is slowly mixed with 3.1 g (0.0271) with stirring. mol) = 2.1 ml mesyl chloride. After completion of the addition, it is allowed to stand overnight and then the clear solution is evaporated to dryness. The residue is chromatographed over silica gel, eluting with dichloromethane.

Výťažok: 3,75 g (89 % teórie)Yield: 3.75 g (89% of theory)

Teplota topenia: 56 až 58 ’CMelting point: 56-58 ° C

R^-hodnota: 0,47 (silikagél, dichlórmetán)Rf value: 0.47 (silica gel, dichloromethane)

c) 1-terc.butyloxykarbonyl-4-[4-[[4-[2-(metoxykarbonyl)etyl]piperidino]metyl]fenyl]piperidínc) 1-tert-butyloxycarbonyl-4- [4 - [[4- [2- (methoxycarbonyl) ethyl] piperidino] methyl] phenyl] piperidine

Zmes 1,8 g (0,0058 mol) zlúčeniny vyrobenej pod b) 1,44 g (0,007 mol) hydrochloridu metylesteru kyseliny piperidinopropiónovej, 1,42 g = 1,95 ml (0,014 mol) trietylamínu a 3 g jodidu sodného v 150 ml chloroformu sa zohrievajú 36 hodín na teplotu refluxu. Potom sa odsaje nerozpustný podiel. Filtrát sa dvakrát premyje vodou, suší sa nad síranom sodným a odparí sa za vákua. Zvyšok sa prečistí pomocou chromatografie na silikagéli, pričom ako elučné činidlo slúži metylénchlorid/metanol (35:1).A mixture of 1.8 g (0.0058 mol) of the compound produced under b) 1.44 g (0.007 mol) of methyl piperidinopropionate hydrochloride, 1.42 g = 1.95 ml (0.014 mol) of triethylamine and 3 g of sodium iodide in 150 ml. ml of chloroform are heated at reflux temperature for 36 hours. The insoluble matter is then aspirated. The filtrate was washed twice with water, dried over sodium sulfate and evaporated in vacuo. The residue was purified by silica gel chromatography eluting with methylene chloride / methanol (35: 1).

Výťažok: 2,05 g (79,8 % teórie) živicaYield: 2.05 g (79.8% of theory) of resin

R^-hodnota: 0,41 (silikagél, dichlórmetán/metanol = 9,5:0,5)Rf value: 0.41 (silica gel, dichloromethane / methanol = 9.5: 0.5)

Analogicky sa získa nasledujúca zlúčenina:The following compound is obtained analogously:

1) 1-terc.butyloxykarbonyl-4-[4-[[trans-4-[2-(metoxykarbonyl)etyl]cyklohexyl]aminometyl]fenyl]piperidín1) 1-tert-butyloxycarbonyl-4- [4 - [[trans -4- [2- (methoxycarbonyl) ethyl] cyclohexyl] aminomethyl] phenyl] piperidine

Vyrobí sa z 1-terc.butyloxykarbonyl-4-(4-chlórmetylfenyl)piperidínu a metylesteru kyseliny trans-3-[4-aminocyklohexán]propiónovej.Prepared from 1-tert-butyloxycarbonyl-4- (4-chloromethylphenyl) piperidine and trans -3- [4-aminocyclohexane] propionic acid methyl ester.

živicaresin

Príklad XVIIIExample XVIII

1-[terc.butyloxykarbonyl]-4-[4-[[trans-4-metoxykarbonylcyklohexyl]aminokarbonylamino]fenyl]piperidín1- [tert-butyloxycarbonyl] -4- [4 - [[trans-4-metoxykarbonylcyklohexyl] aminocarbonyl amino] phenyl] piperidine

Roztok 1,2 g (0,0044 mol) 1-terc.butyloxykarbonyl-4-[4aminofenyl]piperidínu a 0,8 g (0,0044 mol) trans-[4-metoxykarbonyl-cyklohexyl]izokyanátu v 20 ml dioxánu sa počas 2 hodín zohrieva na 50 C. Potom sa za zníženého tlaku odparí do sucha a tuhý zvyšok sa mieša s terc.butylmetyléterom. Zvyšné tuhé častice sa odsajú, premyjú sa terc.butylmetyléterom a sušia sa.A solution of 1.2 g (0.0044 mol) of 1-tert-butyloxycarbonyl-4- [4-aminophenyl] piperidine and 0.8 g (0.0044 mol) of trans- [4-methoxycarbonyl-cyclohexyl] isocyanate in 20 ml of dioxane was added during It is heated to 50 DEG C. for 2 hours. It is then evaporated to dryness under reduced pressure and the solid residue is stirred with tert-butyl methyl ether. The residual solids are aspirated, washed with tert-butyl methyl ether and dried.

Rjp-hodnota: 0,30 (silikagél, cyklohexán/etylacetát = 1:1)Rf value: 0.30 (silica gel, cyclohexane / ethyl acetate = 1: 1)

Príklad XIXExample XIX

1-terc.butyloxykarbonyl-[4-[[trans-4-[2-(metoxykarbonyl)etyl]cyklohexyl]aminokarbonyl]piperidino]piperidín1-tert-butyloxycarbonyl [4 - [[trans-4- [2- (methoxycarbonyl) ethyl] cyclohexyl] aminocarbonyl] piperidino] piperidine

a) 1-terc.butyloxykarbonyl-4-[4-[(4-etoxykarbonyl)piperidino]piperidína) 1- tert -Butyloxycarbonyl-4- [4 - [(4-ethoxycarbonyl) piperidino] piperidine

Zmes 24,9 g (0,1249 mol) N-terc.butyloxykarbonyl-4-pi41 peridónu, 19,3 ml (0,1249 mol) etylesteru kyseliny piperidino-4-karboxylovej a 46,5 ml (0,1562 mol) titán(IV)-izopropylátu sa počas jednej hodiny mieša pri teplote miestnosti. Pridá sa 170 ml bezvodého etanolu a potomA mixture of 24.9 g (0.1249 mol) of N-tert-butyloxycarbonyl-4-pi41 peridone, 19.3 ml (0.1249 mol) of piperidino-4-carboxylic acid ethyl ester and 46.5 ml (0.1562 mol) the titanium (IV) -isopropylate was stirred at room temperature for one hour. 170 ml of anhydrous ethanol are added and then

5,3 g 0,0837 mol) nátriumkyanobórhydridu a mieša sa ďalších 20 hodín. Potom sa zmieša s 34 ml vody, odsaje sa vylúčený tuhý podiel a premyje sa etanolom. Spojené filtráty sa odparia do sucha. Zvyšok sa rozpustí v etylacetáte. Anorganický nerozpustný podiel sa odfiltruje a filtrát sa za vákua odparí do sucha. Zvyšok sa prečistí pomocou chromatografie cez stĺpec silikagélu, pričom sa ako elučné činidlo použije etylacetát/cyklohexán = 3:2).5.3 g of 0.0837 mol) of sodium cyanoborohydride and stirred for a further 20 hours. It is then mixed with 34 ml of water, the precipitated solid is filtered off with suction and washed with ethanol. The combined filtrates were evaporated to dryness. The residue was dissolved in ethyl acetate. The inorganic insoluble matter was filtered off and the filtrate was evaporated to dryness in vacuo. The residue was purified by silica gel column chromatography using ethyl acetate / cyclohexane = 3: 2 as eluent.

Výťažok: 32,9 g olej ovitej substancie (77,3 % teórie) Rf-hodnota: 0,36 (silikagél, etylacetát)Yield: 32.9 g of oily substance (77.3% of theory) Rf value: 0.36 (silica gel, ethyl acetate)

b) 1-terc.butyloxykarbonyl-4-[4-[[trans-4-[2-(metoxykarbonyl)etyl]cyklohexyl]aminokarbonyl]piperidino]piperidínb) 1- tert -Butyloxycarbonyl-4- [4 - [[trans -4- [2- (methoxycarbonyl) ethyl] cyclohexyl] aminocarbonyl] piperidino] piperidine

3,4 g (0,01 mol) pod a) vyrobenej zlúčeniny sa cez noc mieša v 20 ml 1 N hydroxidu sodného. Po tejto dobe došlo k úplnému zmydelneniu etylesteru. Pridá sa 20 ml 1 N kyseliny chlorovodíkovej a premyje sa etylacetátom. Vodná fáza sa odparí za vákua do sucha, zvyšok sa dvakrát vyberie do etanolu, vždy sa potom odparí do sucha a potom sa suší za vákua pri 80 °C. Zvyšok sa rozpustí v 100 ml dimetylformamidu. Tento roztok sa zmieša s 2 ml (0,0102 mol) difenylfosforylchloridu, ochladí sa na -5 °C, za miešania sa pridá 1,4 ml (0,0102 mol) trietylamínu a mieša sa ďalej pri -5 °C jednu hodinu. Potom sa pridá 2,26 g (0,0102 mol) trans-3-[4-aminocyklohexyl]propiónovej kyseliny vo. forme hydrochloridu metylesteru a 1,4 ml (0,0102 mol) trietylamínu a mieša sa ďalšie 4 hodiny pri teplote miestnosti a potom 1 hodinu pri 60 °C. Pre úplné prebehnutie reakcie sa znova pridá 1 ml difenylfosforylchloridu a 1,4 ml trietylamínu a mieša sa cez noc pri teplote miestnosti. Potom sa za vákua odparí do sucha, zvyšok sa vyberie so etylacetátu, etylacetátový roztok sa dvakrát premyje nasýteným roztokom hydro42 génuhličitanu sodného a raz vodou a suší sa nad síranom sodným. Po odparení za vákua zostanú 4 g zvyšku, ktorý sa prečistí stĺpcovou chromatografiou na silikagéli za použitia dichlórmetánu/metanolu = 20:1 a 10:1 ako elučného činidla.3.4 g (0.01 mol) of (a) of the compound obtained are stirred overnight in 20 ml of 1 N sodium hydroxide. After this time, the ethyl ester was saponified completely. 20 ml of 1N hydrochloric acid are added and washed with ethyl acetate. The aqueous phase is evaporated to dryness in vacuo, the residue is taken up twice in ethanol, then evaporated to dryness and then dried under vacuum at 80 ° C. The residue is dissolved in 100 ml of dimethylformamide. This solution was mixed with 2 ml (0.0102 mol) of diphenylphosphoryl chloride, cooled to -5 ° C, 1.4 ml (0.0102 mol) of triethylamine was added with stirring and stirred at -5 ° C for one hour. Then, 2.26 g (0.0102 mol) of trans-3- [4-aminocyclohexyl] propionic acid in is added. methyl ester hydrochloride and 1.4 ml (0.0102 mol) triethylamine and stirred for an additional 4 hours at room temperature and then 1 hour at 60 ° C. To complete the reaction, 1 ml of diphenylphosphoryl chloride and 1.4 ml of triethylamine are added again and stirred overnight at room temperature. It is then evaporated to dryness in vacuo, the residue is taken up in ethyl acetate, the ethyl acetate solution is washed twice with saturated sodium bicarbonate solution and once with water and dried over sodium sulfate. After evaporation in vacuo, 4 g of residue remained, which was purified by column chromatography on silica gel using dichloromethane / methanol = 20: 1 and 10: 1 as eluent.

Zvyšok sa rozotrie s éterom/petroléterom, odsaje sa a suší. Výťažok: 2,98 g (62,1 % teórie)The residue was triturated with ether / petroleum ether, filtered off with suction and dried. Yield: 2.98 g (62.1% of theory)

Teplota topenia: 182 až 184 “C.Melting point: 182-184 ° C.

PríkladXXPríkladXX

4-[4-[[trahs-4-[2-(metoxykarbonyl)etyl]cyklohexyl]aminokarbony1]fenyl]-1-benzy1-piperazín4- [4 - [[of trans-4- [2- (methoxycarbonyl) ethyl] cyclohexyl] aminokarbony1] phenyl] -1-piperazine-benzy1

a) l-benzyl-4-(4-kyanofenyl)piperazína) 1-benzyl-4- (4-cyanophenyl) piperazine

Zmes 26 g (0,2147 mol) 4-fluórbenzonitrilu, 37,3 ml (0,2147 mol) N-benzylpiperazínu a 36,7 ml (0,2147 mol) N-etyl-diizopropylamínu sa počas 8 hodín zohrieva na 140 °C. Po ochladení sa mieša vo vode a extrahuje dichlórmetánom. Spojené dichlórmetánové fázy sa sušia nad síranom sodným a odparia sa za vákua. Zvyšok sa kryštalizuje z éteru/petroléteru.A mixture of 26 g (0.2147 mol) of 4-fluorobenzonitrile, 37.3 ml (0.2147 mol) of N-benzylpiperazine and 36.7 ml (0.2147 mol) of N-ethyl-diisopropylamine is heated to 140 ° for 8 hours. C. After cooling, it is stirred in water and extracted with dichloromethane. The combined dichloromethane phases are dried over sodium sulfate and evaporated in vacuo. The residue was crystallized from ether / petroleum ether.

Výťažok: 29,8 g (50,1 % teórie)Yield: 29.8 g (50.1% of theory)

Teplota topenia: 106 až 108 ’C.Melting point: 106 to 108 ° C.

b) l-benzyl-4-(4-karboxyfenyl)piperazínb) 1-benzyl-4- (4-carboxyphenyl) piperazine

29,8 g (0,1074 mol) l-benzyl-4-(4-kyanofenyl)piperazínu sa rozpustí v 200 ml etylénglykolu. Po prídavku 48 g (0,8592 mol) hydroxidu draselného sa zohrieva počas 8 hodín na teplotu refluxu. Potom sa ďalej oddestiluje etylénglykol za vákua a zvyšný olej sa zriedi vodou. Po okysléní kyselinou octovou sa odsajú vylúčené tuhé čiastočky, premyjú sa vodou a potom malým množstvom acetónu a sušia sa.29.8 g (0.1074 mol) of 1-benzyl-4- (4-cyanophenyl) piperazine are dissolved in 200 ml of ethylene glycol. After the addition of 48 g (0.8592 mol) of potassium hydroxide, it is heated at reflux temperature for 8 hours. The ethylene glycol is then further distilled off under vacuum and the residual oil is diluted with water. After acidification with acetic acid, the precipitated solids are filtered off with suction, washed with water and then with a small amount of acetone and dried.

Výťažok: 31,4 g (98,7 % teórie)Yield: 31.4 g (98.7% of theory)

Teplota topenia: 225 až 227 “C (rozklad).Melting point: 225-227 ° C (decomposition).

c) 4-[4-[[trans-4-[2-(metoxykarbonyl)etyl]cyklohexyl]aminokarbonyl ]fenyl]-1-benzyl-piperazínc) 4- [4 - [[trans -4- [2- (methoxycarbonyl) ethyl] cyclohexyl] aminocarbonyl] phenyl] -1-benzylpiperazine

K roztoku 1,5 g (0,051 mol) l-benzyl-4-(4-karboxyfenyl)piperazínu v 80 ml dimetylformamidu sa pridá pri -5 °C a za miešania 1 ml (0,0051 mol) chloridu kyseliny difenylfosfínovej a 0,7 ml (0,051 mol) trietylamínu a mieša sa ďalšiu hodinu pri -5 “C. Potom sa pridá 1,13 g (0,051 mol) hydroehloridu metylesteru kyseliny 3-(4-trans-aminocyklohexyl)propiónovej a 0,7 ml (0,051 mol) trietylamínu a mieša sa cez noc pri teplote miestnosti. Potom sa odparí vo vákuu do sucha a zvyšok sa prečistí chromatografiou na stĺpci silikagélu za použitia dichlórmetánu, ktorý obsahuje 2,5 % metanolu, ako elučného činidla. Po odparení elučného činidla získaný zvyšok sa rozotrie s petroléterom a odsaje.To a solution of 1.5 g (0.051 mol) of 1-benzyl-4- (4-carboxyphenyl) piperazine in 80 ml of dimethylformamide was added at -5 ° C and stirred with 1 ml (0.0051 mol) of diphenylphosphinic chloride and 0, 7 ml (0.051 mol) triethylamine and stirred for an additional hour at -5 ° C. Then, 1.13 g (0.051 mol) of methyl 3- (4-trans-aminocyclohexyl) propionic acid hydrochloride hydrochloride and 0.7 ml (0.051 mol) of triethylamine are added and stirred overnight at room temperature. It is then evaporated to dryness in vacuo and the residue is purified by silica gel column chromatography using dichloromethane containing 2.5% methanol as eluent. After evaporation of the eluent, the residue obtained is triturated with petroleum ether and filtered off with suction.

Výťažok: 1,04 g (44 % teórie)Yield: 1.04 g (44% of theory)

Teplota topenia: 188 až 189 °C.Melting point: 188-189 ° C.

Príklad XXIExample XXI

4- [2-[trans-4-[2-(metoxykarbonyl)etyl]cyklohexyl]-1-oxo2,3-dihydroizoindol-6-yl]pyridín4- [2- [trans-4- [2- (methoxycarbonyl) ethyl] cyclohexyl] -1-oxo-2,3-dihydroisoindol-6-yl] pyridine

a) metylester kyseliny 2-metyl-5-trifluórmetylsulfonyloxybenzoovej(a) 2-methyl-5-trifluoromethylsulfonyloxybenzoic acid methyl ester

K roztoku 10 g (60 mol) metylesteru kyseliny 3-hydroxy5- metyl-benzoovej v 40 ml sušeného pyridínu sa prikvapká za miešania pri -8 až 4 °C 18,2 ml (66 mmol) anhydridu kyseliny trifluórmetánsulfónovej počas 35 minút. Po skončení pridávania sa mieša cez noc na ľadovom kúpeli a potom sa naleje do vody. Extrahuje sa terc.butylmetyléterom, spojené extrakty sa premyjú zriedenou kyselinou chlorovodíkovou a potom vodou, sušia sa nad síranom sodným a odparia sa za vákua do sucha. Zvyšný oranžovo červený olej sa prečistí pomocou stĺpcovej chromatografie na silikagéli, pričom ako rozpúšťadlo slúži cyklohexán/etylacetát = 9:1.To a solution of 10 g (60 mol) of 3-hydroxy-5-methyl-benzoic acid methyl ester in 40 mL of dried pyridine was added dropwise 18.2 mL (66 mmol) of trifluoromethanesulfonic anhydride over 35 minutes with stirring at -8 to 4 ° C. After addition was complete, stir overnight in an ice bath and then pour into water. It is extracted with tert-butyl methyl ether, the combined extracts are washed with dilute hydrochloric acid and then with water, dried over sodium sulphate and evaporated to dryness in vacuo. The residual orange-red oil was purified by column chromatography on silica gel using cyclohexane / ethyl acetate = 9: 1 as the solvent.

bezfarebný olejcolorless oil

Výťažok: 15,3 g (85,5 % teórie)Yield: 15.3 g (85.5% of theory)

R^-hodnota: 0,60 (silikagél, etylacetát/cyklohexán = 9:1)Rf value: 0.60 (silica gel, ethyl acetate / cyclohexane = 9: 1)

b) metylester kyseliny 2-brómmetyl-5-trifluórmetylsulfonyloxy-benzoovejb) 2-bromomethyl-5-trifluoromethylsulfonyloxy-benzoic acid methyl ester

Zmes 8,3 g (27,8 mmol) zlúčeniny vyrobenej pod a), 5,3 g (30 mmol) N-brómsukcínimidu a 20 mg 2,2’-azaizobutyronitrilu v 100 ml chloridu uhličitého sa počas jednej hodiny ožaruje 300 V UV-ponornou lampou. Ochladí sa, odfiltruje sa nerozpustný sukcínimid a filtrát sa za vákua odparí do sucha. Zvyšok sa prečistí stĺpcovou chromatografiou na silikagéli za použitia cyklohexánu/etylacetátu = 9:1 ako elučného činidla .A mixture of 8.3 g (27.8 mmol) of the compound produced under a), 5.3 g (30 mmol) of N-bromosuccinimide and 20 mg of 2,2'-azaisobutyronitrile in 100 ml of carbon tetrachloride is irradiated with 300 V of UV for 1 hour. - by submersible lamp. It is cooled, the insoluble succinimide is filtered off and the filtrate is evaporated to dryness in vacuo. The residue was purified by column chromatography on silica gel using cyclohexane / ethyl acetate = 9: 1 as eluent.

Bezfarebný olej.Colorless oil.

Výťažok: 7,7 g (73,3 % teórie)Yield: 7.7 g (73.3% of theory).

R.£-hodnota: 0,55 (silikagél, etylacetát/cyklohexán = 9:1)Rf value: 0.55 (silica gel, ethyl acetate / cyclohexane = 9: 1)

c) 2-[trans-4-(2-metoxykarbonyl-etyl)cyklohexyl]-l-oxo-2,3dihydro-6-trifluórmetylsulfonyloxy-izoindolc) 2- [trans-4- (2-methoxycarbonyl-ethyl) cyclohexyl] -1-oxo-2,3-dihydro-6-trifluoromethylsulfonyloxy-isoindole

K roztoku 2,2 g (10 mmol) hydrochloridu metylesteru kyseliny trans-4-aminocyklohexylpropiónovej a 3,9 g =5,1 ml (30 mmol) N,N-diizopropyl-etylamínu v 100 ml sušeného dimetylformamidu sa za miešania pridá pri teplote miestnosti roztok 3,8 g (10 mmol) zlúčeniny získanej pod b) v 10 ml dimetylformamidu a mieša sa počas 16 hodín ďalej pri teplote miestnosti. Potom sa za vákua odparí a zvyšok sa rozdelí medzi vodu a dichlórmetán. Organická fáza sa oddelí, suší nad síranom sodným za vákua sa odparí do sucha. Tuhý zvyšok sa rozotrie s petroléterom a odsaje sa.To a solution of 2.2 g (10 mmol) of methyl trans-4-aminocyclohexylpropionate hydrochloride and 3.9 g = 5.1 ml (30 mmol) of N, N-diisopropylethylamine in 100 ml of dried dimethylformamide is added under stirring at temperature A solution of 3.8 g (10 mmol) of the compound obtained under b) in 10 ml of dimethylformamide was stirred at room temperature for 16 hours. It was then evaporated in vacuo and the residue partitioned between water and dichloromethane. The organic phase is separated, dried over sodium sulphate in vacuo and evaporated to dryness. The solid residue is triturated with petroleum ether and filtered off with suction.

Výťažok: 1,9 g (42,2 % teórie)Yield: 1.9 g (42.2% of theory)

Teplota topenia: 104 až 105 °CMelting point: 104-105 ° C

d) 4-2-[trans-4-(2-metoxykarbonyletyl)cyklohexyl]-l-oxo-2,3dihydro-izoindol-6-yl]pyridínd) 4-2- [trans-4- (2-methoxycarbonylethyl) cyclohexyl] -1-oxo-2,3-dihydro-isoindol-6-yl] pyridine

- 45 Roztok 2,3 g (5,1 mmol) zlúčeniny získanej pod c), 1 g (8 mmol) kyseliny 4-pyridylbóritej, 0,58 g (0,5 mmol) tetrakis-trifenylfosfín-paládia(O) a 3,3 ml (24 mmol) trietylamínu v 35 ml dimetylformamidu sa počas 8 hodín zohrieva na 100 °C. Po ochladení sa naleje do 150 ml vody zrazenina sa odsaje a premyje sa vodou. Po sušení za vákua pri 40 ’C sa prečistí pomocou stĺpcovej chromatografie na silikagéli, pričom slúži ako elučné činidlo dichlórmetán/metanol = 19:1. Výťažok: 1,2 g (62,2 % teórie)- 45 A solution of 2.3 g (5.1 mmol) of the compound obtained under c), 1 g (8 mmol) of 4-pyridylboronic acid, 0.58 g (0.5 mmol) of tetrakis-triphenylphosphine-palladium (0) and 3 Triethylamine (3 mL, 24 mmol) in DMF (35 mL) was heated at 100 ° C for 8 h. After cooling, it is poured into 150 ml of water and the precipitate is filtered off with suction and washed with water. After vacuum drying at 40 ° C, it is purified by column chromatography on silica gel, eluting with dichloromethane / methanol = 19: 1. Yield: 1.2 g (62.2% of theory)

Teplota topenia: 210 až 211 ’C.Melting point: 210-211 ° C.

Príklad· XXII l-benzyl-4-[2-[trans-4-[2-(metoxykarbonyl)etyl]cyklohexyl]l-oxo-2,3-dihydroizoindol-6-yl]-3,4-dehydro-piperidínExample XXII 1-benzyl-4- [2- [trans-4- [2- (methoxycarbonyl) ethyl] cyclohexyl] 1-oxo-2,3-dihydroisoindol-6-yl] -3,4-dehydro-piperidine

a) l-benzyl-4-[2-[trans-4-[2-(metoxykarbonyl)etyl]cyklohexyl]-l-oxo-2,3-dihydroizoindol-6-yl]pyridíniumbromida) 1-Benzyl-4- [2- [trans-4- [2- (methoxycarbonyl) ethyl] cyclohexyl] -1-oxo-2,3-dihydroisoindol-6-yl] pyridinium bromide

Zmes 0,32 g (0,84 mmol) 4-[2-[trans-4-(2-metoxykarbonyl)etyl]cyklohexyl]-l-oxo-2,3-dihydroizoindol-pyridínu, 0,2 ml (1,68 mmol) benzylbromidu a 3 ml acetonitrilu sa zohrieva počas pol hodiny na teplotu spätného toku, vylúčia sa pritom tuhé častice. Po ochladení a zriedení terc.butyl-metyléterom sa odsaje a sušia sa tuhé častice pri 40 ’C za vákua. Výťažok: 0,4 g (86,7 % teórie)A mixture of 0.32 g (0.84 mmol) of 4- [2- [trans-4- (2-methoxycarbonyl) ethyl] cyclohexyl] -1-oxo-2,3-dihydroisoindole-pyridine, 0.2 mL (1, 68 mmol) of benzyl bromide and 3 ml of acetonitrile are heated to reflux for half an hour, solids are formed. After cooling and diluting with tert-butyl methyl ether, it is aspirated and the solids are dried at 40 ° C under vacuum. Yield: 0.4 g (86.7% of theory)

Teplota topenia: 252 až 255 ’CMelting point: 252-255 ° C

b) metylester kyseliny 4-metoxykarbonyl-trans-škoricovejb) 4-methoxycarbonyl-trans-cinnamic acid methyl ester

Zmes 184,8 g (0,896 mol) kyseliny 4-metoxykarbonyltransškoricovej, 10 ml kyseliny sírovej a 3 1 metanolu sa zohrieva 18 hodín pod refluxom. Po ochladení na ľadovom kúpeli sa získané kryštály odsajú, premyjú sa metanolom a sušia sa. Výťažok: 175,9 g (89,2 % teórie)A mixture of 184.8 g (0.896 mol) of 4-methoxycarbonyltrans cinnamic acid, 10 ml of sulfuric acid and 3 l of methanol is heated under reflux for 18 hours. After cooling in an ice bath, the crystals obtained are filtered off with suction, washed with methanol and dried. Yield: 175.9 g (89.2% of theory)

Teplota topenia: 121 až 123 ’C.Melting point: 121-123 ° C.

- 46 c) metylester kyseliny 3-(4-metoxykarbonylfenyl)-3-(nitrometyl)propiónovej g (0,1 mol) metylesteru kyseliny 4-metoxykarbonyltrans-škoricovej sa suspenduje v 59 g (0,966 mol) = 52 ml nitrometánu a pridá sa 2,4 g (0,021 mol) = 2,6 ml 1,1,3,3tetrametylguanidínu. Získaná suspenzia sa 5 hodín zohrieva na 70 ’C, potom sa ochladí a odparí vo vákuu do sucha. Získaný zvyšok sa rozdelí medzi etylacetát a 2 N kyselinu chlorovodíkovú. Získaná organická fáza sa premyje vodou, suší a odparí sa vo vákuu do sucha. Získaný hnedý olejovitý zvyšok sa chromatografuje cez silikágél pomocou cyklohexánu/etylacetátu (7:3 až 3:2).(C) 3- (4-methoxycarbonylphenyl) -3- (nitromethyl) propionic acid methyl ester (0.1 mol) methyl 4-methoxycarbonyltrans cinnamate is suspended in 59 g (0.966 mol) = 52 ml of nitromethane and added 2.4 g (0.021 mol) = 2.6 ml 1,1,3,3-tetramethylguanidine. The suspension obtained is heated at 70 ° C for 5 hours, then cooled and evaporated to dryness in vacuo. The residue was partitioned between ethyl acetate and 2 N hydrochloric acid. The organic phase obtained is washed with water, dried and evaporated to dryness in vacuo. The brown oily residue obtained is chromatographed over silica gel with cyclohexane / ethyl acetate (7: 3 to 3: 2).

Výťažok: 20,8 g žltastého oleja (74 % teórie)Yield: 20.8 g of a yellowish oil (74% of theory)

Rjr-hodnota: 0,52 (silikágél, cyklohexán/etylacetát = 3:2)Rf value: 0.52 (silica, cyclohexane / ethyl acetate = 3: 2)

d) 3-(4-metoxykarbonyl-fenyl)pyrolidin-5-ond) 3- (4-methoxycarbonylphenyl) pyrrolidin-5-one

20,3 g (0,72 mol) kyseliny 3-(4-metoxykarbonyl-fenyl)3-(nit-rometyl) propiónovej sa hydrogénuje v 200 ml metanolu za prítomnosti 2 g Raney-niklu 7 hodín pri teplote 60 °C a za tlaku 0,3 MPa. Potom sa odfiltruje katalyzátor a získaný filtrát sa odparí vo vákuu. Získa sa žltý zvyšok, ktorý sa rozotrie v dichlórmetáne, takto získaná zrazenina sa odfiltruje, premyje sa dichlórmetánom a suší.20.3 g (0.72 mol) of 3- (4-methoxycarbonylphenyl) 3- (nitromethyl) propionic acid are hydrogenated in 200 ml of methanol in the presence of 2 g of Raney-nickel at 60 ° C for 7 hours at pressure 0.3 MPa. The catalyst was then filtered off and the filtrate was evaporated in vacuo. A yellow residue is obtained, which is triturated in dichloromethane, the precipitate thus obtained is filtered off, washed with dichloromethane and dried.

Výťažok: 11,2 g (70,9 % teórie)Yield: 11.2 g (70.9% of theory)

Teplota topenia: 154 až 156 °C.Melting point: 154-156 ° C.

e) hydrochlorid 3-(4-metoxykarbonyl-fenyl)-pyrolidinónue) 3- (4-methoxycarbonyl-phenyl) -pyrrolidinone hydrochloride

16,5 g (274 mmol) = 15,7 ml ľadovej kyseliny octovej sa pomaly pridá k roztoku 6 g (27 mmol) 3-(4-metoxykarbonylfenyl)pyrolidin-5-onu a 10,4 g (274 mmol) nátriumbórhydridu v 120 ml dioxánu za miešania a pri teplote 10 až 15 °C. Získaná reakčná zmes sa 7 hodín zohrieva pod spätným chladičom. Po miešaní cez noc pri teplote miestnosti sa znova pridá 5,2 g nátriumbórhydridu a 7,9 ml ľadovej kyseliny octovej v 30 ml dioxánu. Získaný roztok sa zohrieva 6 hodín pod refluxom, potom sa odparí na malý objem, zmieša s 500 ml vody a extrahuje sa dichlórmetánom. Získaná organická fáza sa premyje vodou, suší a odparí na malý objem. Získaný roztok sa spracuje s chlorovodíkom a odparí do sucha.16.5 g (274 mmol) = 15.7 ml of glacial acetic acid are slowly added to a solution of 6 g (27 mmol) of 3- (4-methoxycarbonylphenyl) pyrrolidin-5-one and 10.4 g (274 mmol) of sodium borohydride in 120 ml of dioxane with stirring at 10 to 15 ° C. The resulting reaction mixture was heated at reflux for 7 hours. After stirring overnight at room temperature, 5.2 g of sodium borohydride and 7.9 ml of glacial acetic acid in 30 ml of dioxane were added again. The solution obtained is heated at reflux for 6 hours, then evaporated to a small volume, treated with 500 ml of water and extracted with dichloromethane. The organic phase obtained is washed with water, dried and evaporated to a small volume. The solution obtained is treated with hydrogen chloride and evaporated to dryness.

Výťažok: 6,2 g bezvodého oleja (93,9 % teórie)Yield: 6.2 g of anhydrous oil (93.9% of theory)

R^-hodnota: 0,63 (doštička RP8 s reverznou fázou, metanol/5% roztok chloridu sodného =6:4)Rf value: 0.63 (reverse phase RP8 plate, methanol / 5% sodium chloride solution = 6: 4)

f) l-terc.butyloxykarbonyl-3-(4-metoxykarbonylfenyl)pyrolidínf) 1- tert -Butyloxycarbonyl-3- (4-methoxycarbonylphenyl) pyrrolidine

9,0 g (41,17 mmol) di.terc.butyldikarbonátu sa za chladenia ľadom pridá zmes 6,2 g (25,6 mmol) hydrochloridu 3-(4-metoxykarbonyl-fenyl)pyrolidínu, rozpusteného v zmesi 40 ml dioxánu, 20 ml vody a 14,3 ml trietylamínu. Po miešaní cez noc sa odparí zmes do sucha. Získaný olej sa rozdelí medzi dichlórmetán a vodu. Organická fáza sa premyje vodou, suší a odparí do sucha. Takto získaná olej ovitá substancia sa chromatografia cez silikagél cyklohexán/etylacetátom (4: 1).A mixture of 6.2 g (25.6 mmol) of 3- (4-methoxycarbonylphenyl) pyrrolidine hydrochloride, dissolved in a mixture of 40 ml of dioxane, is added with 9.0 g (41.17 mmol) of di-tert-butyl dicarbonate under ice-cooling, 20 ml of water and 14.3 ml of triethylamine. After stirring overnight, the mixture was evaporated to dryness. The oil obtained is partitioned between dichloromethane and water. The organic phase is washed with water, dried and evaporated to dryness. The oily substance thus obtained is chromatographed over silica gel with cyclohexane / ethyl acetate (4: 1).

Výťažok: 4,8 g (žltastý olej, 61,5 % teórie)Yield: 4.8 g (yellowish oil, 61.5% of theory)

Rf-hodnota: 0,62 (silikagél, cyklohexán/etylacetát = 3:2)Rf value: 0.62 (silica gel, cyclohexane / ethyl acetate = 3: 2)

g) l-terc.butyloxykarbonyl-3-(4-karboxy-fenyl)pyrolidíng) 1- tert -butyloxycarbonyl-3- (4-carboxyphenyl) pyrrolidine

Zmes 4,7 g (15,4 mmol) l-terc.butylkarbonyl-3-(4-metoxykarbonyl-f enyl) pyrolidínu, 15,4 ml 2 N hydroxidu sodného, 100 ml tetrahydrofuránu a 3,3 ml vody sa 24 hodín mieša pri teplote miestnosti. Potom sa znova pridá 15,4 ml 2 N hydroxidu sodného a roztok sa zohrieva 7 hodín na 50 °C. Po ochladení na teplotu miestnosti sa pridá 31 ml 2 N kyseliny chlorovodíkovej a vodná kyselina citrónová až na hodnotu pH 3. Získaný roztok sa odparí na malý objem, získané kryštály sa odsajú, premyjú sa vodou a sušia.A mixture of 4.7 g (15.4 mmol) of 1-tert-butylcarbonyl-3- (4-methoxycarbonylphenyl) pyrrolidine, 15.4 ml of 2 N sodium hydroxide, 100 ml of tetrahydrofuran and 3.3 ml of water was stirred for 24 hours. Stir at room temperature. 15.4 ml of 2 N sodium hydroxide are then added again and the solution is heated at 50 ° C for 7 hours. After cooling to room temperature, 31 ml of 2 N hydrochloric acid and aqueous citric acid are added to pH 3. The solution obtained is evaporated to a small volume, the crystals obtained are filtered off with suction, washed with water and dried.

Výťažok: 3,8 g (84,4 % teórie)Yield: 3.8 g (84.4% of theory)

Teplota topenia: 145 až 147 °C.Melting point: 145-147 ° C.

h) 1-terc.butyloxykarbonyl-3-[4-[[trans-4-[2-(metoxykarbonyl)etyl]cyklohexyl]aminokarbonyl]fenyl]pyrolidính) 1- tert -Butyloxycarbonyl-3- [4 - [[trans-4- [2- (methoxycarbonyl) ethyl] cyclohexyl] aminocarbonyl] phenyl] pyrrolidine

Zmes 3,75 g (12,87 mmol) 1-terc.butyloxykarbonyl-3-(4karboxy-fenyl)pyrolidínu, 3,1 g (13,86 mmol) metylesteru kyseliny trans-(4-amino-cyklohexyl)propiónovej, 7,9 g (77,67 mmol) = 10,8 ml trietylaminu a 4,45 g (13,86 mmol)A mixture of 3.75 g (12.87 mmol) of 1-tert-butyloxycarbonyl-3- (4-carboxyphenyl) pyrrolidine, 3.1 g (13.86 mmol) of methyl trans- (4-aminocyclohexyl) propionate, 7 9 g (77.67 mmol) = 10.8 ml triethylamine and 4.45 g (13.86 mmol)

2-[(1H)-benzotriazol-l-yl]-1,1,3,3-tetra-metyl-uróniumtetrafluórborátu v 100 ml absolútneho dimetylformamidu sa 2 hodiny mieša pri teplote miestnosti. Po zriedení získanej suspenzie 250 ml vody sa získaná bezfarebná zrazenina odfiltruje, premyje sa vodou a suší.2 - [(1H) -benzotriazol-1-yl] -1,1,3,3-tetra-methyl-uronium tetrafluoroborate in 100 ml of absolute dimethylformamide was stirred at room temperature for 2 hours. After diluting the obtained suspension with 250 ml of water, the colorless precipitate obtained is filtered off, washed with water and dried.

Výťažok: 5,75 g (100 % teórie)Yield: 5.75 g (100% of theory)

Teplota topenia: 99 až 103 °C.Melting point: 99-103 ° C.

Príklad XXIVExample XXIV

1-terc.butyloxykarbonyl-3-[4-[[trans-4-[2-(metoxykarbonyl)etyl]cyklohexyl]aminokarbonyl]fenyl]-3-metyl-pyrolidín1-tert-butyloxycarbonyl-3- [4 - [[trans-4- [2- (methoxycarbonyl) ethyl] cyclohexyl] aminocarbonyl] phenyl] -3-methyl-pyrrolidine

a) nitril kyseliny 2-(4-metoxykarbonyl-fenyl)propiónovej(a) 2- (4-methoxycarbonylphenyl) propionic acid nitrile

1,3 g hydridu sodného (55 až 62% v oleji) sa pridá k roztoku 5,3 g (30,25 mmol) 4-metoxykarbonyl-fenylacetonitrilu v 50 ml dimetylformamidu za chladenia ladom. Po 10 minútach sa prikvapká za chladenia ladom 4,3 g (30,25 mmol) = 1,9 metyljodidu. Získaná suspenzia sa 1,5 hodiny mieša, zriedi sa vodou a odparí sa na malý objem. Získaný roztok sa znova zriedi vodou, okyslí sa kyselinou citrónovou a extrahuje etylacetátom. Spojené organické fázy sa premyjú vodou, sušia a vo vákuu do sucha odparia. Získaná olej ovitá substancia sa chromatografuje na silikagéli cyklohexánom/etylacetátom (17:3).1.3 g of sodium hydride (55 to 62% in oil) was added to a solution of 5.3 g (30.25 mmol) of 4-methoxycarbonyl-phenylacetonitrile in 50 ml of dimethylformamide under ice-cooling. After 10 minutes, 4.3 g (30.25 mmol) = 1.9 methyl iodide was added dropwise under ice-cooling. The resulting suspension was stirred for 1.5 hours, diluted with water and evaporated to a small volume. The resulting solution was diluted with water again, acidified with citric acid and extracted with ethyl acetate. The combined organic phases are washed with water, dried and evaporated to dryness in vacuo. The oily substance obtained is chromatographed on silica gel with cyclohexane / ethyl acetate (17: 3).

Výťažok: 32 g nažltlého oleja (47,1 % teórie)Yield: 32 g of a yellowish oil (47.1% of theory)

R£-hodnota: 0,5 (silikagél, cyklohexán/etylacetát = 7:3)Rf value: 0.5 (silica gel, cyclohexane / ethyl acetate = 7: 3)

b) metylester kyseliny 3-kyano-3-(4-metoxykarbonyl-fenyl)- 49 maslovejb) 3-Cyano-3- (4-methoxycarbonyl-phenyl) -49-butyric acid methyl ester

0,72 g hydridu sodného (55 až 65 % v oleji) sa pridá k roztoku 3,1 g (16,38 mmol) kyseliny 2-(4-metoxykarbonylfenyl)propiónovej v 50 ml dimetylformamidu za chladenia ladom. Po 15 minútach za prípadného chladenia ladom sa prikvapká0.72 g of sodium hydride (55-65% in oil) was added to a solution of 3.1 g (16.38 mmol) of 2- (4-methoxycarbonylphenyl) propionic acid in 50 ml of dimethylformamide under ice-cooling. After 15 minutes with optional ice-cooling, it is added dropwise

2,5 g (16,4 mmol) = 1,55 ml metylesteru kyseliny brómoctovej . Získaná suspenzia sa 2,5 hodiny mieša, zriedi sa vodou a odparí na malý objem. Získaný roztok sa znova zriedi vodou, ♦ okyslí sa kyselinou citrónovou a extrahuje etylacetátom.2.5 g (16.4 mmol) = 1.55 ml of methyl bromoacetate. The suspension was stirred for 2.5 hours, diluted with water and evaporated to a small volume. The solution obtained is diluted with water again, acidified with citric acid and extracted with ethyl acetate.

Spojené organické fázy sa premyjú vodou, sušia a odparia vo vákuu do sucha. Získaná olej ovitá substancia sa chromatografuje na silikagéli cyklohexánom/etylacetátom (7:3).The combined organic phases are washed with water, dried and evaporated to dryness in vacuo. The oily substance obtained is chromatographed on silica gel with cyclohexane / ethyl acetate (7: 3).

Výťažok: 3,6 g (83,7 % teórie)Yield: 3.6 g (83.7% of theory)

Teplota topenia: 75 až 77 °C.Melting point: 75 to 77 ° C.

c) 3-(4-metoxykarbonyl-fenyl)-3-metyl-pyrolidin-5-onc) 3- (4-methoxycarbonyl-phenyl) -3-methyl-pyrrolidin-5-one

Roztok metylesteru kyseliny 3-kyano-3-(4-metoxykarbonylfenyl)maslovej (3,3 g 12,6 ml metanolu sa okyslí 12 ml metanolickej kyseliny chlorovodíkovej a za prítomnosti 1 g paládia na živočíšnom uhlí (10%) sa hydrogenuje pri tlaku 0,3 MPa 6 hodín pri teplote miestnosti. Po odfiltrovaní katalyzátora sa filtrát odparí vo vákuu do sucha. Získaný tuhý zvyšok sa rozpustí v etylacetáte a organická fáza sa extrahuje vodou. Vodná fáza sa zalkalizuje prídavkom vodného roztoku uhličitanu draselného a extrahuje sa etylacetátom. Organická fáza sa suší a vo vákuu odparí do sucha. Získaný zvyšok sa rozotrie s etylacetátom, odfiltruje, premyje sa etylacetátom a suší.A solution of 3-cyano-3- (4-methoxycarbonylphenyl) butyric acid methyl ester (3.3 g of 12.6 ml of methanol is acidified with 12 ml of methanolic hydrochloric acid and hydrogenated at 0 pressure in the presence of 1 g of palladium on charcoal (10%). The filtrate is evaporated to dryness in vacuo, the solid residue is dissolved in ethyl acetate and the organic phase is extracted with water, the aqueous phase is made alkaline by the addition of aqueous potassium carbonate solution and extracted with ethyl acetate. The residue obtained is triturated with ethyl acetate, filtered, washed with ethyl acetate and dried.

Výťažok: 2,2 g (75,9 % teórie)Yield: 2.2 g (75.9% of theory)

Teplota topenia: 188 až 189 C.Melting point: 188-189 ° C.

d) hydrochlorid 3-(4-metoxykarbonyl-fenyl)-3-metyl-pyrolidínu )d) 3- (4-methoxycarbonyl-phenyl) -3-methyl-pyrrolidine hydrochloride

5,6 g (92,5 mmol) = 5,3 ml etylacetátu sa pomaly pridá5.6 g (92.5 mmol) = 5.3 ml of ethyl acetate are added slowly

- 50 k roztoku 2,15 g (9,22 mmol) 3-(4-metoxykarbonyl-fenyl)-3metyl-pyrolidin-5-onu a 3,5 g (92,5 mmol) nátrium bórhydridu v 60 ml dioxánu za miešania a pri teplotách medzi 10 až 15 °C. Takto získaná zmes sa 6 hodín zohrieva pod refluxom. Po miešaní cez noc pri teplote miestnosti sa znova pridá 1,8 g nátrium bórhydridu a potom 2,7 ml ľadovej kyseliny octovej v 10 ml dioxánu. Po 7 hodinách zohrievania pod refluxom sa získaný roztok odparí na malý objem, zmieša s 300 ml vody a extrahuje dichlórmetánom. Organická fáza sa premyje vodou, suší a odparí na malý objem. Takto získaný roztok sa spracuje s chlorovodíkom a odparí sa do sucha.- 50 to a solution of 3- (4-methoxycarbonyl-phenyl) -3-methyl-pyrrolidin-5-one (2.15 g, 9.22 mmol) and sodium borohydride (3.5 g, 92.5 mmol) in dioxane (60 ml) with stirring and at temperatures between 10 and 15 ° C. The mixture thus obtained was heated under reflux for 6 hours. After stirring overnight at room temperature, 1.8 g of sodium borohydride is added again, followed by 2.7 ml of glacial acetic acid in 10 ml of dioxane. After heating at reflux for 7 hours, the solution obtained is evaporated to a small volume, mixed with 300 ml of water and extracted with dichloromethane. The organic phase is washed with water, dried and evaporated to a small volume. The solution thus obtained is treated with hydrogen chloride and evaporated to dryness.

Výťažok: 1,14·g bezvodého oleja (48,6 % teórie)Yield: 1.14 g of anhydrous oil (48.6% of theory)

R^-hodnota: 0,5 (doštička RP8 s reverznou fázou, metanol/5% roztok chloridu sodného = 6:7)Rf value: 0.5 (reverse phase RP8 plate, methanol / 5% sodium chloride solution = 6: 7)

e) 1-terc.butyloxykarbonyl-3-(4-metoxykarbonyl-fenyl)-3metyl-pyrolidíne) 1- tert -Butyloxycarbonyl-3- (4-methoxycarbonylphenyl) -3-methylpyrrolidine

1,6 g (7,15 mmol) di-terc.butylkarbonátu sa pridá za chladenia ľadom k roztoku 1,14 g (4,46 mmol) hydrochloridu1.6 g (7.15 mmol) of di-tert-butyl carbonate are added to a solution of 1.14 g (4.46 mmol) of hydrochloride under ice-cooling.

3-(4-metoxykarbonyl-fenyl)-3-metyl-pyrolidínu v zmesi 4 ml vody, 8 ml dioxánu a 2,5 ml trietylamínu ža chladenia ľadom. Po 2 hodinovom miešaní sa roztok odparí do sucha a získaný olej ovitý zvyšok sa rozdelí medzi dichlórmetán a vodu. Organická fáza sa premyje vodou, suší a odparí sa do sucha. Výťažok: 1,18 g bezfarebného oleja (83,12 % teórie)3- (4-methoxycarbonyl-phenyl) -3-methyl-pyrrolidine in a mixture of 4 ml of water, 8 ml of dioxane and 2.5 ml of triethylamine under ice-cooling. After stirring for 2 hours, the solution was evaporated to dryness and the resulting oily residue was partitioned between dichloromethane and water. The organic phase is washed with water, dried and evaporated to dryness. Yield: 1.18 g of a colorless oil (83.12% of theory)

Rj-hódnota: 0,62 (silikagél, cyklohexán/etylacetát = 3:2)Rf value: 0.62 (silica gel, cyclohexane / ethyl acetate = 3: 2)

f) l-terc.butyloxykarbonyl-3-(4-karboxy-fenyl)-3-metylpyrolidínf) 1- tert -Butyloxycarbonyl-3- (4-carboxyphenyl) -3-methylpyrrolidine

Zmes 1,1 g (3,44 mmol) l-terc.butyloxykarbonyl-3-(4-metoxykarbonyl-fenyl) -3-metyl-pyrolidínu, 7 ml 2 N hydroxidu sodného, 20 ml tetrahydrofuránu a 1 ml vody sa 3 dni mieša. Potom sa 7 ml 2 N kyseliny chlorovodíkovej a kyselinou citrónovou nastaví pH na hodnotu 2. Získaný roztok sa odparí na malý objem a extrahuje sa dichlórmetánom. Organická fáza sa premyje vodou, suší a odparí do sucha. Získaná olej ovitá substancia sa chromatografuje na silikagéli cyklohexánom/etylacetátom (4:1 až 1:1).A mixture of 1.1 g (3.44 mmol) of 1-tert-butyloxycarbonyl-3- (4-methoxycarbonylphenyl) -3-methylpyrrolidine, 7 ml of 2 N sodium hydroxide, 20 ml of tetrahydrofuran and 1 ml of water was added for 3 days. stirred. Then 7 ml of 2 N hydrochloric acid and citric acid are adjusted to pH 2. The solution obtained is evaporated to a small volume and extracted with dichloromethane. The organic phase is washed with water, dried and evaporated to dryness. The oily substance obtained is chromatographed on silica gel with cyclohexane / ethyl acetate (4: 1 to 1: 1).

Výťažok: 600 mg žltastého oleja (51,1 % teórie)Yield: 600 mg of yellowish oil (51.1% of theory)

R^-hodnota: 0,5 (silikagél, cyklohexán/etylacetát = 3:2).Rf value: 0.5 (silica gel, cyclohexane / ethyl acetate = 3: 2).

g) l-terc.butylkarbonyl-3-[4-[[trans-4-[2-(metoxykarbonyl)etyl]cyklohexyl]aminokarbonyl]fenyl]-1-metyl-pyrolidíng) 1-tert-butylcarbonyl-3- [4 - [[trans -4- [2- (methoxycarbonyl) ethyl] cyclohexyl] aminocarbonyl] phenyl] -1-methylpyrrolidine

Zmes 0,57 g (1,87 mmol) l-terc.butyloxykarbonyl-3-(4karboxy-fenyl)-3-metyl-pyrolidínu, 0,445 g (2,01 mmol) metylesteru kyseliny trans-(4-amino-cyklohexyl)propiónovej, 1,14 g (0,113 mmol) = 1,56 ml trietylamínu a 0,645 g (2 mmol) 2-[(1H)-benzotriazol-l-yl]-1,1,3,3-tetrametyluróniumtetraf luórborátu v 15 ml absolútneho dimetylformamidu sa 2 hodiny mieša pri teplote miestnosti. Získaná suspenzia sa zriedi vodou a odparí sa do sucha. Získaný zvyšok sa rozdelí medzi etylacetát a zriedený roztok uhličitanu draselného. Získaná organická fáza sa premyje vodou, suší a odparí sa do sucha.· Zvyšný olej sa chromatografuje cez silikagél cyklohexánom/etylacetátom (4:1).A mixture of 0.57 g (1.87 mmol) of 1-tert-butyloxycarbonyl-3- (4-carboxyphenyl) -3-methylpyrrolidine, 0.445 g (2.01 mmol) of trans- (4-amino-cyclohexyl) methyl ester propionic acid, 1.14 g (0.113 mmol) = 1.56 ml triethylamine and 0.645 g (2 mmol) 2 - [(1H) -benzotriazol-1-yl] -1,1,3,3-tetramethyluronium tetrafluoroborate in 15 ml of absolute dimethylformamide was stirred at room temperature for 2 hours. The suspension obtained is diluted with water and evaporated to dryness. The residue is partitioned between ethyl acetate and dilute potassium carbonate solution. The resulting organic phase was washed with water, dried and evaporated to dryness. The remaining oil was chromatographed over silica gel with cyclohexane / ethyl acetate (4: 1).

Výťažok: 300 mg bezfarebného oleja (37,5 % teórie)Yield: 300 mg of a colorless oil (37.5% of theory)

R^-hodnota: 0,31 (silikagél, cyklohexán/etylacetát = 3:2).Rf value: 0.31 (silica gel, cyclohexane / ethyl acetate = 3: 2).

Výroba konečných zlúčenín:Production of final compounds:

Príklad 1 l-terc.butyloxykarbonyl-4-[4-[[trans-4-[2-(metoxykarbonyl)etyl]cyklohexyl]aminokarbonyl]fenyl]piperidínExample 1 1- tert -Butyloxycarbonyl-4- [4 - [[trans -4- [2- (methoxycarbonyl) ethyl] cyclohexyl] aminocarbonyl] phenyl] piperidine

Roztok 0,76 g l-terc.butyloxykarbonyl-4-(4-karboxy-fenyl)piperidínu, 0,90 g 2-[(1H)-benzotriazol-l-yl]-1,1,3,3tetrametylurónium-tetrafluórborátu, 0,55 g hydrochloridu metylesteru kyseliny 3-(trans-4-aminocyklohexyl)-propiónovej, 0,38 g 1-hydroxy-(1H)-benzotriazolu a 0,67 g N-metylmorfolínu v 50 ml dimetylformamidu sa mieša 16 hodín pri teplote miestnosti. Rozpúšťadlo sa odstráni za zníženého tlaku. K zvyšku sa pridá voda (200 ml) a vodná fáza sa extrahuje etylacetátom. Organická fáza sa suší nad síranom sodným, filtruje a rozpúšťadlo sa odstráni za zníženého tlaku. Získa sa 1,8 g tuhých látok, ktoré sa chromatografujú cez silikagél metylénchloridom/metanolom (9:1).A solution of 0.76 g of 1-tert-butyloxycarbonyl-4- (4-carboxyphenyl) piperidine, 0.90 g of 2 - [(1H) -benzotriazol-1-yl] -1,1,3,3-tetramethyluronium tetrafluoroborate, 0.55 g of 3- (trans-4-aminocyclohexyl) -propionic acid methyl ester hydrochloride, 0.38 g of 1-hydroxy- (1H) -benzotriazole and 0.67 g of N-methylmorpholine in 50 ml of dimethylformamide are stirred for 16 hours at a temperature of rooms. The solvent was removed under reduced pressure. Water (200 mL) was added to the residue and the aqueous phase was extracted with ethyl acetate. The organic phase is dried over sodium sulfate, filtered and the solvent is removed under reduced pressure. 1.8 g of solids are obtained, which are chromatographed over silica gel with methylene chloride / methanol (9: 1).

Výťažok: 1,15 g (98 % teórie)Yield: 1.15 g (98% of theory)

Teplota topenia: sintruje pri 169 °CMelting point: sintered at 169 ° C

Rf-hodnota: 0,60 (silikagél, metylénchlorid/metanol = 9:1).Rf value: 0.60 (silica gel, methylene chloride / methanol = 9: 1).

Analogicky sa získajú nasledujúce zlúčeniny:The following compounds are obtained analogously:

1) 1-terc.butyloxykarbonyl-4-[4-[[4-[2-(metoxykarbonyl)etyl]fenyl]aminokarbonyl]fenyl]piperidín1) 1-tert-butyloxycarbonyl-4- [4 - [[4- [2- (methoxycarbonyl) ethyl] phenyl] aminocarbonyl] phenyl] piperidine

Teplota topenia: 157 až 162 °CMp .: 157-162 ° C

Rf-hodnota: 0,53 (silikagél, cyklohexán/etylacetát = 1:1)Rf value: 0.53 (silica gel, cyclohexane / ethyl acetate = 1: 1)

2) 4-[4-[[4-[2-(n-butánsulfonylamino)-2-(metoxykarbonyl)etyl]fenyl]aminokarbonyl]fenyl]-l-terc.butyloxykarbonylpiperidín2) 4- [4 - [[4- [2- (n-butanesulfonylamino) -2- (methoxycarbonyl) ethyl] phenyl] aminocarbonyl] phenyl] -1-tert-butyloxycarbonylpiperidine

R^-hodnota: 0,41 (silikagél, cyklohexán/etylacetát = 1:1) hmotové spektrum: (M+Na)+ = 624Rf value: 0.41 (silica gel, cyclohexane / ethyl acetate = 1: 1) mass spectrum: (M + Na) + = 624

3) 4-[4-[[trans-4-[2-(metoxykarbonyl)etyl]cyklohexyl]aminokarbonyl ] f enyl ] chinuklidín3) 4- [4 - [[trans-4- [2- (methoxycarbonyl) ethyl] cyclohexyl] aminocarbonyl] phenyl] quinuclidine

4) 4-[4-[[trans-4-[2-(metoxykarbonyl)etyl]cyklohexyl]aminokarbonyl ]fenyl]pyridín4) 4- [4 - [[trans -4- [2- (methoxycarbonyl) ethyl] cyclohexyl] aminocarbonyl] phenyl] pyridine

5) 4-[4-[[4-[2-(metoxykarbonyl)etyl]fenyl]aminokarbonyl]piperidino]pyridín5) 4- [4 - [[4- [2- (methoxycarbonyl) ethyl] phenyl] aminocarbonyl] piperidino] pyridine

6) 4-[4-[[trans-4-[2-(metoxykarbonyl)etyl]cyklohexyl]aminokarbonyl ]piperidino]pyridín6) 4- [4 - [[trans -4- [2- (methoxycarbonyl) ethyl] cyclohexyl] aminocarbonyl] piperidino] pyridine

7) 4-[4-[[4-[2-(n-butánsulfonylamino)-2-(metoxykarbonyl)etyl]fenyl]aminokarbonyl]piperidino]pyridín7) 4- [4 - [[4- [2- (n-butanesulfonylamino) -2- (methoxycarbonyl) ethyl] phenyl] aminocarbonyl] piperidino] pyridine

8) 4-[4-[[4-[2-(n-hexanoylamino)-2-(metoxykarbonyl)etyl]fenyl]aminokarbonyl]piperidino]pyridín8) 4- [4 - [[4- [2- (n-hexanoylamino) -2- (methoxycarbonyl) ethyl] phenyl] aminocarbonyl] piperidino] pyridine

9) 4-[4-[[trans-4-[2-(n-butánsulfonylamino)-2-(metoxykarbonyl )etyl]cyklohexyl]aminokarbonyl]piperidino]pyridín9) 4- [4 - [[trans -4- [2- (n-butanesulfonylamino) -2- (methoxycarbonyl) ethyl] cyclohexyl] aminocarbonyl] piperidino] pyridine

10) 4-[4-[[trans-4-[2-(n-hexanoylamino)-2-(metoxykarbonyl)etyl]cyklohexyl]aminokarbonyl]piperidino]pyridín10) 4- [4 - [[trans -4- [2- (n-hexanoylamino) -2- (methoxycarbonyl) ethyl] cyclohexyl] aminocarbonyl] piperidino] pyridine

11) 1-terc.butyloxykarbonyl-4-[4-[[trans-4-(metoxykarbonyl) cyklohexyl]aminokarbonyl]fenyl]piperidín11) 1-tert-butyloxycarbonyl-4- [4 - [[trans -4- (methoxycarbonyl) cyclohexyl] aminocarbonyl] phenyl] piperidine

Teplota topenia: 197 až 200 °CMelting point: 197-200 ° C

R^-hodnota: 0,20 (silikagél, metylénchlorid/metanol = 20:1)Rf value: 0.20 (silica gel, methylene chloride / methanol = 20: 1)

12) 4-[4-[[4-(terc.butyloxykarbonyl-metoxy)fenyl]karbonylaminojfenyl]-1-trifluóracetyl-piperidín12) 4- [4 - [[4- (tert-butyloxycarbonylmethoxy) phenyl] carbonylamino] phenyl] -1-trifluoroacetylpiperidine

Vyrobí sa z kyseliny 4-[4-aminofenyl]-l-trifluóracetylpiperidínu a kyseliny 4-[terc.butyloxykarbonylmetyloxy] benzoovej.Prepared from 4- [4-aminophenyl] -1-trifluoroacetylpiperidine and 4- [tert-butyloxycarbonylmethyloxy] benzoic acid.

Teplota topenia: 177 až 178 °C.Melting point: 177-178 ° C.

4) hydrochlorid 4-[4-[[trans-4-[2-(metoxykarbonyl)etyl]cyklohexyl]oxymetyl]fenyl]piperidínu4) 4- [4 - [[trans-4- [2- (methoxycarbonyl) ethyl] cyclohexyl] oxymethyl] phenyl] piperidine hydrochloride

5) hydrochlorid 4-[4-[[trans-4-[2-(metoxykarbonyl)etyl]cyklohexyl]metyloxy]fenyl]piperidínu5) 4- [4 - [[trans-4- [2- (methoxycarbonyl) ethyl] cyclohexyl] methyloxy] phenyl] piperidine hydrochloride

6) hydrochlorid 4-[4-[[trans-4-[2-(n-butánsulfonylamino)-2(metoxykarbonyl)-etyl]cyklohexyl]aminokarbonyl]fenyl]piperidínu6) 4- [4 - [[trans-4- [2- (n-butanesulfonylamino) -2 (methoxycarbonyl) ethyl] cyclohexyl] aminocarbonyl] phenyl] piperidine hydrochloride

7) hydrochlorid 4-[4-[[trans-4-[2-(metánsulfonylamino)-2(metoxykarbonyl)etyl]-cyklohexyl]aminokarbonyl]fenyl]piperidínu7) 4- [4 - [[trans-4- [2- (methanesulfonylamino) -2 (methoxycarbonyl) ethyl] -cyclohexyl] aminocarbonyl] phenyl] piperidine hydrochloride

8) hydrochlorid 4-[4-[[trans-4-[2-(n-hexanoylamino)-2(metoxykarbony1)etyl]-cyklohexyl]aminokarbony1]fenyl]piperidínu8) 4- [4 - [[trans-4- [2- (n-hexanoylamino) -2 (methoxycarbonyl) ethyl] -cyclohexyl] aminocarbonyl] phenyl] piperidine hydrochloride

9) hydrochlorid 4-[4-[[trans-4-[2-(metoxykarbonyl)propyl]cyklohexyl]aminokarbonyl]fenyl]piperidínu9) 4- [4 - [[trans-4- [2- (methoxycarbonyl) propyl] cyclohexyl] aminocarbonyl] phenyl] piperidine hydrochloride

10) hydrochlorid 4-[4-[N-[trans-4-[2-(metoxykarbonyl)etyl] cyklohexyl]-N-metyl-aminokarbonyl]fenyl]piperidínu10) 4- [4- [N- [trans-4- [2- (methoxycarbonyl) ethyl] cyclohexyl] -N-methylaminocarbonyl] phenyl] piperidine hydrochloride

11) hydrochlorid 4-[4-[[trans-4-[2-(metoxykarbonyl)etyl]cyklohexyl]karbonylamino]fenyl]piperidínu11) 4- [4 - [[trans-4- [2- (methoxycarbonyl) ethyl] cyclohexyl] carbonylamino] phenyl] piperidine hydrochloride

12) hydrochlorid 4-[4-[[trans-4-[3-(metoxykarbonyl)propyl] cyklohexyl]aminokarbonyl]fenyl]piperidínu12) 4- [4 - [[trans-4- [3- (methoxycarbonyl) propyl] cyclohexyl] aminocarbonyl] phenyl] piperidine hydrochloride

13) hydrochlorid 4-[4-[[trans-4-(metoxykarbonylmetyl)cyklo hexyl]aminokarbonyl]fenyl]piperidínu13) 4- [4 - [[trans-4- (methoxycarbonylmethyl) cyclohexyl] aminocarbonyl] phenyl] piperidine hydrochloride

Teplota topenia: >250 °CMelting point: > 250 ° C

R.£-hodnota: 0,4 (doštička RP8 s reverznou fázou, metanol/50 roztok chloridu sodného = 6:4)R. £ -value: 0.4 (reverse phase RP8 plate, methanol / 50 sodium chloride solution = 6: 4)

14) hydrochlorid 4-[4-[[4-[3-(metoxykarbonyl)-propyl]piperidino]karbonyl]fenyl]piperidínu14) 4- [4 - [[4- [3- (methoxycarbonyl) -propyl] piperidino] carbonyl] phenyl] piperidine hydrochloride

15) hydrochlorid 4-[4-[[4-[4-(metoxykarbonyl)-butyl]piperidino]karbonyl]fenyl]piperidínu15) 4- [4 - [[4- [4- (methoxycarbonyl) butyl] piperidino] carbonyl] phenyl] piperidine hydrochloride

16) dihydrochlorid 4-[4-[[4-[3-(metoxykarbonyl)-propyl]piperazino]karbonyl]fenyl]piperidínu16) 4- [4 - [[4- [3- (methoxycarbonyl) -propyl] piperazino] carbonyl] phenyl] piperidine dihydrochloride

17) dihydrochlorid 4-[4-[[1-[2-(metoxykarbonyl)-etyl]4-piperidinyl]aminokarbonyl]fenyl]piperidínu17) 4- [4 - [[1- [2- (methoxycarbonyl) ethyl] 4-piperidinyl] aminocarbonyl] phenyl] piperidine dihydrochloride

18) hydrochlorid 4-[4-[[4-[3-(metoxykarbonyl)-propyl]-3oxo-piperazino]karbonyl]fenyl]piperidínu18) 4- [4 - [[4- [3- (methoxycarbonyl) propyl] -3-oxo-piperazino] carbonyl] phenyl] piperidine hydrochloride

19) hydrochlorid 1-[4-[[trans-4-[2-(metoxykarbonyl)etyl]cyklohexyl]aminokarbonyl]fenyl]piperazínu19) 1- [4 - [[trans-4- [2- (methoxycarbonyl) ethyl] cyclohexyl] aminocarbonyl] phenyl] piperazine hydrochloride

Teplota topenia: 190 až 192 °CMelting point: 190-192 ° C

20) hydrochlorid 4-[4-[[trans-4-[2-(metoxykarbonyl)etyl]cyklohexyl]aminokarbonyl]fenyl]-3,4-dehydro-piperidínu20) 4- [4 - [[trans-4- [2- (methoxycarbonyl) ethyl] cyclohexyl] aminocarbonyl] phenyl] -3,4-dehydro-piperidine hydrochloride

21) hydrochlorid 4-[4-[[trans-4-[2-(metoxykarbonyl)-noktyl]cyklohexyl]aminokarbonyl]fenyl]piperidínu21) 4- [4 - [[trans-4- [2- (methoxycarbonyl) -octyl] cyclohexyl] aminocarbonyl] phenyl] piperidine hydrochloride

22) hydrochlorid 4-[4-[[trans-4-[2-(benzylsulfonylamino)-2(metoxykarbonyl)etyl]cyklohexyl]aminokarbonyl]fenyl]piperidínu22) 4- [4 - [[trans-4- [2- (benzylsulfonylamino) -2 (methoxycarbonyl) ethyl] cyclohexyl] aminocarbonyl] phenyl] piperidine hydrochloride

23) hydrochlorid 4-[4-[[trans-4-[2-(metoxykarbonyl)etyl]cyklohexyl]aminokarbonyl]fenyl]-4-metyl-piperidínu23) 4- [4 - [[trans-4- [2- (methoxycarbonyl) ethyl] cyclohexyl] aminocarbonyl] phenyl] -4-methylpiperidine hydrochloride

24) hydrochlorid 4-kyano-4-[4-[[trans-4-[2-(metoxykarbonyl) etyl]cyklohexyl]aminokarbonyl]fenyl]piperidínu24) 4-Cyano-4- [4 - [[trans-4- [2- (methoxycarbonyl) ethyl] cyclohexyl] aminocarbonyl] phenyl] piperidine hydrochloride

25) hydrochlorid 4-aminokarbonyl-4-[4-[[trans-4-[2-(metoxykarbonyl) etyl]cyklohexyl]aminokarbonyl]fenyl]piperidínu25) 4-Aminocarbonyl-4- [4 - [[trans-4- [2- (methoxycarbonyl) ethyl] cyclohexyl] aminocarbonyl] phenyl] piperidine hydrochloride

26) hydrochlorid 4-(metoxykarbonyl)-4-[4-[[trans-4-[2(metoxykarbonyl)etyl]cyklohexyl]aminokarbonyl]fenyl]piperidínu26) 4- (Methoxycarbonyl) -4- [4 - [[trans-4- [2 (methoxycarbonyl) ethyl] cyclohexyl] aminocarbonyl] phenyl] piperidine hydrochloride

27) hydrochlorid 3-[4-[[trans-4-[2-(metoxykarbonyl)etyl]cyklohexyl]aminokarbonyl]fenyl]-n-propylamínu27) 3- [4 - [[trans-4- [2- (methoxycarbonyl) ethyl] cyclohexyl] aminocarbonyl] phenyl] -n-propylamine hydrochloride

28) hydrochlorid 5-[4-[[trans-4-[2-(metoxykarbonyl)etyl]cyklohexyl]aminokarbonyl]fenyl]-n-pentylamínu28) 5- [4 - [[trans-4- [2- (methoxycarbonyl) ethyl] cyclohexyl] aminocarbonyl] phenyl] -n-pentylamine hydrochloride

29) hydrochlorid 5-[4-[[trans-4-[2-(n-butánsulfonylamino)2-(metoxykarbonyl)etyl]cyklohexyl]aminokarbonyl]fenyl]n-pentylamínu29) 5- [4 - [[trans-4- [2- (n-butanesulfonylamino) -2- (methoxycarbonyl) ethyl] cyclohexyl] aminocarbonyl] phenyl] n-pentylamine hydrochloride

- 56 30) hydrochlorid 5-[4-[[trans-4-[2-(n-hexanoylamino)-2(metoxykarbonyl)etyl]cyklohexyl]aminokarbonyl]fenyl]n-pentylamínu56) 5- [4 - [[trans-4- [2- (n-hexanoylamino) -2 (methoxycarbonyl) ethyl] cyclohexyl] aminocarbonyl] phenyl] n-pentylamine hydrochloride

31) dihydrochlorid 1-[5-[[trans-4-[2-(metoxykarbonyl)etyl] cyklohexyl]aminokarbonyl]pyridin-2-yl]piperazínu31) 1- [5 - [[trans-4- [2- (methoxycarbonyl) ethyl] cyclohexyl] aminocarbonyl] pyridin-2-yl] piperazine dihydrochloride

32) hydrochlorid 4-[4-[[trans-4-[2-(metoxykarbonyl)etyl]cyklohexyl]aminokarbonyl]-3-metyl-fenyl]piperidínu32) 4- [4 - [[trans-4- [2- (methoxycarbonyl) ethyl] cyclohexyl] aminocarbonyl] -3-methylphenyl] piperidine hydrochloride

33) hydrochlorid 4-[3-metoxy-4-[[trans-4-[2-(metoxykarbonyl) etyl]cyklohexyl]aminokarbonyl]fenyl]piperidínu33) 4- [3-Methoxy-4 - [[trans-4- [2- (methoxycarbonyl) ethyl] cyclohexyl] aminocarbonyl] phenyl] piperidine hydrochloride

34) dihydrochlorid 4-[4-[[trans-4-[2-amino-2-(metoxykarbonyl) etyl]cyklohexyl]aminokarbonyl]fenyl]piperidínu34) 4- [4 - [[trans-4- [2-amino-2- (methoxycarbonyl) ethyl] cyclohexyl] aminocarbonyl] phenyl] piperidine dihydrochloride

35) hydrochlorid 4-[4-[[cis-4-[2-(metoxykarbonyl)etyl]cyklohexyl]aminokarbonyl]fenyl]piperidínu35) 4- [4 - [[cis-4- [2- (methoxycarbonyl) ethyl] cyclohexyl] aminocarbonyl] phenyl] piperidine hydrochloride

36) hydrochlorid 4-[4-[[cis-4-[2-(n-butánsulfonylamino)-2(metoxykarbonyl)etyl]cyklohexyl]aminokarbonyl]fenyl]piperidínu36) 4- [4 - [[cis-4- [2- (n-butanesulfonylamino) -2 (methoxycarbonyl) ethyl] cyclohexyl] aminocarbonyl] phenyl] piperidine hydrochloride

37) hydrochlorid 4-[4-[[4-[2-(n-hexanoylamino)-2-(metoxykarbonyl) etyl]fenyl]aminokarbonyl]fenyl]-piperidínu37) 4- [4 - [[4- [2- (n-hexanoylamino) -2- (methoxycarbonyl) ethyl] phenyl] aminocarbonyl] phenyl] piperidine hydrochloride

38) hydrochlorid 4-[4-[[trans-4-(metoxykarbonyl-metoxy)cyklohexyl]aminokarbonyl]fenyl]-piperidínu38) 4- [4 - [[trans -4- (methoxycarbonylmethoxy) cyclohexyl] aminocarbonyl] phenyl] piperidine hydrochloride

39) hydrochlorid 4-[3-[[4-[2-(benzylsulfonylamino)-2(metoxykarbonyl)etyl]fenyl]aminokarbonyl]fenyl]piperidínu39) 4- [3 - [[4- [2- (benzylsulfonylamino) -2 (methoxycarbonyl) ethyl] phenyl] aminocarbonyl] phenyl] piperidine hydrochloride

40) hydrochlorid 4-[3-[[4-[2-(n-hexanoylamino)-2-(metoxykarbonyl) etyl]fenyl]aminokarbonyl]fenyl]-piperidínu40) 4- [3 - [[4- [2- (n-hexanoylamino) -2- (methoxycarbonyl) ethyl] phenyl] aminocarbonyl] phenyl] piperidine hydrochloride

41) hydrochlorid 4-[4-[[4-[2-(benzylsulfonylamino)-2(metoxykarbonyl)etyl]fenyl]aminokarbonyl]fenyl]piperidínu41) 4- [4 - [[4- [2- (Benzylsulfonylamino) -2 (methoxycarbonyl) ethyl] phenyl] aminocarbonyl] phenyl] piperidine hydrochloride

42) hydrochlorid 4-[3-fluór-4-[[trans-4-[2-(metoxykarbonyl)etyl]cyklohexyl]aminokarbonyl]fenyl]piperidínu42) 4- [3-Fluoro-4 - [[trans-4- [2- (methoxycarbonyl) ethyl] cyclohexyl] aminocarbonyl] phenyl] piperidine hydrochloride

43) hydrochlorid 4-[3-etoxy-4-[[trans-4-[2-(metoxykarbonyl)etyl]cyklohexyl]aminokarbonyl]fenyl]piperidínu43) 4- [3-ethoxy-4 - [[trans-4- [2- (methoxycarbonyl) ethyl] cyclohexyl] aminocarbonyl] phenyl] piperidine hydrochloride

44) hydrochlorid 4-[2-bróm-4-[[trans-4-[2-(metoxykarbonyl)etyl]cyklohexyl]aminokarbonyl]fenyl]piperazínu44) 4- [2-Bromo-4 - [[trans-4- [2- (methoxycarbonyl) ethyl] cyclohexyl] aminocarbonyl] phenyl] piperazine hydrochloride

45) hydrochlorid 4-[3-chlór-4-[[trans-4-[2-(metoxykarbonyl)etyl]cyklohexyl]aminokarbonyl]fenyl]piperidínu45) 4- [3-chloro-4 - [[trans -4- [2- (methoxycarbonyl) ethyl] cyclohexyl] aminocarbonyl] phenyl] piperidine hydrochloride

46) hydrochlorid 4-[4-[[2-bróm-4-[2-(metoxykarbonyl)etyl]fenyl]aminokarbonyl]fenyl]piperidínu46) 4- [4 - [[2-Bromo-4- [2- (methoxycarbonyl) ethyl] phenyl] aminocarbonyl] phenyl] piperidine hydrochloride

47) hydrochlorid 4-[4-[[2-metoxy-4-[2-(metoxykarbonyl)etyl] fenyl]aminokarbonyl]fenyl]piperidínu47) 4- [4 - [[2-methoxy-4- [2- (methoxycarbonyl) ethyl] phenyl] aminocarbonyl] phenyl] piperidine hydrochloride

48) hydrochlorid 4-[4-[[trans-4-[2-(metoxykarbonyl)etyl]cyklohexyl]aminokarbonyl]-2-metyltiofenyl]piperazínu48) 4- [4 - [[trans-4- [2- (methoxycarbonyl) ethyl] cyclohexyl] aminocarbonyl] -2-methylthiophenyl] piperazine hydrochloride

49) hydrochlorid 1-[4-[[trans-4-[2-(metoxykarbonyl)etyl]cyklohexyl]aminokarbonyl]-2-metylsulfonylfenyl]piperazínu49) 1- [4 - [[trans-4- [2- (methoxycarbonyl) ethyl] cyclohexyl] aminocarbonyl] -2-methylsulfonylphenyl] piperazine hydrochloride

50) hydrochlorid 4-[4-[[4-[2-(metoxykarbonyl)etyl]-2-metylfenyl]aminokarbonyl]fenyl]piperidínu50) 4- [4 - [[4- [2- (methoxycarbonyl) ethyl] -2-methylphenyl] aminocarbonyl] phenyl] piperidine hydrochloride

51) hydrochlorid 4-[4-[[4-[2-(metoxykarbonyl)etyl]fenyl]sulfonylamino]fenyl]piperidínu51) 4- [4 - [[4- [2- (methoxycarbonyl) ethyl] phenyl] sulfonylamino] phenyl] piperidine hydrochloride

52) hydrochlorid 4-[4-[[4-[2-(metoxykarbonyl)etenyl]fenyl]aminokarbonyl]fenyl]piperidínu52) 4- [4 - [[4- [2- (methoxycarbonyl) ethenyl] phenyl] aminocarbonyl] phenyl] piperidine hydrochloride

53) hydrochlorid 4-[4-[[trans-4-(metoxykarbonyl)cyklohexyl]aminokarbonyl]fenyl]piperidínu53) 4- [4 - [[trans-4- (methoxycarbonyl) cyclohexyl] aminocarbonyl] phenyl] piperidine hydrochloride

Teplota topenia: 260 až 265 °CMelting point: 260-265 ° C

R^-hodnota: 0,39 (silikagél, metylénchlorid/metanol/konc. amoniak = 4:1:0,25Rf value: 0.39 (silica gel, methylene chloride / methanol / conc. Ammonia = 4: 1: 0.25

54) dihydrochlorid 4-[4-[[4-[2-(metoxykarbonyl)etyl]piperidino]metyl]fenyl]piperidínu54) 4- [4 - [[4- [2- (methoxycarbonyl) ethyl] piperidino] methyl] phenyl] piperidine dihydrochloride

Výťažok: 0,44 g (88 % teórie, živica)Yield: 0.44 g (88% of theory, resin)

Rf-hodnota: 0,65 (doštička RP8 reverzná fáza, metanol/Rf value: 0.65 (RP8 plate, reverse phase, methanol /

5% roztok chloridu sodného = 6:4) ^H-NMR spektrum (200 MHz, DMSO-Dg) , signály pri ppm: 1,2-1,6 (m, 4H) , 1,6-2,05 (m, 6+1H), 2,25-2,4 (t, 2H) , 2,8-3,1 (m, 4+1H), 3,3-3,55 (t, 4H), 3,6 (s, 3H), 4,2 (d, 2H), 7,3 (d, 2H), 7,5 (d, 2H), 8,4-8,9 (m, 2H), 9,9 (s, 1H)5% sodium chloride solution = 6: 4) 1 H-NMR spectrum (200 MHz, DMSO-D 6), signals at ppm: 1.2-1.6 (m, 4H), 1.6-2.05 (m 6 + 1H, 2.25-2.4 (t, 2H), 2.8-3.1 (m, 4 + 1H), 3.3-3.55 (t, 4H), 3.6 (s, 3H), 4.2 (d, 2H), 7.3 (d, 2H), 7.5 (d, 2H), 8.4-8.9 (m, 2H), 9.9 ( s, 1H)

55) hydrochlorid 1-[4-[[4-(metoxykarbonyl-metoxy)fenyl]kárbonylamino]fenyl]piperazínu55) 1- [4 - [[4- (methoxycarbonylmethoxy) phenyl] carbonylamino] phenyl] piperazine hydrochloride

56) hydrochlorid 4-[4-[[4-[2-(metoxykarbonyl)etenyl]fenyl]karbonylamino]fenyl]piperazínu56) 4- [4 - [[4- [2- (methoxycarbonyl) ethenyl] phenyl] carbonylamino] phenyl] piperazine hydrochloride

57) hydrochlorid 4-[4-[[4-[2-(metoxykarbonyl)etyl]fenyl]karbonylamino]fenyl]piperidínu57) 4- [4 - [[4- [2- (methoxycarbonyl) ethyl] phenyl] carbonylamino] phenyl] piperidine hydrochloride

58) hydrochlorid 4-[4-[[trans-4-(metoxykarbonyl)cyklohexyl]metylaminokarbonyl]fenyl]piperidínu58) 4- [4 - [[trans-4- (methoxycarbonyl) cyclohexyl] methylaminocarbonyl] phenyl] piperidine hydrochloride

Teplota topenia: >250 CMelting point: > 250 ° C

R^-hodnota: 0,43 (doštička RP8 reverzná fáza, metanol/5% roztok chloridu sodného =6:4)Rf value: 0.43 (RP8 plate reverse phase, methanol / 5% sodium chloride solution = 6: 4)

59) hydrochlorid 4-[4-[[trans-4-(metoxykarbonyl)cyklohexyl]metylaminokarbonyl]fenyl]piperidínu59) 4- [4 - [[trans-4- (methoxycarbonyl) cyclohexyl] methylaminocarbonyl] phenyl] piperidine hydrochloride

Rf-hodnota: 0,43 (doštička RP8 reverzná fáza, metanol/5% roztok chloridu sodného = 6:4)Rf value: 0.43 (RP8 plate reverse phase, methanol / 5% sodium chloride solution = 6: 4)

60) hydrochlorid 4-[4-[[trans-4-(metoxykarbonyl)cyklohexyl]aminokarbonylamino]fenyl]piperidínu60) 4- [4 - [[trans-4- (methoxycarbonyl) cyclohexyl] aminocarbonylamino] phenyl] piperidine hydrochloride

61) hydrochlorid 4-[4-[[trans-4-(metoxykárbonylmetoxy)cyklohexyl ]aminokarbonyl]fenyl]piperidínu61) 4- [4 - [[trans-4- (methoxycarbonylmethoxy) cyclohexyl] aminocarbonyl] phenyl] piperidine hydrochloride

R£-hodnota: 0,6 (doštička RP8 reverzná fáza, metanol/5% roztok chloridu sodného = 6:4)Rf value: 0.6 (RP8 plate reverse phase, methanol / 5% sodium chloride solution = 6: 4)

62) hydrochlorid 4-[4-[[4-[2-(metoxykarbonyl)etyl]piperidinyl]karbonyl]fenyl]piperidínu62) 4- [4 - [[4- [2- (methoxycarbonyl) ethyl] piperidinyl] carbonyl] phenyl] piperidine hydrochloride

Namiesto kyseliny chlorovodíkovej sa použije kyselina trifluóroctová.Trifluoroacetic acid is used instead of hydrochloric acid.

Teplota topenia: 177 až 179 °C (rozklad)Melting point: 177-179 ° C (decomposition)

63) dihydrochlorid 4-[4-[[trans-4-[2-(metoxykarbonyl)etyl]cyklohexyl]aminokarbonyl]piperidino]piperidínu Namiesto kyseliny chlorovodíkovej sa použije kyselina trifluóroctová.63) 4- [4 - [[trans-4- [2- (methoxycarbonyl) ethyl] cyclohexyl] aminocarbonyl] piperidino] piperidine dihydrochloride Trifluoroacetic acid is used in place of hydrochloric acid.

Výťažok: 1,98 g (75,4 % teórie)Yield: 1.98 g (75.4% of theory)

Teplota topenia: 302 až 303 °C (rozklad).Melting point: 302 DEG-303 DEG C. (decomposition).

Príklad 3Example 3

Hydrochlorid 4-[4-[[trans-4-(2-karboxy-etyl)cyklohexyl]aminokarbonyl]fenyl]piperidínu4- [4 - [[trans-4- (2-carboxyethyl) cyclohexyl] aminocarbonyl] phenyl] piperidine hydrochloride

0,41 g hydrochloridu 4-[4-[[trans-4-[2-(metoxykarbonyl) etyl) cyklohexyl ] aminokarbonyl ] fenyl ] piperidínu sa mieša s 80 ml 6 N kyseliny chlorovodíkovej 4 hodiny pri teplote miestnosti. Vytvorená zrazenina sa odfiltruje a premyje sa vodou.0.41 g of 4- [4 - [[trans-4- [2- (methoxycarbonyl) ethyl) cyclohexyl] aminocarbonyl] phenyl] piperidine hydrochloride was stirred with 80 ml of 6 N hydrochloric acid for 4 hours at room temperature. The precipitate formed is filtered off and washed with water.

Výťažok: 0,33 g (84 % teórie)Yield: 0.33 g (84% of theory)

Teplota topenia: 280 až 285 °CMelting point: 280-285 ° C

R.f-hodnota: 0,07 (silikagél, metylénchlorid/metanol/konc. amoniak = 4:1:0,25)R.f-value: 0.07 (silica gel, methylene chloride / methanol / conc. Ammonia = 4: 1: 0.25)

Hmotové spektrum: M+ = 358.Mass Spectrum: M + = 358.

Analogicky sa získajú nasledujúce zlúčeniny:The following compounds are obtained analogously:

1) hydrochlorid 4-[4-[[4-(2-karboxy-etyl)fenyl]aminokarbonyl ]fenyl]piperidínu1) 4- [4 - [[4- (2-carboxyethyl) phenyl] aminocarbonyl] phenyl] piperidine hydrochloride

Teplota topenia: 290 až 293 °CMelting point: 290-293 ° C

R-p-hodnota: 0,11 (silikagél, metylénchlorid/metanol/ kone. amoniak = 4:1:0,25)R-p value: 0.11 (silica gel, methylene chloride / methanol / conc. Ammonia = 4: 1: 0.25)

Hmotové spektrum: M+ = 352Mass Spectrum: M + = 352

2) hydrochlorid 4-[4-[[4-(2-karboxy-etyl)fenyl]aminokarbonyl ]fenyl]-l-metyl-piperidínu2) 4- [4 - [[4- (2-carboxyethyl) phenyl] aminocarbonyl] phenyl] -1-methylpiperidine hydrochloride

Zmydelní sa hydroxidom lítnym v zmesi 5:4 tetrahydrofuránu a vody', zmieša sa s 1 N kyselinou chlorovodíkovou a tetrahydrofurán sa odparí vo vákuu.It is saponified with lithium hydroxide in a 5: 4 mixture of tetrahydrofuran and water, treated with 1 N hydrochloric acid and the tetrahydrofuran evaporated in vacuo.

Teplota topenia: nad 300 ’CMelting point: above 300 ° C

Rjľ-hodnota: 0,13 (silikagél, metylénchlorid/metanol/ kone. amoniak = 4:1:0,25)Rf value: 0.13 (silica gel, methylene chloride / methanol / conc. Ammonia = 4: 1: 0.25)

Hmotové spektrum: M+ = 366Mass Spectrum: M + = 366

3) hydrochlorid 4-[4-[[4-[2-(n-butánsulfonyl-amino)- 2karboxy-etyl)fenyl]aminokarbonyl]fenyl]piperidínu Teplota topenia: 130 °C (sintruje pri 120 °C)3) 4- [4 - [[4- [2- (n-butanesulfonylamino) -2-carboxyethyl) phenyl] aminocarbonyl] phenyl] piperidine hydrochloride Melting point: 130 ° C (sintered at 120 ° C)

R^-hodnota: 0,15 (silikagél, metylénchlorid/metanol/ kone. amoniak = 4:1:0,25)Rf value: 0.15 (silica gel, methylene chloride / methanol / conc. Ammonia = 4: 1: 0.25)

Hmotové spektrum: (M-H)~ = 486Mass spectrum: (M-H) - = 486

4) hydrochlorid 4-[3-[[trans-4-(2-karboxyetyl)cyklohexyl]aminokarbonyl]fenyl]piperidínu4) 4- [3 - [[trans-4- (2-carboxyethyl) cyclohexyl] aminocarbonyl] phenyl] piperidine hydrochloride

Použije sa zmes 1:1:0,5 vody, kone. kyseliny chlorovodíkovej a ľadovej kyseliny octovej.A 1: 1: 0.5 mixture of water is used. hydrochloric acid and glacial acetic acid.

Rj-hodnota: 0,60 (doštička RP8 reverzná fáza, metanol/5% roztok chloridu sodného = 6:4)Rj value: 0.60 (RP8 plate reverse phase, methanol / 5% sodium chloride solution = 6: 4)

Hmotové spektrum: M+ = 358Mass Spectrum: M + = 358

5) hydrochlorid 4-[3-[[4-(2-karboxyetyl)fenyl]aminokarbonyl ]fenyl]piperidínu5) 4- [3 - [[4- (2-carboxyethyl) phenyl] aminocarbonyl] phenyl] piperidine hydrochloride

Použije sa zmes 1:1:1 vody, kone. kyseliny chlorovodíkovej a ľadovej kyseliny octovej.Use 1: 1: 1 water, horse. hydrochloric acid and glacial acetic acid.

- 6l R^-hodnota: 0,43 (doštička RP8 reverzná fáza, metanol/5% roztok chloridu sodného = 6:4)- 6l Rf -value: 0.43 (RP8 plate reverse phase, methanol / 5% sodium chloride solution = 6: 4)

Elementárna analýza pre xHCl x 1,3.H2O vypočítané 60,47 % C 6,67 % H 6,71 % N nájdené 60,25 % C 6,77 % H 6,65 % NElemental Analysis Found: C, 60.25%; H, 6.77%; H, 6.65%. Found: C, 60.47; H, 6.77;

6) hydrochlorid 4-[3-[[4-[2-(n-butánsulfonylamino)-2karboxyetyl]fenyl]aminokarbonyl]fenyl]piperidínu Vykonáva sa tak, ako v bode 4).6) 4- [3 - [[4- [2- (n-butanesulfonylamino) -2-carboxyethyl] phenyl] aminocarbonyl] phenyl] piperidine hydrochloride Carried out as in 4).

Teplota topenia: nad 200 °CMelting point: above 200 ° C

R^-hodnota: 0,60 (doštička RP8 reverzná fáza, metanol/5% roztok chloridu sodného = 6:4)Rf value: 0.60 (RP8 plate reverse phase, methanol / 5% sodium chloride solution = 6: 4)

Hmotové spektrum. (M+H)+ = 488Mass spectrum. (M + H) &lt; + &gt; = 488

7) hydrochlorid 4-[4-[[trans-4-(2-acetamino-2-karboxyetyl)cyklohexyl]aminokarbonyl]fenyl]piperidínu7) 4- [4 - [[trans-4- (2-acetamino-2-carboxyethyl) cyclohexyl] aminocarbonyl] phenyl] piperidine hydrochloride

8) hydrochlorid 4-[4-[[trans-4-(2-karboxýetyl)cyklohexyl]aminokarbonyl]fenyl]-1-izopropyl-piperidínu8) 4- [4 - [[trans-4- (2-carboxyethyl) cyclohexyl] aminocarbonyl] phenyl] -1-isopropylpiperidine hydrochloride

9) hydrochlorid 4-[4-[[trans-4-(2-karboxy-etyl)cyklohexyl]oxymetyl]fenyl]piperidínu9) 4- [4 - [[trans-4- (2-carboxyethyl) cyclohexyl] oxymethyl] phenyl] piperidine hydrochloride

10) hydrochlorid 4-[4-[[trans-4-(2-karboxy-etyl)cyklohexyl] metyloxy]fenyl]piperidínu10) 4- [4 - [[trans-4- (2-carboxyethyl) cyclohexyl] methyloxy] phenyl] piperidine hydrochloride

11) hydrochlorid 4-[4-[[trans-4-[2-(n-butánsulfonylamino)-2 karboxy-etyl]cyklohexyl]aminokarbonyl]fenyl]piperidínu11) 4- [4 - [[trans-4- [2- (n-butanesulfonylamino) -2-carboxyethyl] cyclohexyl] aminocarbonyl] phenyl] piperidine hydrochloride

12) hydrochlorid 4-[4-[[trans-4-[2-karboxy-2-(metánsulfonyl amino)etyl]cyklohexyl]aminokarbonyl]fenyl]piperidínu12) 4- [4 - [[trans-4- [2-carboxy-2- (methanesulfonyl amino) ethyl] cyclohexyl] aminocarbonyl] phenyl] piperidine hydrochloride

13) hydrochlorid 4-[4-[[trans-4-[2-karboxy-2-(n-hexanoylamino)etyl]cyklohexyl]aminokarbonyl]fenyl]piperidínu13) 4- [4 - [[trans-4- [2-carboxy-2- (n-hexanoylamino) ethyl] cyclohexyl] aminocarbonyl] phenyl] piperidine hydrochloride

14) hydrochlorid 4-[4-[[trans-4-(2-karboxy-propyl)cyklohexyl ]aminokarbonyl]fenyl]piperidínu14) 4- [4 - [[trans-4- (2-carboxypropyl) cyclohexyl] aminocarbonyl] phenyl] piperidine hydrochloride

15) hydrochlorid 4-[4-[N-[trans-4-(2-karboxy-etyl)cyklohexyl]-N-metyl-aminokarbony1]fenyl]piperidínu Teplota topenia: 245 až 247 °C15) 4- [4- [N- [trans-4- (2-carboxyethyl) cyclohexyl] -N-methylaminocarbonyl] phenyl] piperidine hydrochloride Melting point: 245-247 ° C

16) hydrochlorid 4-[4-[[trans-4-(2-karboxy-etyl)cyklohexyl] karbonylamino]fenyl]piperidínu16) 4- [4 - [[trans-4- (2-carboxyethyl) cyclohexyl] carbonylamino] phenyl] piperidine hydrochloride

17) hydrochlorid 4-[4-[[trans-4-(3-karboxy-propyl)-cyklohexyl ]aminokarbonyl]fenyl]piperidínu17) 4- [4 - [[trans-4- (3-carboxy-propyl) -cyclohexyl] aminocarbonyl] phenyl] piperidine hydrochloride

18) hydrochlorid 4-[4-[(trans-4-karboxymetyl-cyklohexyl)aminokarbonyl]fenyl]piperidínu18) 4- [4 - [(trans-4-carboxymethyl-cyclohexyl) aminocarbonyl] phenyl] piperidine hydrochloride

Teplota topenia: >250 °CMelting point: > 250 ° C

Rf-hodnota: 0,5 (doštička RP8 reverzná fáza, metanol/5% roztok chloridu sodného = 6:4)Rf value: 0.5 (RP8 plate reverse phase, methanol / 5% sodium chloride solution = 6: 4)

19) hydrochlorid 4-[4-[[4-(3-karboxy-propyl)-piperidino]karbonyl]fenyl]piperidínu19) 4- [4 - [[4- (3-Carboxy-propyl) -piperidino] carbonyl] phenyl] piperidine hydrochloride

20) hydrochlorid 4-[4-[[4-(4-karboxy-butyl)-piperidino]karbonyl]fenyl]piperidínu20) 4- [4 - [[4- (4-Carboxy-butyl) -piperidino] carbonyl] phenyl] piperidine hydrochloride

21) dihydrochlorid 4-[4-[[4-(3-karboxypropyl)-piperazino]karbonyl]fenyl]piperidínu21) 4- [4 - [[4- (3-Carboxypropyl) -piperazino] carbonyl] phenyl] piperidine dihydrochloride

22) dihydrochlorid 4-[4-[[1-(2-karboxy-etyl)-4-piperidinyl] aminokarbonyl]fenyl]piperidínu22) 4- [4 - [[1- (2-Carboxyethyl) -4-piperidinyl] aminocarbonyl] phenyl] piperidine dihydrochloride

23) hydrochlorid 4-[4-[[4-(3-karboxypropyl)-3-oxo-piperazino]karbonyl]fenyl]piperidínu23) 4- [4 - [[4- (3-carboxypropyl) -3-oxo-piperazino] carbonyl] phenyl] piperidine hydrochloride

24) hydrochlorid 4-[4-[[trans-4-(2-karboxy-etyl)cyklohexyl] aminokarbonyl]fenyl]piperazínu24) 4- [4 - [[trans-4- (2-carboxyethyl) cyclohexyl] aminocarbonyl] phenyl] piperazine hydrochloride

Teplota topenia: 300 až 302 °C (rozklad)Melting point: 300 to 302 ° C (decomposition)

25) hydrochlorid 4-[4-[[trans-4-(2-karboxy-etyl)cyklohexyl] aminokarbonyl]fenyl]chinuklidínu25) 4- [4 - [[trans-4- (2-carboxyethyl) cyclohexyl] aminocarbonyl] phenyl] quinuclidine hydrochloride

26) hydrochlorid 4-[4-[[trans-4-(2-karboxy-etyl)cyklohexyl] aminokarbonyl]fenyl]pyridínu26) 4- [4 - [[trans-4- (2-carboxyethyl) cyclohexyl] aminocarbonyl] phenyl] pyridine hydrochloride

27) hydrochlorid 4-[4-[[trans-4-(2-karboxy-etyl)cyklohexyl] aminokarbonyl]fenyl]-3,4-dehydro-piperidínu27) 4- [4 - [[trans-4- (2-carboxyethyl) cyclohexyl] aminocarbonyl] phenyl] -3,4-dehydro-piperidine hydrochloride

28) hydrochlorid 4-[4-[[trans-4-(2-karboxy-n-oktyl)cyklohexyl ]aminokarbonyl]fenyl]-piperidínu28) 4- [4 - [[trans-4- (2-carboxy-n-octyl) cyclohexyl] aminocarbonyl] phenyl] piperidine hydrochloride

29) hydrochlorid 4-[4-[[trans-4-[2-(benzylsulfonylamino)-2karboxyetyl]cyklohexyl]aminokarbonyl]fenyl]-piperidínu29) 4- [4 - [[trans-4- [2- (benzylsulfonylamino) -2-carboxyethyl] cyclohexyl] aminocarbonyl] phenyl] -piperidine hydrochloride

30) hydrochlorid 4-[4-[[trans-4-(2-karboxy-etyl)cyklohexyl ]aminokarbonyl]fenyl]-4-metyl-piperidínu30) 4- [4 - [[trans-4- (2-carboxyethyl) cyclohexyl] aminocarbonyl] phenyl] -4-methylpiperidine hydrochloride

31) hydrochlorid 4-[4-[[trans-4-(2-karboxy-etyl)cyklohexyl ]aminokarbonyl]fenyl]-4-kyano-piperidínu31) 4- [4 - [[trans-4- (2-carboxyethyl) cyclohexyl] aminocarbonyl] phenyl] -4-cyano-piperidine hydrochloride

32) hydrochlorid 4-aminokarbonyl-4-[4-[[trans-4-(2-karboxyetyl) cyklohexyl]aminokarbonyl]fenyl]piperidínu32) 4-Aminocarbonyl-4- [4 - [[trans-4- (2-carboxyethyl) cyclohexyl] aminocarbonyl] phenyl] piperidine hydrochloride

33) hydrochlorid 4-karboxy-4-[4-[[trans-4-(2-karboxyetyl)cyklohexyl]aminokarbonyl]fenyl]piperidínu33) 4-carboxy-4- [4 - [[trans-4- (2-carboxyethyl) cyclohexyl] aminocarbonyl] phenyl] piperidine hydrochloride

34) hydrochlorid 3-[4-[[trans-4-(2-karboxy-etyl)cyklohexyl ]aminokarbonyl]fenyl]-n-propylamínu34) 3- [4 - [[trans-4- (2-carboxyethyl) cyclohexyl] aminocarbonyl] phenyl] -n-propylamine hydrochloride

35) hydrochlorid 5-[4-[[trans-4-(2-karboxy-etyl)cyklohexyl ]aminokarbonyl]fenyl]-n-pentylamínu35) 5- [4 - [[trans-4- (2-carboxyethyl) cyclohexyl] aminocarbonyl] phenyl] -n-pentylamine hydrochloride

36) hydrochlorid 5-[4-[[trans-4-[2-(n-butánsulfonylamino)-2 karboxyetyl]cyklohexyl]aminokarbonyl]fenyl]-n-pentylamínu36) 5- [4 - [[trans-4- [2- (n-butanesulfonylamino) -2-carboxyethyl] cyclohexyl] aminocarbonyl] phenyl] -n-pentylamine hydrochloride

37) hydrochlorid 5-[4-[[trans-4-[2-karboxy-2-(n-hexanoylamino)etyl]cyklohexyl]aminokarbonyl]fenyl]-n-pentylamínu37) 5- [4 - [[trans-4- [2-carboxy-2- (n-hexanoylamino) ethyl] cyclohexyl] aminocarbonyl] phenyl] -n-pentylamine hydrochloride

38) dihydrochlorid 1-[5-[[trans-4-(2-karboxy-etyl)cyklohexyl ]aminokarbonyl]pyridin-2-yl]piperazínu38) 1- [5 - [[trans -4- (2-carboxyethyl) cyclohexyl] aminocarbonyl] pyridin-2-yl] piperazine dihydrochloride

39) hydrochlorid 4-[4-[[trans-4-(2-karboxy-etyl)cyklohexyl ]aminokarbonyl]-3-metyl-fenyl]piperidínu39) 4- [4 - [[trans-4- (2-carboxyethyl) cyclohexyl] aminocarbonyl] -3-methylphenyl] piperidine hydrochloride

40) hydrochlorid 4-[4-[[trans-4-(2-karboxy-etyl)cyklohexyl] aminokarbonyl] -3-metoxy-fenyl]piperidínu Postupuje sa ako v bode 2).40) 4- [4 - [[trans-4- (2-carboxyethyl) cyclohexyl] aminocarbonyl] -3-methoxyphenyl] piperidine hydrochloride Proceed as in 2).

41) dihydrochlorid 4-[4-[[trans-4-(2-amino-2-karboxy-etyl)cyklohexyl]aminokarbonyl]fenyl]piperidínu41) 4- [4 - [[trans-4- (2-amino-2-carboxyethyl) cyclohexyl] aminocarbonyl] phenyl] piperidine dihydrochloride

42) hydrochlorid 4-[4-[[cis-4-(2-karboxy-etyl)cyklohexyl]aminokarbonyl]fenyl]piperidínu42) 4- [4 - [[cis-4- (2-carboxyethyl) cyclohexyl] aminocarbonyl] phenyl] piperidine hydrochloride

43) hydrochlorid 4-[4-[[cis-4-[2-(n-butánsulfonylamino-2karboxy-etyl]cyklohexyl]aminokarbonyl]fenyl]piperidínu43) 4- [4 - [[cis-4- [2- (n-butanesulfonylamino-2-carboxyethyl) cyclohexyl] aminocarbonyl] phenyl] piperidine hydrochloride

44) hydrochlorid 4-[4-[[4-[2-karboxy-2-(hexanoylamino)etyl] fenyl]aminokarbonyl]fenyl]piperidínu44) 4- [4 - [[4- [2-Carboxy-2- (hexanoylamino) ethyl] phenyl] aminocarbonyl] phenyl] piperidine hydrochloride

45) hydrochlorid 4-[4-[[trans-4-(karboxy-metoxy)cyklohexyl] aminokarbonyl]fenyl]piperidínu45) 4- [4 - [[trans-4- (carboxymethoxy) cyclohexyl] aminocarbonyl] phenyl] piperidine hydrochloride

46) hydrochlorid 4-[4-[[4-(2-karboxy-etyl)fenyl]aminokarbonyl ]piperidino]pyridínu46) 4- [4 - [[4- (2-Carboxyethyl) phenyl] aminocarbonyl] piperidino] pyridine hydrochloride

47) hydrochlorid 4-[4-[[trans-4-(2-karboxy-etyl)cyklohexyl] aminokarbonyl]piperidino]pyridínu47) 4- [4 - [[trans-4- (2-carboxyethyl) cyclohexyl] aminocarbonyl] piperidino] pyridine hydrochloride

48) hydrochlorid 4-[4-[[4-[2-(n-butánsulfonylamino)- 2karboxy-etyl]fenyl]aminokarbonyl]piperidino]piperidínu48) 4- [4 - [[4- [2- (n-Butanesulfonylamino) -2-carboxyethyl] phenyl] aminocarbonyl] piperidino] piperidine hydrochloride

49) hydrochlorid 4-[4-[[4-[2-karboxy-2-(n-hexanoylamino)etyl]fenyl]aminokarbonyl]piperidino]piperidínu49) 4- [4 - [[4- [2-Carboxy-2- (n-hexanoylamino) ethyl] phenyl] aminocarbonyl] piperidino] piperidine hydrochloride

50) hydrochlorid 4-[4-[[trans-4-[2-(n-butánsulfonylamino)-2karboxyetyl]cyklohexyl]aminokarbonyl]piperidino]pyridínu50) 4- [4 - [[trans-4- [2- (n-butanesulfonylamino) -2-carboxyethyl] cyclohexyl] aminocarbonyl] piperidino] pyridine hydrochloride

51) hydrochlorid 4-[4-[[trans-4-[2-karboxy-2-(n-hexanoylamino)etyl]cyklohexyl]aminokarbonyl]piperidino]pyridínu51) 4- [4 - [[trans-4- [2-carboxy-2- (n-hexanoylamino) ethyl] cyclohexyl] aminocarbonyl] piperidino] pyridine hydrochloride

52) hydrochlorid 4-[3-[[4-[2-(benzylsulfonylamino)-2karboxy-etyl]fenyl]aminokarbonyl]fenyl]piperidínu52) 4- [3 - [[4- [2- (Benzylsulfonylamino) -2-carboxyethyl] phenyl] aminocarbonyl] phenyl] piperidine hydrochloride

53) hydrochlorid 4-[3-[[4-[2-karboxy-2-(n-hexanoylamino)etyl]fenyl]aminokarbonyl]fenyl]piperidínu53) 4- [3 - [[4- [2-Carboxy-2- (n-hexanoylamino) ethyl] phenyl] aminocarbonyl] phenyl] piperidine hydrochloride

54) hydrochlorid 4-[4-[[4-[2-(benzylsulfonylamino)-2karboxy-etyl]fenyl]aminokarbonyl]fenyl]piperidínu54) 4- [4 - [[4- [2- (Benzylsulfonylamino) -2-carboxyethyl] phenyl] aminocarbonyl] phenyl] piperidine hydrochloride

55) hydrochlorid 4-[4-[[trans-4-(2-karboxy-etyl)cyklohexyl]aminokarbonyl]-3-fluór-fenyl]piperidínu55) 4- [4 - [[trans-4- (2-carboxyethyl) cyclohexyl] aminocarbonyl] -3-fluorophenyl] piperidine hydrochloride

56) hydrochlorid 4-[4-[[trans-4-(2-karboxy-etyl)cyklohexyl]aminokarbonyl]-3-etoxy-feny1]piperidínu56) 4- [4 - [[trans-4- (2-carboxyethyl) cyclohexyl] aminocarbonyl] -3-ethoxyphenyl] piperidine hydrochloride

Postupuje sa ako v bode 2).Proceed as in 2).

57) hydrochlorid 1-[2-bróm-4-[[trans-4-(2-karboxy-etyl)cyklohexyl]aminokarbonyl]fenyl]piperazínu57) 1- [2-Bromo-4 - [[trans -4- (2-carboxyethyl) cyclohexyl] aminocarbonyl] phenyl] piperazine hydrochloride

58) hydrochlorid 4-[4-[[trans-4-(2-karboxy-etyl)cyklohexyl]aminokarbonyl]-3-chlór-fenyl]piperidínu58) 4- [4 - [[trans-4- (2-carboxyethyl) cyclohexyl] aminocarbonyl] -3-chlorophenyl] piperidine hydrochloride

59) hydrochlorid 4-[4-[[2-bróm-4-(2-karboxyetyl)fenyl]aminokarbonyl ]fenyl]piperidínu59) 4- [4 - [[2-Bromo-4- (2-carboxyethyl) phenyl] aminocarbonyl] phenyl] piperidine hydrochloride

60) hydrochlorid 4-[4-[[4-(2-karboxy-etyl)-2-metoxy-fenyl]aminokarbonyl]fenyl]piperidínu60) 4- [4 - [[4- (2-Carboxyethyl) -2-methoxyphenyl] aminocarbonyl] phenyl] piperidine hydrochloride

61) hydrochlorid 1-[4-[[trans-4-(2-karboxy-etyl)cyklohexyl]aminokarbonyl]-2-metyltiofenyl]piperazínu61) 1- [4 - [[trans-4- (2-carboxyethyl) cyclohexyl] aminocarbonyl] -2-methylthiophenyl] piperazine hydrochloride

62) hydrochlorid 1-[4-[[trans-4-(2-karboxy-etyl)cyklohexyl] aminokarbonyl]-2-metylsulfonylfenyl]piperazínu62) 1- [4 - [[trans-4- (2-carboxyethyl) cyclohexyl] aminocarbonyl] -2-methylsulfonylphenyl] piperazine hydrochloride

63) hydrochlorid 4-[4-[[4-(2-karboxy-etyl-2-metylfenyl]aminokarbonyl]fenyl]piperidínu63) 4- [4 - [[4- (2-Carboxyethyl-2-methylphenyl) aminocarbonyl] phenyl] piperidine hydrochloride

64) hydrochlorid 4-[4-[[4-(2-karboxy-etyl-fenyl]-sulfonylamino]fenyl]piperidínu64) 4- [4 - [[4- (2-Carboxy-ethyl-phenyl] -sulfonylamino] -phenyl] -piperidine hydrochloride

65) hydrochlorid 4-[4-[[4-(2-karboxy-etenylfenyl]aminokarbonyl ]fenyl]piperidínu65) 4- [4 - [[4- (2-Carboxy-ethenylphenyl] aminocarbonyl] phenyl] piperidine hydrochloride

66) hydrochlorid 4-[4-[[trans-4-(2-karboxy-etyl)cyklohexyl] aminokarbonyl]fenyl]-1-metyl-piperidínu66) 4- [4 - [[trans-4- (2-carboxyethyl) cyclohexyl] aminocarbonyl] phenyl] -1-methylpiperidine hydrochloride

Teplota topenia: >300 ’C Hmotové spektrum: M+ = 372Melting point:> 300 ° C Mass spectrum: M + = 372

67) hydrochlorid 4-[1-[[trans-4-(2-karboxy-etyl)cyklohexyl] aminokarbonyl]piperidino]piperidínu67) 4- [1 - [[trans-4- (2-carboxyethyl) cyclohexyl] aminocarbonyl] piperidino] piperidine hydrochloride

68) dihydrochlorid 4-[4-[[trans-4-(2-karboxy-etyl)cyklohexyl ]aminokarbonyl]piperidino]piperidínu Výťažok: 0,77 g (79,5 % teórie)68) 4- [4 - [[trans-4- (2-carboxyethyl) cyclohexyl] aminocarbonyl] piperidino] piperidine dihydrochloride Yield: 0.77 g (79.5% of theory)

Teplota topenia:.297 až 300 °C (rozklad)Melting point: .297-300 ° C (decomposition)

69) hydrochlorid 1-[4-[[4-(karboxy-metoxy)fenyl]karbonylamino]fenyl]piperazínu69) 1- [4 - [[4- (carboxymethoxy) phenyl] carbonylamino] phenyl] piperazine hydrochloride

70) hydrochlorid 4-[4-[[4-(2-karboxy-etenyl)fenyl]karbonylamino]fenyl]piperidínu70) 4- [4 - [[4- (2-Carboxy-ethenyl) phenyl] carbonylamino] phenyl] piperidine hydrochloride

71) hydrochlorid 4-[4-[[4-(2-karboxy-etyl)fenyl]karbonylamino]fenyl]piperidínu71) 4- [4 - [[4- (2-Carboxyethyl) phenyl] carbonylamino] phenyl] piperidine hydrochloride

72) hydrochlorid 4-[4-[[trans-4-(karboxy)cyklohexyl]metylaminokarbonyl]fenyl]piperidínu72) 4- [4 - [[trans-4- (carboxy) cyclohexyl] methylaminocarbonyl] phenyl] piperidine hydrochloride

Teplota topenia: 109 až 110 °CMelting point: 109-110 ° C

73) hydrochlorid 4-[2-[4-(2-karboxy-etyl)fenyl]-1-oxo-2,3dihydroizoindol-6-yl]piperidínu73) 4- [2- [4- (2-Carboxy-ethyl) -phenyl] -1-oxo-2,3-dihydro-isoindol-6-yl] -piperidine hydrochloride

Teplota topenia: 291 až 293 °CMp .: 291-293 ° C

R^-hodnota: 0,52 (doštička RP8 reverzná fáza, metanol/5% roztok chloridu sodného - 6:4)Rf value: 0.52 (RP8 plate reverse phase, methanol / 5% sodium chloride solution - 6: 4)

74) hydrochlorid 2-[4-[[trans-4-(2-karboxy-etyl)cyklohexyl]aminokarbonyl]fenyl]etylaminu74) 2- [4 - [[trans-4- (2-carboxyethyl) cyclohexyl] aminocarbonyl] phenyl] ethylamine hydrochloride

Teplota topenia: 250 °CMelting point: 250 ° C

R£-hodnota: 0,65 (doštička RP8 reverzná fáza, metanol/5% roztok chloridu sodného - 6:4)Rf value: 0.65 (RP8 plate reversed phase, methanol / 5% sodium chloride solution - 6: 4)

75) hydrochlorid 4-[4-[[trans-4-(2-karboxy-metoxy)cyklohexyl ]aminokarbonyl]fenyl]piperidínu75) 4- [4 - [[trans-4- (2-carboxymethoxy) cyclohexyl] aminocarbonyl] phenyl] piperidine hydrochloride

Teplota topenia: >250 °CMelting point: > 250 ° C

R£-hodnota: 0,65 (doštička RP8 reverzná fáza, metanol/5% roztok chloridu sodného - 6:4)Rf value: 0.65 (RP8 plate reversed phase, methanol / 5% sodium chloride solution - 6: 4)

76) hydrochlorid 4-[4-[[trans-4-karboxy-cyklohexyl]aminokarbonyl]fenyl]piperidínu76) 4- [4 - [[trans-4-carboxy-cyclohexyl] aminocarbonyl] phenyl] piperidine hydrochloride

Teplota topenia: >200 °CMelting point: > 200 ° C

R£-hodnota: 0,70 (doštička RP8 reverzná fáza, metanol/5% roztok chloridu sodného - 6:4)Rf value: 0.70 (RP8 plate reverse phase, methanol / 5% sodium chloride solution - 6: 4)

77) hydrochlorid 4-[4-[[4-(2-karboxy-etyl)fenyl]aminokarbonyl ]fenyl]piperidínu77) 4- [4 - [[4- (2-Carboxyethyl) phenyl] aminocarbonyl] phenyl] piperidine hydrochloride

78) hydrochlorid 4-[4-[[4-(2-karboxy-etyl)piperidinyl]karbonyl]fenyl]piperidínu78) 4- [4 - [[4- (2-Carboxyethyl) piperidinyl] carbonyl] phenyl] piperidine hydrochloride

Teplota topenia: 207 až 208 °C (rozklad)Melting point: 207 to 208 ° C (decomposition)

79) hydrochlorid 4-[2-[trans-4-(2-karboxy-etyl)cyklohexyl]1-oxo-2,3-dihydro-izoindol-6-yl]piperidínu R£-hodnota: 0,50 (doštička RP8 reverzná fáza, metanol/5% roztok chloridu sodného - 6:4)79) 4- [2- [trans-4- (2-carboxyethyl) cyclohexyl] 1-oxo-2,3-dihydro-isoindol-6-yl] piperidine hydrochloride R 6 -value: 0.50 (RP8 plate) reverse phase, methanol / 5% sodium chloride solution - 6: 4)

- 68 80) hydrochlorid 4-[2-[trans-4-(2-karboxy-etyl)cyklohexyl]1-oxo-2,3-dihydro-izoindol-5-yl]piperidínu R.£-hodnota: 0,50 (doštička RP8 reverzná fáza, metanol/5% roztok chloridu sodného - 6:4)80) 4- [2- [trans-4- (2-carboxyethyl) cyclohexyl] 1-oxo-2,3-dihydro-isoindol-5-yl] piperidine R hydrochloride. (RP8 plate reverse phase, methanol / 5% sodium chloride solution - 6: 4)

Teplota topenia: >300 ’CMelting point: > 300 ° C

81) hydrochlorid 4-[2-[4-(2-karboxy-etyl)fenyl]-l-oxo-2,3dihydro-izoindol-5-yl]piperidínu81) 4- [2- [4- (2-Carboxy-ethyl) -phenyl] -1-oxo-2,3-dihydro-isoindol-5-yl] -piperidine hydrochloride

Teplota topenia: 303 až 306 ’CMelting point: 303-306 ° C

82) hydrochlorid 4-[4-[[trans-4-(2-karboxy-etyl)cyklohexyl]aminokarbonyl]fenyl]-1-aza-bicyklo[2.2.1]heptánu R^-hodnota: 0 (doštička RP8 reverzná fáza, metanol/5% roztok chloridu sodného - 6:4)82) 4- [4 - [[trans-4- (2-carboxyethyl) cyclohexyl] aminocarbonyl] phenyl] -1-aza-bicyclo [2.2.1] heptane hydrochloride Rf -value: 0 (plate RP8 reverse phase) , methanol / 5% sodium chloride solution - 6: 4)

83) hydrochlorid 4-[4-[[trans-4-(karboxy)cyklohexyl]metylaminokarbonyl]piperidínu83) 4- [4 - [[trans-4- (carboxy) cyclohexyl] methylaminocarbonyl] piperidine hydrochloride

R^-hodnota: 0,56 (doštička RP8 reverzná fáza, metanol/5% roztok chloridu sodného - 6:4) iRf value: 0.56 (RP8 plate reverse phase, methanol / 5% sodium chloride solution - 6: 4) i

Príklad4 'Example4 '

Hydrochlorid 4-[4-[[4-[2-(metoxykarbonyl)etyl]fenyl]aminokarbonyl ] fenyl ] -1-metyl-piperidínu4- [4 - [[4- [2- (methoxycarbonyl) ethyl] phenyl] aminocarbonyl] phenyl] -1-methylpiperidine hydrochloride

0,8 g hydrochloridu 4-[4-[[4-[2-(metoxykarbonyl)etyl]fenyl]aminokarbonyl]fenyl]piperidínu sa rozpustí v 35 ml metanolu, zmieša s 0,42 g paraformaldehydu a 0,45 g nátriumkyánbórhydridu a 3 hodiny sa mieša pri teplote miestnosti, pričom sa hodnota pH udržuje pridávaním 1 N kyseliny chlorovodíkovej medzi 3 a 6. Potom sa pridá ďalších 0,5 g paraformaldehydu a 0,5 g nátriumkyánbórhydridu a 16 hodín sa mieša pri teplote miestnosti a udržovaní vyššie uvedenej acidity roztoku. Zalkalizuje sa 10 N hydroxidom sodným, extrahuje sa etylacetátm, organická fáza sa odparí a čistí sa chromatografiou na silikagéli (elučné činidlo: metylénchlorid/metanol 9:1).0.8 g of 4- [4 - [[4- [2- (methoxycarbonyl) ethyl] phenyl] aminocarbonyl] phenyl] piperidine hydrochloride is dissolved in 35 ml of methanol, mixed with 0.42 g of paraformaldehyde and 0.45 g of sodium cyanoborohydride and Stir for 3 hours at room temperature, maintaining the pH by adding 1 N hydrochloric acid between 3 and 6. An additional 0.5 g of paraformaldehyde and 0.5 g of sodium cyanoborohydride are added and stirred for 16 hours at room temperature while maintaining the above. acidity of the solution. Basify with 10 N sodium hydroxide, extract with ethyl acetate, evaporate the organic phase and purify by silica gel chromatography (eluent: methylene chloride / methanol 9: 1).

Výťažok: 0,58 g (76 % teórie)Yield: 0.58 g (76% of theory)

Teplota topenia: 161 až 164 °CMelting point: 161-164 ° C

R^-hodnota: 0,17 (silikágél, metylénchlorid/metanol = 9:1). Hmotové spektrum: M+ = 380Rf value: 0.17 (silica, methylene chloride / methanol = 9: 1). Mass Spectrum: M + = 380

Analogicky sa získajú nasledujúce zlúčeniny:The following compounds are obtained analogously:

1) l-izopropyl-4-[4-[[trans-4-[2-(metoxykarbonyl)etyl]cyklohexyl]aminokarbonyl]fenyl]piperidín1) 1-isopropyl-4- [4 - [[trans -4- [2- (methoxycarbonyl) ethyl] cyclohexyl] aminocarbonyl] phenyl] piperidine

2) 4-[4-[[trans-4-[2-(metoxykarbonyl)etyl]cyklohexyl]aminokarbonyl ]fenyl]-1-metyl-piperidín2) 4- [4 - [[trans-4- [2- (methoxycarbonyl) ethyl] cyclohexyl] aminocarbonyl] phenyl] -1-methylpiperidine

Teplota topenia: 202 až 204 °CMelting point: 202-204 ° C

3) hydrochlorid 4-[2-[trans-4-(2-karboxy-etyl)cyklohexyl]1-oxo-2,3-dihydro-izoindol-5-yl]-1-metyl-piperidínu Teplota topenia: 301 až 303 °C3) 4- [2- [trans-4- (2-carboxyethyl) cyclohexyl] 1-oxo-2,3-dihydro-isoindol-5-yl] -1-methylpiperidine hydrochloride Melting point: 301 to 303 ° C

Vyrobený zo 4-[2-[trans-4-(2-karboxy-etyl)cyklohexyl]-1oxo-2,3-dihydro-izoindol-5-yl]piperidínu s paraformaldehydom a kyselinou mravčou.Made from 4- [2- [trans-4- (2-carboxyethyl) cyclohexyl] -1-oxo-2,3-dihydro-isoindol-5-yl] piperidine with paraformaldehyde and formic acid.

4) hydrochlorid 3-[4-[[trans-4-(2-karboxy-etyl)cyklohexyl]aminokarbonyl] fenyl] --l-metyl-pyrolidí'nu4) 3- [4 - [[trans-4- (2-carboxyethyl) cyclohexyl] aminocarbonyl] phenyl] -1-methylpyrrolidine hydrochloride

Teplota topenia: 246 až 250 °CMelting point: 246-250 ° C

Vyrobený z hydrochloridu 3-[4-[[trans-4-(2-karboxy-etyl)cyklohexyl]aminokarbonyl]fenyl]pyrolidínu s paraformaldehydom a kyselinou mravčou.Made from 3- [4 - [[trans-4- (2-carboxyethyl) cyclohexyl] aminocarbonyl] phenyl] pyrrolidine hydrochloride with paraformaldehyde and formic acid.

Príklad5Example 5

Hydrochlorid 4-[3-[[trans-4-[2-(metoxykarbonyl)etyl]cyklohexyl ]aminokarbonyl]fenyl]piperidínu4- [3 - [[trans-4- [2- (methoxycarbonyl) ethyl] cyclohexyl] aminocarbonyl] phenyl] piperidine hydrochloride

1,7 g l-benzyl-4-[3-[[trans-4-[2-(metoxykarbonyl)etyl]cyklohexyl]aminokarbonyl]fenyl]- 3,4-dehydro-piperidínu sa rozpustí v 40 ml metanolu, zmieša sa 2 ml matanolickej kyseliny chlorovodíkovej a 0,5 g hydroxidu paládia na Uhlí a hydrogenuje sa pri 50 °C a tlaku vodíka 0,5 MPa. Potom sa katalyzátor odfiltruje a zmes sa odparí vo vákuu.Dissolve 1.7 g of 1-benzyl-4- [3 - [[trans-4- [2- (methoxycarbonyl) ethyl] cyclohexyl] aminocarbonyl] phenyl] -3,4-dehydro-piperidine in 40 ml of methanol, mix 2 ml of methanolic hydrochloric acid and 0.5 g of palladium hydroxide on carbon are hydrogenated at 50 DEG C. and a hydrogen pressure of 0.5 MPa. The catalyst was then filtered off and the mixture was evaporated in vacuo.

Výťažok: 1,30 g (87 % teórie)Yield: 1.30 g (87% of theory)

Rj?-hodnota: 0,25 (doštička RP8 reverzná fáza, metanol/5% roztok chloridu sodného = 6:4)Rf value: 0.25 (RP8 plate reverse phase, methanol / 5% sodium chloride solution = 6: 4)

Hmotové spektrum = M+ = 372Mass Spectrum = M + = 372

Analogicky sa získajú nasledujúce zlúčeniny:The following compounds are obtained analogously:

1) 4-[3-[[4-[2-(metoxykarbonyl)etyl]fenyl]aminokarbonyl]fenyl]piperidín1) 4- [3 - [[4- [2- (methoxycarbonyl) ethyl] phenyl] aminocarbonyl] phenyl] piperidine

Pracuje sa bez prídavku kyseliny chlorovodíkovej s 10% paládiom na uhlí.It is operated without the addition of hydrochloric acid with 10% palladium on carbon.

R^-hodnota·: 0,27 (doštička RP8 reverzná fáza, metanol/5%. roztok chloridu sodného = 6:4)Rf value: 0.27 (RP8 plate reverse phase, methanol / 5% sodium chloride solution = 6: 4)

2) hydrochlorid 4-[3-[[4-[2-(n-butylsulfonylamino)-2(metoxykarbonyl)etyl]fenyl]aminokarbonyl]fenyl]piperidínu Postupuje sa ako v bode 1) ale pri 60 °C.2) 4- [3 - [[4- [2- (n-butylsulfonylamino) -2 (methoxycarbonyl) ethyl] phenyl] aminocarbonyl] phenyl] piperidine hydrochloride The procedure is as in 1) but at 60 ° C.

Rf-hodnota: 0,28 (doštička RP8 reverzná fáza, metanol/5% roztok chloridu sodného = 6:4)Rf value: 0.28 (RP8 plate reverse phase, methanol / 5% sodium chloride solution = 6: 4)

Hmotové spektrum: (M+H)+ = 502.Mass Spectrum: (M + H) + = 502.

3) hydrochlorid 1-[4-[[trans-4-[2-(metoxykarbonyl)etyl]cyklohexyl]aminokarbonyl]fenyl]piperazínu3) 1- [4 - [[trans-4- [2- (methoxycarbonyl) ethyl] cyclohexyl] aminocarbonyl] phenyl] piperazine hydrochloride

Vyrobí sa debenzyláciou 4-[4-[[trans-4-[2-(metoxykarbonyl) etyl ]cyklohexyl]aminokarbonyl]fenyl]-1-benzyl-pipeŕazínu za prítomnosti 10% paládia na uhlí.It is produced by debenzylation of 4- [4 - [[trans -4- [2- (methoxycarbonyl) ethyl] cyclohexyl] aminocarbonyl] phenyl] -1-benzylpiperazine in the presence of 10% palladium on carbon.

Teplota topenia: 190 až 192 °C.Melting point: 190-192 ° C.

4) hydrochlorid 4-[2-[4-[2-(metoxykarbonyl)etyl]fenyl]-1oxo-2,3-dihydro-izoindol-6-yl]piperidínu4) 4- [2- [4- [2- (methoxycarbonyl) ethyl] phenyl] -1-oxo-2,3-dihydro-isoindol-6-yl] piperidine hydrochloride

5) hydrochlorid 4-[2-[trans-4-(metoxykarbonyl)etyl]cyklohexyl] -l-oxo-2,3-dihydro-izoindol-6-yl]piperidínu Teplota topenia: 175 až 178 °C5) 4- [2- [trans-4- (methoxycarbonyl) ethyl] cyclohexyl] -1-oxo-2,3-dihydro-isoindol-6-yl] piperidine hydrochloride Melting point: 175-178 ° C

Vyrobený z l-benzyl-4-[2-[trans-4-[2-(metoxykarbonyl)etyl]-cyklohexyl]-l-oxo-2,3-dihydro-izoindol-6-yl]-3,4dehydro-piperidínu a hydroxidu paládia na uhlí ako kata71 lyzátora.Made from 1-benzyl-4- [2- [trans-4- [2- (methoxycarbonyl) ethyl] -cyclohexyl] -1-oxo-2,3-dihydro-isoindol-6-yl] -3,4-dehydro-piperidine and palladium hydroxide on carbon as the catalyst of the lysator.

6) hydrochlorid 4-[2-[trans-4-[2-(metoxykarbonyl)etyl]cyklohexyl ]-1-oxo-2,3-dihydro-izoindol-5-ýl]piperidínu Teplota topenia: 260 až 262 ’C6) 4- [2- [trans-4- [2- (methoxycarbonyl) ethyl] cyclohexyl] -1-oxo-2,3-dihydro-isoindol-5-yl] piperidine hydrochloride Melting point: 260-262 ° C

7) hydrochlorid 4-[2-[4-[2-(metoxykarbonyl)etyl]cyklohexyl]l-oxo-2,3-dihydro-izoindol-5-yl]piperidínu7) 4- [2- [4- [2- (methoxycarbonyl) ethyl] cyclohexyl] 1-oxo-2,3-dihydro-isoindol-5-yl] piperidine hydrochloride

Teplota topenia: 232 až 235 “CMp .: 232-235 ° C

Príklad 6 l-benzyl-4-[3-[[trans-4-[2-(metoxykarbonyl)etyl]cyklohexyl]aminokarbonyl]fenyl]-3,4-dehydro-piperidín g hydrochloridu l-benzyl-4-(3-karboxy-fenyl)-3,4-dehydro-piperidínu sa zohrieva v 3,5 ml tionylchloridu 45 minút na teplotu refluxu a potom sa za vákua odparí do sucha. Takto získaný chlorid kyseliny sa po častiach pridá k 0 ’C ochladenému roztoku 1,3 g hydrochloridu metylesteru kyseliny 3-(trans-4-amino-cyklohexyl)-propiónovej a 3,3 ml N-etyl-diizopropylamínu v 50 ml metylénchloridu.’ Po 2 hodinách sa pridá 300 ml metylénchloridu a 15 ml metanolu, premyje sa postupne vodou, 0,1 N hydroxidom sodným, vodou, 0,1 N kyselinou chlorovodíkovou a vodou a odparí sa organická fáza. Produkt sa prečistí stĺpcovou chromatografiou na silikagéli (elučné činidlo: metylénchlorid/metanol = 9:1).Example 6 1-Benzyl-4- [3 - [[trans-4- [2- (methoxycarbonyl) ethyl] cyclohexyl] aminocarbonyl] phenyl] -3,4-dehydro-piperidine g 1-benzyl-4- (3- of carboxy-phenyl) -3,4-dehydro-piperidine was heated in refluxing thionyl chloride (3.5 ml) for 45 minutes and then evaporated to dryness in vacuo. The acid chloride thus obtained is added in portions to a cooled solution of 1.3 g of 3- (trans-4-amino-cyclohexyl) -propionic acid methyl ester hydrochloride and 3.3 ml of N-ethyl-diisopropylamine in 50 ml of methylene chloride. After 2 hours 300 ml of methylene chloride and 15 ml of methanol are added, washed successively with water, 0.1 N sodium hydroxide, water, 0.1 N hydrochloric acid and water and the organic phase is evaporated. The product was purified by column chromatography over silica gel (eluent: methylene chloride / methanol = 9: 1).

Výťažok: 1,8 g (64 % teórie)Yield: 1.8 g (64% of theory)

R^-hodnota: 0,42 (silikagél, metylénchlorid/metanol = 9:1)Rf value: 0.42 (silica gel, methylene chloride / methanol = 9: 1)

Analogicky sa získajú nasledujúce zlúčeniny:The following compounds are obtained analogously:

1) l-benzyl-4-[3-[[4-[2-(metoxykarbonyl)etyl]fenyl]aminokarbonyl] fenyl]-3,4-dehydro-piperidín Teplota topenia: 194 až 196 ’C1) 1-Benzyl-4- [3 - [[4- [2- (methoxycarbonyl) ethyl] phenyl] aminocarbonyl] phenyl] -3,4-dehydro-piperidine M.p .: 194-196 ° C

R^-hodnota: 0,66 (silikagél, metylénchlorid/metanol =Rf value: 0.66 (silica gel, methylene chloride / methanol =

9:1)9: 1)

2) hydrochlorid l-benzyl-4-[3-[[4-[2-(n-butánsulfonylamino)2-(metoxykarbonyl)etyl]fenyl]aminokarbonyl]fenyl]-3,4dehydro-piperidínu2) 1-benzyl-4- [3 - [[4- [2- (n-butanesulfonylamino) -2- (methoxycarbonyl) ethyl] phenyl] aminocarbonyl] phenyl] -3,4-dehydro-piperidine hydrochloride

R^-hodnota: 0,25 (silikagél, metylénchlorid/metanol = 20:1)Rf value: 0.25 (silica gel, methylene chloride / methanol = 20: 1)

Príklad 7Example 7

Hydrochlorid 4-[4-[[4-(2-karboxy-etyl)fenyl]aminometyl]fenyl]piperidínu4- [4 - [[4- (2-Carboxyethyl) phenyl] aminomethyl] phenyl] piperidine hydrochloride

0,7 g· 4-[4-[[4-[2-(metoxykarbonyl)etyl]fenyl]aminometyl]fenyl]-1-trifluóracetyl-piperidínu, 10 ml ladovej kyseliny octovej a 1 ml kone. kyseliny chlorovodíkovej sa 4 hodiny mieša pri 80 “C a 16 hodín pri teplote miestnosti. Za vákua sa odparí do sucha, viackrát sa odparí s toluénom a zvyšok sa mieša s 50 ml acetónu.0.7 g of 4- [4 - [[4- [2- (methoxycarbonyl) ethyl] phenyl] aminomethyl] phenyl] -1-trifluoroacetylpiperidine, 10 ml of glacial acetic acid and 1 ml of horse. hydrochloric acid was stirred at 80 ° C for 4 hours and at room temperature for 16 hours. It is evaporated to dryness in vacuo, evaporated several times with toluene and the residue is stirred with 50 ml of acetone.

Výťažok: 0,39 g (66 % teórie)Yield: 0.39 g (66% of theory)

R^-hodnota: 0,76 (doštička RP8 reverzná fáza, metanol/5% roztok chloridu sodného = 9:1)Rf value: 0.76 (RP8 plate reverse phase, methanol / 5% sodium chloride solution = 9: 1)

Hmotové spektrum: M+ = 338Mass Spectrum: M + = 338

Analogicky sa získajú nasledujúce zlúčeniny:The following compounds are obtained analogously:

1) hydrochlorid 4-[2-[trans-4-(2-karboxy-etyl)cyklohexyl]l-oxo-2,3-dihydro-izoindol-6-yl]-piperidínu1) 4- [2- [trans-4- (2-carboxy-ethyl) cyclohexyl] 1-oxo-2,3-dihydro-isoindol-6-yl] -piperidine hydrochloride

2) hydrochlorid 4-[2-[4-[2-(n-butánsulfonylamino)-2-karboxyetyljfenyl]-l-oxo-2,3-dihydro-izoindol-6-yl]-piperidínu2) 4- [2- [4- [2- (n-Butanesulfonylamino) -2-carboxyethyl] phenyl] -1-oxo-2,3-dihydro-isoindol-6-yl] -piperidine hydrochloride

3) dihydrochlorid 4-[4-[[trans-4-(2-karboxyetyl)cyklohexyl]aminometyl]fenyl]piperidínu3) 4- [4 - [[trans-4- (2-carboxyethyl) cyclohexyl] aminomethyl] phenyl] piperidine dihydrochloride

Teplota topenia: 308 až 311 °C (rozklad)Melting point: 308-311 ° C (decomposition)

4) dihydrochlorid 4-[4-[N-[trans-4-(2-karboxyetyl)cyklohexyl ]-N-metylaminometyl]fenyl]piperidínu4) 4- [4- [N- [trans-4- (2-carboxyethyl) cyclohexyl] -N-methylaminomethyl] phenyl] piperidine dihydrochloride

5) dihydrochlorid 4-[4-[N-[trans-4-(2-karboxyetyl)cyklo73 hexyl]-N-(2-fenyletyl)-aminometyl]fenyl]piperidínu5) 4- [4- [N- [trans-4- (2-carboxyethyl) cyclo73 hexyl] -N- (2-phenylethyl) aminomethyl] phenyl] piperidine dihydrochloride

6) hydrochlorid 4-[4-[[trans-4-(2-karboxyetyl)cyklohexyl]aminosulfonyl]fenyl]piperidínu6) 4- [4 - [[trans-4- (2-carboxyethyl) cyclohexyl] aminosulfonyl] phenyl] piperidine hydrochloride

7) hydrochlorid 4-[4-[2-[4-(2-karboxyetyl)fenyl]etenyl]fenyl]piperidínu7) 4- [4- [2- [4- (2-carboxyethyl) phenyl] ethenyl] phenyl] piperidine hydrochloride

8) hydrochlorid 4-[2-[trans-4-(2-karboxyetyl)cyklohexyl]1-oxo-2,3-dihydro-izoindol-5-yl]piperidínu8) 4- [2- [trans-4- (2-carboxyethyl) cyclohexyl] 1-oxo-2,3-dihydro-isoindol-5-yl] piperidine hydrochloride

9) hydrochlorid 4-[2-[4-(2-karboxyetyl)fenyl]-l-oxo-2,3dihydro-izoindol-5-yl]piperidínu9) 4- [2- [4- (2-carboxyethyl) phenyl] -1-oxo-2,3-dihydro-isoindol-5-yl] piperidine hydrochloride

10) hydrochlorid 4-[2-[4-[2-(n-butánsulfonylamino)-2karboxyetyl]fenyl]-l-oxo-2,3-dihydro-izoindol-5-yl]piperidínu10) 4- [2- [4- [2- (n-Butanesulfonylamino) -2-carboxyethyl] phenyl] -1-oxo-2,3-dihydro-isoindol-5-yl] piperidine hydrochloride

11) hydrochlorid 4-[2-[trans-4-(2-karboxyetyl)cyklohexyl]1-oxo-2,3-dihydro-izochinolin-7-yl]piperidínu11) 4- [2- [trans-4- (2-carboxyethyl) cyclohexyl] 1-oxo-2,3-dihydroisoquinolin-7-yl] piperidine hydrochloride

12) hydrochlorid 4-[2-[4-(2-karboxyetyl)f’enyl]-l-oxo-2,3dihydro-izochinolin-7-y1]piperidínu12) 4- [2- [4- (2-Carboxyethyl) phenyl] -1-oxo-2,3-dihydro-isoquinolin-7-yl] piperidine hydrochloride

13) hydrochlorid 4-[2-[4-(2-karboxyetyl)fenyl]-l-oxo-2,3dihydro-izoindol-6-yl]piperidínu13) 4- [2- [4- (2-Carboxyethyl) phenyl] -1-oxo-2,3-dihydro-isoindol-6-yl] piperidine hydrochloride

14) hydrochlorid 4-[4-[2-[4-(2-karboxyetyl)-fenyl]-etyl]f eňyl]piperidínu14) 4- [4- [2- [4- (2-Carboxyethyl) -phenyl] -ethyl] -phenyl] -piperidine hydrochloride

15) hydrochlorid 4-[4-[[4-(2-karboxyetyl)fenyl]metyl]amino] fenyl]piperidínu15) 4- [4 - [[4- (2-carboxyethyl) phenyl] methyl] amino] phenyl] piperidine hydrochloride

16) hydrochlorid 4-[4-[(trans-4-karboxy-cyklohexyl)aminokarbonyl ] f enyl ] piperidínu16) 4- [4 - [(trans-4-carboxy-cyclohexyl) aminocarbonyl] phenyl] piperidine hydrochloride

Teplota topenia: nad 310 °CMelting point: above 310 ° C

R^-hodnota: 0,13 (silikagél, metylénchlorid/metanol/ kone. amoniak = 4:1:0,25)Rf value: 0.13 (silica gel, methylene chloride / methanol / conc. Ammonia = 4: 1: 0.25)

17) hydrochlorid 4-[4-[[4-(karboxy-metyloxy)fenyl]karbonylamino]fenyl]piperidínu17) 4- [4 - [[4- (carboxymethyloxy) phenyl] carbonylamino] phenyl] piperidine hydrochloride

Vyrobený zo 4-[4-[[4-(terc.butyloxykarbonyl-metyloxy)fenyl]karbonylamino]fenyl]-1-trifluóracetyl-piperidínu R^-hodnota: 0,10 (silikagél, metylénchlorid/metanol = 9:1)Made from 4- [4 - [[4- (tert-butyloxycarbonylmethyloxy) phenyl] carbonylamino] phenyl] -1-trifluoroacetylpiperidine Rf value: 0.10 (silica gel, methylene chloride / methanol = 9: 1)

Hmotové spektrum: (M+H)+ = 355Mass Spectrum: (M + H) + = 355

Príklad 8Example 8

4-[4-[[4-[2-(metoxykarboxy)-etyl]fenyl]aminometyl]fenyl]1-trifluóracetyl-piperidínu4- [4 - [[4- [2- (metoxykarboxy) ethyl] phenyl] aminomethyl] phenyl] -1-trifluoroacetyl-piperidine

8,6 g 4-[4-[[4-[2-(metoxykarboxy)etyl]fenyl]iminometyl]fenyl]-l-trifluóracetyl-piperidínu sa rozpustí v 100 ml etylacetátu a za prítomnosti 0,5 g oxidu platičitého sa hydrogenuje najskôr 1,5 hodiny pri teplote miestnosti vodíkom pri tlaku 0,5 MPa. Pridá sa ďalších 0,5 g oxidu platičitého a teplota vystúpi na 50 °C. Po 3 hodinách sa ešte pridá 0,5 g oxidu platičitého a hydrogenuje sa ďalšie 4 hodiny. Po odfiltrovaní katalyzátora sa odstráni rozpúšťadlo a zvyšok sa prečistí stĺpcovou chromatografiou na silikagéli (elučné činidlo: cyklohexán/etylacetát = 3:1).8.6 g of 4- [4 - [[4- [2- (methoxycarboxy) ethyl] phenyl] iminomethyl] phenyl] -1-trifluoroacetyl-piperidine are dissolved in 100 ml of ethyl acetate and hydrogenated in the presence of 0.5 g of platinum oxide. at least 1.5 hours at room temperature with hydrogen at 0.5 MPa. An additional 0.5 g of platinum oxide was added and the temperature rose to 50 ° C. After 3 hours, 0.5 g of platinum oxide was added and hydrogenated for a further 4 hours. After the catalyst was filtered off, the solvent was removed and the residue was purified by silica gel column chromatography (eluent: cyclohexane / ethyl acetate = 3: 1).

Výťažok: 3,6 g (42 % teórie)Yield: 3.6 g (42% of theory)

R^-hodnota: 0,50 (silikagél, cyklohexán/etylacetát = 2:1)Rf value: 0.50 (silica gel, cyclohexane / ethyl acetate = 2: 1)

Príklad 9Example 9

Hydrochlorid 4-[4-[[trans-4-[2-(izopropylkarbonyl)etyl]cyklohexyl]aminometyl]fenyl]-piperidínu4- [4 - [[trans-4- [2- (isopropylcarbonyl) ethyl] cyclohexyl] aminomethyl] phenyl] -piperidine hydrochloride

0,15 g hydrochloridu 4-[4-[[trans-4-(2-karboxy-etyl)cyklohexyl]aminometyl]fenyl]-piperidínu sa suspenduje v zmesi 100 ml izopropanolu a 50 ml éterickej kyseliny chlorovodíkovej a mieša sa 16 hodín pri teplote miestnosti. Produkt sa získa odparením roztoku vo vákuu.0.15 g of 4- [4 - [[trans-4- (2-carboxyethyl) cyclohexyl] aminomethyl] phenyl] piperidine hydrochloride is suspended in a mixture of 100 ml of isopropanol and 50 ml of ethereal hydrochloric acid and stirred for 16 hours at room temperature. The product is obtained by evaporating the solution in vacuo.

Výťažok: 0,135 g (81 % teórie)Yield: 0.135 g (81% of theory)

Teplota topenia: 255 až 260 °CMelting point: 255-260 ° C

Rf-hodnota: 0,31 (silikagél, metylénchlorid/metanol/konc. amoniak = 4:1:0,25)Rf value: 0.31 (silica gel, methylene chloride / methanol / conc. Ammonia = 4: 1: 0.25)

Hmotové spektrum: M+ = 400.Mass Spectrum: M + = 400.

Sl> Analogicky sa získajú nasledujúce zlúčeniny: Sl > Analogously the following compounds are obtained:

1) hydrochlorid 4-[4-[[trans-4-[2-(sek.-butyloxykarbonyl)* etyl]cyklohexyl]aminokarbonyl]fenyl]-piperidínu1) 4- [4 - [[trans-4- [2- (sec-butyloxycarbonyl) * ethyl] cyclohexyl] aminocarbonyl] phenyl] piperidine hydrochloride

2) hydrochlorid 4-[4-[[trans-4-[2-(cyklohexyloxykarbonyl)etyl]cyklohexyl]aminokarbonyl]fenyl]-piperidínu Teplota topenia: 238 až 240 ’C2) 4- [4 - [[trans -4- [2- (cyclohexyloxycarbonyl) ethyl] cyclohexyl] aminocarbonyl] phenyl] piperidine hydrochloride Melting point: 238-240 ° C

3) hydrochlorid 4-[4-[[trans-4-[2-(izobutyloxykarbonyl)etyl]cyklohexyl]aminokarbonyl]fenyl]-piperidínu Teplota topenia: 238 až 240 °C3) 4- [4 - [[trans -4- [2- (isobutyloxycarbonyl) ethyl] cyclohexyl] aminocarbonyl] phenyl] piperidine hydrochloride Melting point: 238-240 ° C

4) hydrochlorid 4-[4-[[trans-4-[2-[(2-fenyl-etyl)oxykarbonyl]etyl]cyklohexyl]aminokarbonyl]fenyl]-piperidínu4) 4- [4 - [[trans-4- [2 - [(2-phenyl-ethyl) oxycarbonyl] ethyl] cyclohexyl] aminocarbonyl] phenyl] -piperidine hydrochloride

5) hydrochlorid 4-[2-[4-[2-(metoxykarbonyl)etyl]fenyl]-1oxo-2,3-dihydro-izoindol-6-yl]-piperidínu a5) 4- [2- [4- [2- (methoxycarbonyl) ethyl] phenyl] -1-oxo-2,3-dihydro-isoindol-6-yl] -piperidine hydrochloride; and

6) hydrochlorid 4-[2-[trans-4-[2-(metoxykarbonyl)etyl]cyklohexyl] -1-oxo-2,3-dihydro-izoindol-6-yl]-piperidínu6) 4- [2- [trans-4- [2- (methoxycarbonyl) ethyl] cyclohexyl] -1-oxo-2,3-dihydro-isoindol-6-yl] -piperidine hydrochloride

7) hydrochlorid 4-[2-[4-[2-(n-butánsulfonylamino)-2-(metoxykarbonyl) etyl ]fenyl]-1-oxo-2,3-dihydro-izoindol-6-yl]piperidínu7) 4- [2- [4- [2- (n-Butanesulfonylamino) -2- (methoxycarbonyl) ethyl] phenyl] -1-oxo-2,3-dihydro-isoindol-6-yl] piperidine hydrochloride

8) ditrifluóracetát 4-[4-[[trans-4-[2-(metoxykarbonyl)etyl]cyklohexyl]aminometyl]fenyl]-piperidínu8) 4- [4 - [[trans-4- [2- (methoxycarbonyl) ethyl] cyclohexyl] aminomethyl] phenyl] piperidine ditrifluoroacetate

Teplota topenia: 77 až 79 °C (rozklad)Melting point: 77 to 79 ° C (decomposition)

9) dihydrochlorid 4-[4-[N-[trans-4-[2-(metoxykarbonyl)etyl] cyklohexyl]-N-metyl-aminometyl]fenyl]-piperidínu9) 4- [4- [N- [trans-4- [2- (methoxycarbonyl) ethyl] cyclohexyl] -N-methyl-aminomethyl] phenyl] piperidine dihydrochloride

10) dihydrochlorid 4-[4-[N-[trans-4-[2-(metoxykarbonyl)etyl]cyklohexyl]-N-(2-fenyl-etyl)-aminometyl]fenyl]piperidínu10) 4- [4- [N- [trans-4- [2- (methoxycarbonyl) ethyl] cyclohexyl] -N- (2-phenyl-ethyl) -aminomethyl] phenyl] piperidine dihydrochloride

11) hydrochlorid 4-[4-[[trans-4-[2-(metoxykarbonyl)etyl]cyklohexyl]aminosulfonyl]fenyl]piperidínu11) 4- [4 - [[trans-4- [2- (methoxycarbonyl) ethyl] cyclohexyl] aminosulfonyl] phenyl] piperidine hydrochloride

12) hydrochlorid 4-[4-[2-[4-[2-(metoxykarbonyl)etyl]fenyl]etenyl]fenyl]piperidínu12) 4- [4- [2- [4- [2- (methoxycarbonyl) ethyl] phenyl] ethenyl] phenyl] piperidine hydrochloride

13) hydrochlorid 4-[2-[trans-4-[2-(metoxykarbonyl)etyl]cyklohexyl]-l-oxo-2,3-dihydro-izoindol-5-yl]piperidínu13) 4- [2- [trans-4- [2- (methoxycarbonyl) ethyl] cyclohexyl] -1-oxo-2,3-dihydro-isoindol-5-yl] piperidine hydrochloride

14) hydrochlorid 4-[2-[4-[2-(metoxykarbonyl)etyl]fenyl]-1oxo-2,3-dihydro-izoindol-5-yl]piperidínu14) 4- [2- [4- [2- (methoxycarbonyl) ethyl] phenyl] -1-oxo-2,3-dihydro-isoindol-5-yl] piperidine hydrochloride

15) hydrochlorid 4-[2-[4-[2-(n-butánsulfonylamino)-2-(metoxykarbonyl) etyl ]fenyl]-l-oxo-2,3-dihydro-izoindol-5-yl] piperidínu15) 4- [2- [4- [2- (n-Butanesulfonylamino) -2- (methoxycarbonyl) ethyl] phenyl] -1-oxo-2,3-dihydro-isoindol-5-yl] piperidine hydrochloride

16) hydrochlorid 4-[2-[trans-4-[2-(metoxykarbonyl)etyl]cyklohexyl]-l-oxo-3,4-dihydro-izochinolin-7-yl]piperidínu16) 4- [2- [trans-4- [2- (methoxycarbonyl) ethyl] cyclohexyl] -1-oxo-3,4-dihydro-isoquinolin-7-yl] piperidine hydrochloride

17) hydrochlorid 4-[2-[4-[2-(metoxykarbonyl)etyl]fenyl]-1oxo-3,4-dihydro-izochinolin-7-yl]piperidínu17) 4- [2- [4- [2- (methoxycarbonyl) ethyl] phenyl] -1-oxo-3,4-dihydroisoquinolin-7-yl] piperidine hydrochloride

18) hydrochlorid 4-[4-[2-[4-[2-(metoxykarbonyl)etyl]fenyl]etyl]fenyl]piperidínu18) 4- [4- [2- [4- [2- (methoxycarbonyl) ethyl] phenyl] ethyl] phenyl] piperidine hydrochloride

19) hydrochlorid 4-[4-[[4-[2-(metoxykarbonyl)etyl]fenyl]metylamino]fenyl]piperidínu19) 4- [4 - [[4- [2- (methoxycarbonyl) ethyl] phenyl] methylamino] phenyl] piperidine hydrochloride

20) hydrochlorid 4-[4-[[4-[2-(metoxykarbonyl)etyl]fenyl]aminometyl]fenyl]piperidínu20) 4- [4 - [[4- [2- (methoxycarbonyl) ethyl] phenyl] aminomethyl] phenyl] piperidine hydrochloride

21) hydrochlorid 4-[4-[[trans-4-(izopropylkarbonyl)cyklohexyl ]aminokarbonyl]fenyl]piperidínu21) 4- [4 - [[trans-4- (isopropylcarbonyl) cyclohexyl] aminocarbonyl] phenyl] piperidine hydrochloride

Teplota topenia: 270 °C (sintruje pri 250 °C)Melting point: 270 ° C (sintered at 250 ° C)

R^-hodnota: 0,38 (silikagél, metylénchlorid/metanol/konc. amoniak =4:1:0,25)Rf value: 0.38 (silica gel, methylene chloride / methanol / conc. Ammonia = 4: 1: 0.25)

22) hydrochlorid 4-[4-[[trans-4-[2-(etoxykarbonyl)etyl]cyklohexyl]aminokarbonyl]fenyl]piperidínu22) 4- [4 - [[trans-4- [2- (ethoxycarbonyl) ethyl] cyclohexyl] aminocarbonyl] phenyl] piperidine hydrochloride

Teplota topenia: 246 až 248 ’CMelting point: 246-248 ° C

23) hydrochlorid 4-[4-[[trans-4-(etoxykarbonyl-metyloxy)cyklohexyl]aminokarbonyl]fenyl]piperidínu Rf-hodnota: 0,60 (doštička RP8 reverzná fáza, metanol/5% roztok chloridu sodného = 6:4)23) 4- [4 - [[trans -4- (ethoxycarbonylmethyloxy) cyclohexyl] aminocarbonyl] phenyl] piperidine hydrochloride Rf value: 0.60 (RP8 plate, reverse phase, methanol / 5% sodium chloride solution = 6: 4) )

24) 4-[4-[[4-(metoxykarbonyl-metyloxy)fenyl]karbonylamino]fenyl]piperidín24) 4- [4 - [[4- (methoxycarbonylmethyloxy) phenyl] carbonylamino] phenyl] piperidine

25) hydrochlorid 4-[2-[trans-4-[2-(etoxykarbonyl)etyl]cyklohexyl]-l-oxo-2,3-dihydro-izoindol-5-y1]piperidínu Teplota topenia: 260 až 264 ’C.25) 4- [2- [trans-4- [2- (ethoxycarbonyl) ethyl] cyclohexyl] -1-oxo-2,3-dihydro-isoindol-5-yl] piperidine hydrochloride Melting point: 260-264 ° C.

Príklad 10Example 10

1-(metoxykarbonyl)-4-[4-[[trans-4-[2-(metoxykarbonyl)etyl]cyklohexyl]aminokarbonyl]fenyl]-piperidín1- (methoxycarbonyl) -4- [4 - [[trans-4- [2- (methoxycarbonyl) ethyl] -cyclohexyl] -aminocarbonyl] -phenyl] -piperidine

Vyrobí sa zo 4-[4-[[trans-4-[2-(metoxykarbonyl)etyl]cyklohexyl]aminometyl]fenyl]-piperidínu a metylesteru kyseliny chlórmravčej v metylénchloride za prítomnosti 0,2 N hydroxidu sodného.Prepared from 4- [4 - [[trans-4- [2- (methoxycarbonyl) ethyl] cyclohexyl] aminomethyl] phenyl] -piperidine and methyl chloroformate in methylene chloride in the presence of 0.2 N sodium hydroxide.

Analogicky sa získa nasledujúca zlúčenina:The following compound is obtained analogously:

1) 1-(acetoxy-metoxykarbonyl)-4-[4-[[trans-4-[2-(metoxykarbonyl) ety 1 ]cyklohexyl]aminokarbonyl]fenyl]-piperidín1) 1- (acetoxymethoxycarbonyl) -4- [4 - [[trans-4- [2- (methoxycarbonyl) ethyl] cyclohexyl] aminocarbonyl] phenyl] piperidine

Príklad 11Example 11

Hydrochlorid 2-[4-[[trans-4-[2-(metoxykarbonyl)etyl]cyklohexyl ]aminokarbonyl]fenyl]etylamínu2- [4 - [[trans-4- [2- (methoxycarbonyl) ethyl] cyclohexyl] aminocarbonyl] phenyl] ethylamine hydrochloride

Roztok 1,6 g (4,87 mmol) 2-[4-[[trans-4-[2-(metoxykarbonyl) -etyl]-cyklohexyl]-aminokarbonyl]-fenyl]-acetonitrilu v 400 ml metanolu sa po okyslení metanolickou kyselinou chlorovodíkovou hydrogenuje za prítomnosti 0,5 g paládia na uhlí (10%) pri teplote miestnosti a tlaku 0,3 MPa až do skončenia spotreby vodíka. Potom sa katalyzátor odsaje a odparí do sucha' za zníženého tlaku. Zvyšok sa rozotrie so zmesou 1:1 terc.butylmetyléteru a etylacetátu, zohrieva sa, opäť sa ochladí na teplotu miestnosti a odsaje sa. Po povarení s acetónom a novom odstátí sa získa 1,2 g = 66,7 % žltastej kryštalickej zlúčeniny.A solution of 1.6 g (4.87 mmol) of 2- [4 - [[trans-4- [2- (methoxycarbonyl) -ethyl] -cyclohexyl] -aminocarbonyl] -phenyl] -acetonitrile in 400 ml of methanol was acidified with methanolic acid. hydrochloric acid was hydrogenated in the presence of 0.5 g palladium on carbon (10%) at room temperature and 50 psi pressure until hydrogen consumption was complete. The catalyst is then filtered off with suction and evaporated to dryness under reduced pressure. The residue was triturated with a 1: 1 mixture of tert-butyl methyl ether and ethyl acetate, heated, re-cooled to room temperature and suction filtered. After boiling with acetone and re-standing, 1.2 g = 66.7% of a yellowish crystalline compound is obtained.

Teplota topenia: >250 ’CMelting point: > 250 ° C

Rjc-hodnota: 0,45 (silikagél, dichlórmetán/metanol = 4:1)Rf value: 0.45 (silica gel, dichloromethane / methanol = 4: 1)

Príklad 12Example 12

4-[1-[[trans-4-[2-(metoxykarbonyl)etyl]cyklohexyl]aminokarbonyl ]piperidino]-piperidín4- [1 - [[trans-4- [2- (methoxycarbonyl) ethyl] cyclohexyl] aminocarbonyl] piperidino] -piperidine

K ekvimolárnemu roztoku trans-4-[2-(metoxykarbonyl)etyl]cyklohexylamínu a p-nitrofenylesteru kyseliny chlórmravčej v suchom tetrahydrofuráne sa prikvapká za miešania a pri 0 ’C roztok 2 ekvivalentov trietylamínu v tetrahydrofuráne a mieša sa ďalšie 2,5 hodiny pri 0 °C, Potom sa za ďalšieho miešania prikvapká ekvivalent 4,4’-bipiperidylu, mieša sa ďalších 16 hodín pri teplote miestňosti a ďalšie 4 hodiny pri 50 “C. Odparí sa za zníženého tlaku do sucha, zvyšok sa vyberie do etylacetátu a tento etylacetátový roztok sa premyje 1 N hydroxidom sodným a potom vodou, suší sa nad síranom sodným a za zníženého tlaku sa odparí do sucha. Zvyšný surový produkt sa chromatografuje na silikagéli za použitia etylacetátu ako elučného činidla.To an equimolar solution of trans-4- [2- (methoxycarbonyl) ethyl] cyclohexylamine and p-nitrophenyl chloroformate in dry tetrahydrofuran was added dropwise with stirring at 0 ° C a solution of 2 equivalents of triethylamine in tetrahydrofuran and stirred for an additional 2.5 hours at 0 Then, the equivalent of 4,4'-bipiperidyl is added dropwise with further stirring, stirred for a further 16 hours at room temperature and a further 4 hours at 50 ° C. It is evaporated to dryness under reduced pressure, the residue is taken up in ethyl acetate and this ethyl acetate solution is washed with 1 N sodium hydroxide and then with water, dried over sodium sulphate and evaporated to dryness under reduced pressure. The remaining crude product is chromatographed on silica gel using ethyl acetate as the eluent.

Príklad 13Example 13

Dihydrochlorid 4-[4-[[4-(2-karboxyetyl)-piperidino]-metyl]fenyl]piperidínu4- [4 - [[4- (2-Carboxyethyl) -piperidino] methyl] phenyl] piperidine dihydrochloride

1,3 g (0,0029 mol) 1-terc.butyloxykarbonyl-4-[4-[[2(metoxykarbonyl)etyl]-piperidino]-metyl]fenyl]piperidínu sa mieša v 80 ml polokoncentrovanej kyseliny chlorovodíkovej 15 minút pri teplote miestnosti. Odparí sa potom za vákua a zvyšok sa digeruje trikrát s acetónom a zvyšný živicový zvyšok sa suší za vákua.1.3 g (0.0029 mol) of 1-tert-butyloxycarbonyl-4- [4 - [[2 (methoxycarbonyl) ethyl] -piperidino] -methyl] phenyl] piperidine are stirred in 80 ml of semi-concentrated hydrochloric acid for 15 minutes at a temperature of rooms. It is then evaporated under vacuum and the residue is digested three times with acetone and the residual resin residue is dried under vacuum.

Výťažok: 0,82· g (77,1 % teórie)Yield: 0.82 · g (77.1% of theory)

R-j-hodnota: 0,54 (doštička RP8 reverzná fáza, metanol/5% roztok chloridu sodného =6:4)R-value: 0.54 (RP8 plate reverse phase, methanol / 5% sodium chloride solution = 6: 4)

-^H-NMR spektrum (200 MHz, DMSO-dg) , signály pri ppm: 1,3-1,7 (m, 5H), 1,7-2,0 (m, 6H), 2,15-2,3 (t, 2H), 2,7-3,1 (m, 4+1H), 3,2-3,55 (m, 4H), 4,15-4,2 (d, 2H), 7,3 (d, 2H), 7,6 (d, 2H), 9,1 (s, 2H); 10,7 (s, 1H),1 H-NMR spectrum (200 MHz, DMSO-d 6), signals at ppm: 1.3-1.7 (m, 5H), 1.7-2.0 (m, 6H), 2.15-2 3 (t, 2H), 2.7-3.1 (m, 4 + 1H), 3.2-3.55 (m, 4H), 4.15-4.2 (d, 2H), 7 3 (d, 2H), 7.6 (d, 2H), 9.1 (s, 2H); 10.7 (s, 1 H),

12,05 (s, 1H)12.05 (s, 1 H)

Analogicky sa vyrobia nasledujúce zlúčeniny:The following compounds are prepared analogously:

1) dihydrochlorid 4-[4-[[trans-4-(2-karboxyetyl)cyklohexyl]aminometyl]fenyl]piperidínu1) 4- [4 - [[trans-4- (2-carboxyethyl) cyclohexyl] aminomethyl] phenyl] piperidine dihydrochloride

Teplota topenia: 308 až 311 “CMp: 308-311 ° C

Vyrobí sa z 1-terc.butyloxykarbonyl-4-[4-[[trans-4-(2metoxykarbonyletyl)cyklohexyl]aminometyl]fenyl]piperidínu a polokoncentrovanej kyseliny chlorovodíkovej.Prepared from 1-tert-butyloxycarbonyl-4- [4 - [[trans -4- (2-methoxycarbonylethyl) cyclohexyl] aminomethyl] phenyl] piperidine and semi-concentrated hydrochloric acid.

2) hydrochlorid 3-[4-[[trans-4-(2-karboxyetyl)cyklohexyl]aminokarbonyl]fenyl]pyrolidínu2) 3- [4 - [[trans-4- (2-carboxyethyl) cyclohexyl] aminocarbonyl] phenyl] pyrrolidine hydrochloride

Rf-hodnota: 0 (doštička RP8 reverzná fáza, metanol/5% roztok chloridu sodného =6:4)Rf value: 0 (RP8 plate reverse phase, methanol / 5% sodium chloride solution = 6: 4)

3) hydrochlorid 3-[4-[[trans-4-(2-karboxyetyl)cyklohexyl]aminokarbonyl]fenyl]-3-metylpyrolidínu3) 3- [4 - [[trans-4- (2-carboxyethyl) cyclohexyl] aminocarbonyl] phenyl] -3-methylpyrrolidine hydrochloride

R^-hodnota: 0 (doštička RP8 reverzná fáza, metanol/5% roztok chloridu sodného = 6:4)Rf value: 0 (RP8 plate reverse phase, methanol / 5% sodium chloride solution = 6: 4)

4) 4-[2-[trans-4-(2-karboxyetyl)cyklohexyl]-l-oxo-2,3-dihydro-izoindol-6-yl]piridín4) 4- [2- [trans-4- (2-carboxyethyl) cyclohexyl] -1-oxo-2,3-dihydro-isoindol-6-yl] piridine

R^-hodnota: 0,39 (doštička RP8 reverzná fáza, metanol/5% roztok chloridu sodného = 6:4)Rf value: 0.39 (RP8 plate reverse phase, methanol / 5% sodium chloride solution = 6: 4)

5) dihydrochlorid 1-[4-[[trans-4-(2-karboxyetyl)cyklohexyl]aminometyl]fenyl]piperazínu5) 1- [4 - [[trans-4- (2-carboxyethyl) cyclohexyl] aminomethyl] phenyl] piperazine dihydrochloride

Teplota topenia: 245 až 248 °C (rozklad)Melting point: 245 to 248 ° C (decomposition)

Vyrobí sa z 1-terc.butyloxykarbonyl-4-[4-[[trans-4-(2metoxykarbonyletyl)cyklohexyl]aminometyl]fenyl]piperazínu a polokoncentrovanej kyseliny chlorovodíkovej.Prepared from 1-tert-butyloxycarbonyl-4- [4 - [[trans -4- (2-methoxycarbonylethyl) cyclohexyl] aminomethyl] phenyl] piperazine and semi-concentrated hydrochloric acid.

6) hydrochlorid 3-[4-[[trans-4-(2-karboxyetyl)cyklohexyl]aminokarbonyl]fenyl]pyrolidínu6) 3- [4 - [[trans-4- (2-carboxyethyl) cyclohexyl] aminocarbonyl] phenyl] pyrrolidine hydrochloride

Teplota topenia: >250 °CMelting point: > 250 ° C

R^-hodnota: 0,55 (doštička RP8 reverzná fáza, metanol/5% roztok chloridu sodného =6:4)Rf value: 0.55 (RP8 plate reverse phase, methanol / 5% sodium chloride solution = 6: 4)

Vyrobí sa z 1-terc.butyloxykarbonyl-3-[4-[[trans-4-[2(metoxykarbonyl)etyl)cyklohexyl]aminokarbonyl]fenyl]pyrolidlnu a polokoncentrovanej kyseliny chlorovodíkovej.Prepared from 1-tert-butyloxycarbonyl-3- [4 - [[trans -4- [2 (methoxycarbonyl) ethyl) cyclohexyl] aminocarbonyl] phenyl] pyrrolidine and semi-concentrated hydrochloric acid.

7) hydrochlorid 3-[4-[[trans-4-(2-karboxyetyl)cyklohexyl]aminokarbonyl]fenyl]-3-metyl-pyrolidínu7) 3- [4 - [[trans-4- (2-carboxyethyl) cyclohexyl] aminocarbonyl] phenyl] -3-methylpyrrolidine hydrochloride

Teplota topenia: 250 °CMelting point: 250 ° C

Rf-hodnota: 0,5 (doštička RP8 reverzná fáza, metanol/5% roztok chloridu sodného = 6:4)Rf value: 0.5 (RP8 plate reverse phase, methanol / 5% sodium chloride solution = 6: 4)

Vyrobí sa z 1-terc.butyloxykarbonyl-3-[4-[[trans-4-[2(metoxykarbonyl)etyl)cyklohexyl]aminokarbonyl]fenyl]- 3metyl-pyrolidínu a polokoncentrovanej kyseliny chlorovodíkovej.Prepared from 1-tert-butyloxycarbonyl-3- [4 - [[trans -4- [2 (methoxycarbonyl) ethyl) cyclohexyl] aminocarbonyl] phenyl] -3-methylpyrrolidine and semi-concentrated hydrochloric acid.

Príklad 14Example 14

Suché ampuly s 2,5 mg účinnej látky na 1 mlDry ampoules with 2.5 mg of active substance per ml

Zloženie:Ingredients:

účinná látka 2,5 mg manitol 50,0 mg voda pre injekčné účely adactive substance 2.5 mg mannitol 50.0 mg water for injections ad

1,0 ml1.0 ml

Výroba:Production:

Účinná látka a manitol sa rozpustí vo vode. Po rozplnení sa vysuší vymrazením.The active substance and mannitol are dissolved in water. After filling, freeze-dried.

Roztok na použitie pre injekčné účely sa pripraví rozpustením vo vode.A solution for injection is prepared by dissolving in water.

Príklad 15Example 15

Suché ampuly s 35 mg účinnej látky na 2 mlDry ampoules with 35 mg of active substance per 2 ml

Zloženie:Ingredients:

účinná látka 35,0 mg manitol 100,0 mg voda pre inj ekčné účely ad 2,0 mlactive substance 35.0 mg mannitol 100.0 mg water for injections ad 2.0 ml

Výroba:Production:

Účinná látka a manitol sa rozpustí vo vode. Po rozplnení sa suší vymrazením.The active substance and mannitol are dissolved in water. After filling, freeze-dried.

Roztok na použitie pre injekčné účely sa pripraví s vodou .The solution for injection is prepared with water.

P P r í k 1 a d 16 16 and 16 Tableta s 50 mg účinnej látky Tablet with 50 mg of the active substance Zloženie: Ingredients: 1) 1) účinná látka active substance 50,0 50.0 mg mg 2) 2) mliečny cukor milk sugar 98,0 98.0 mg mg 3) 3) kukuričný škrob maize starch 50,0 50.0 mg mg 4) 4) polyvinylpyrolidón polyvinylpyrrolidone 15,0 15.0 mg mg 5) 5) stearát horečnatý magnesium stearate 2,0 2.0 mg mg 215,0 215.0 mg mg

Výroba:Production:

1) , 2) a 3) sa zmiešajú a granulujú sa s vodným roztokom 4). Primiešajú sa k sušenému granulátu 5). Z tejto zmesi sa lisujú tablety, biplanárne s obojstrannou fazetou a jed82 nostrannou deliacou ryhou. Priemer tabliet: 9 mm.1), 2) and 3) are mixed and granulated with an aqueous solution 4). They are admixed with the dried granulate 5). Tablets are compressed from this mixture, biplanar with a double-faced facet and a single-sided scoring line. Tablet diameter: 9 mm.

PríkladExample

Tableta s 350 mg účinnej látkyTablet with 350 mg of the active substance

Zloženie: Ingredients: 1) účinná látka (1) the active substance 350,0 mg 350.0 mg 2) mliečny cukor 2) milk sugar 136,0 mg 136.0 mg 3) kukuričný škrob 3) corn starch 80,0 mg 80.0 mg 4) polyvinylpyrolidón 4) polyvinylpyrrolidone 30,0 mg 30.0 mg 5) stearát horečnatý 5) magnesium stearate 4,0 mg 4.0 mg 600,0 mg 600.0 mg Výroba: Production: 1) , 2) a 3) sa zmiešajú 1), 2) and 3) are mixed a granulujú sa s and granulated with kom 4). Primiešajú sa k sušenému granulátu 5). com 4). They are admixed with the dried granulate 5). sa lisujú tablety, biplanárne tablets are compressed, biplanar s obojstrannou with double sided nostrannou deliacou ryhou. Priemer tabliet: 12 side-sided groove. Diameter of tablets: 12 Príklad 18 Example 18 Kapsle s 50 mg účinnej látky Capsules containing 50 mg of the active substance Zloženie: Ingredients: 1) účinná látka (1) the active substance 50,0 mg 50.0 mg 2) sušený kukuričný škrob 2) dried corn starch 58,0 mg 58.0 mg 3) práškový mliečny cukor 3) powdered milk sugar 50,0 mg 50.0 mg 5) stearát horečnatý 5) magnesium stearate 2,0 mg 2.0 mg

160,0 mg160.0 mg

Výroba:Production:

1) sa rozotrie s 3). Táto zmes sa za intenzívneho miešania pridáva k zmesi 2) a 4).1) is spread with 3). This mixture is added to mixtures 2) and 4) with vigorous stirring.

Táto prášková zmes sa rozplní na kapslovacom zariadení do tvrdých želatínových zasúvacích kapslí velkosti 3.This powder mixture is filled on a capsule device into size 3 hard gelatin push-fit capsules.

PríkladExample

Kapsle s 350 mg účinnej látky Zloženie:Capsules with 350 mg of the active substance

1) 1) účinná látka active substance 350,0 350.0 mg mg 2) 2) sušený kukuričný škrob dried corn starch 46,0 46.0 mg mg 3) 3) práškový mliečny cukor powdered milk sugar 30,0 30.0 mg mg 5) 5) stearát horečnatý magnesium stearate 4,0 4.0 mg mg 430,0 430.0 mg mg

Výroba:Production:

1) sa rozotrie s 3). Táto zmes sa za intenzívneho miešania pridáva k zmesi 2) a 4).1) is spread with 3). This mixture is added to mixtures 2) and 4) with vigorous stirring.

Táto prášková zmes sa rozplní na kapslovacom zariadení do tvrdých želatínových zasúvacích kapslí veľkosti 0.This powder mixture is filled on a capsule device into hard gelatin push-fit capsules of size 0.

Claims (10)

1. Deriváty karboxylových kyselín všeobecného vzorca ICLAIMS 1. Carboxylic acid derivatives of the general formula I A-B-C-D-E- COORa (I) kdeABCDE-COOR and (I) where Ra atóm vodíka, alkylovú skupinu s 1 až 5 atómami uhlíka, alkenylovú skupinu s 3 až 5 atómami uhlíka, fenylalkylovú skupinu s 1 až 3 atómami uhlíka v alkylovej časti, cykloalkylovú skupinu s 5 až 7 atómami uhlíka alebo R-^-CO-O- (R2CH)-skupinu, kde And R is H, alkyl of 1-5 carbon atoms, alkenyl having 3 to 5 carbon atoms, phenylalkyl having 1 to 3 carbon atoms in the alkyl moiety, cycloalkyl having 5 to 7 carbon atoms, or R - ^ - CO O- (R 2 CH) -group wherein R-£ predstavuje alkylovú skupinu s 1 až 5 atómami uhlíka, cykloalkylovú skupinu s 5 až 7 atómami uhlíka, fenylalkylovú skupinu s 1 až 3 atómami uhlíka v alkylovej časti, alkoxyskupinu s 1 až 5 atómami uhlíka, cykloalkoxyskupinu s 5 až 7 atómami uhlíka alebo fenylovú skupinu aR- £ is C až-C alky alkyl, C až-C cyk cycloalkyl, C až-Ceny phenylalkyl, C až-C alko alkoxy, C až-C 7 cycloalkoxy, or a phenyl group; and R2 predstavuje atóm vodíka, alkylovú skupinu s 1 až 4 atómami uhlíka, cykloalkylovú skupinu s 5 až 7 atómami uhlíka alebo fenylovú skupinu,R 2 represents a hydrogen atom, a C 1 -C 4 alkyl group, a C 5 -C 7 cycloalkyl group or a phenyl group, A znamená cez atóm uhlíka zvyšku A so zvyškom B spojenú aminoalkylovú skupinu s 1 až 5 atómami uhlíka alebo 5-,A represents via a carbon atom of the radical A to the radical B an aminoalkyl group having 1 to 5 carbon atoms or 5-, 6- alebo 7-člennú azacykloalkylovú skupinu, pričom spojenie azacykloalkylovej skupiny so zvyškom B je vykonané cez atóm uhlíka azacykloalkylskupiny ako aj atóm vodíka aminoskupiny v uvedených aminoalkylových skupinách a atóm vodíka na atóme dusíka uvedených azacykloalkylových skupín môže byť nahradený zvyškom Rb a ďalej môžu byť atómy uhlíka azacykloalkylovej skupiny substituované jednou až tromi alkylovými skupinami vždy s 1 až 3 atómami uhlíka, alkylamino-, kyano-, R^O- alebo R^O-CO-skupinou, kde predstavuje alkylovú skupinu s 1 až 3 atómami uhlíka, fenylalkylovú skupinu s 1 až 3 atómami uhlíka v alkylovej časti, alkanoylskupinu s 1 až 3 atómami uhlíka v alkylovej časti, trifluóracetylskupinu, alkoxykarbonylovú skupinu s celkom 2 až 6 atómami uhlíka, fenylalkoxykarbonylovú skupinu s 1 až 3 atómami uhlíka v alkoxylovej časti, alkenyloxykarbonylovú skupinu s celkom 4 až 6 atómami uhlíka alebo R^-CO-O-(R2CH)-O-CO-skupinu, kde a R2 majú už skôr definovaný význam aA 6- or 7-membered azacycloalkyl group, wherein the coupling of the azacycloalkyl group to the B moiety is via a carbon atom of the azacycloalkyl group as well as the hydrogen atom of the amino group in said aminoalkyl groups and the hydrogen atom on the nitrogen atom of said azacycloalkyl groups may be replaced by R b carbon atoms of an azacycloalkyl group substituted by one to three alkyl groups having from 1 to 3 carbon atoms each, alkylamino-, cyano-, R RO- or R OO-CO-, where it represents an alkyl group having 1 to 3 carbon atoms, a phenylalkyl group (C 1 -C 3) alkyl, (C 1 -C 3) alkanoyl, trifluoroacetyl, (C 2 -C 6) alkoxycarbonyl, (C 1 -C 3) phenylalkoxycarbonyl, (C 4 -C 3) alkenyloxycarbonyl up to 6 carbon atoms or an R 1 -CO-O- (R 2 CH) -O-CO-group, where and R2 are as previously defined and Rg predstavuje atóm vodíka, alkylovú alebo fenylalkylovú skupinu vždy s 1 až 3 atómami uhlíka v alkylovej časti, ako aj v takto vytvorenej 6- alebo 7-člennej azacykloalkylovej skupine jedna jednotka >CH- v polohe 4, vztiahnuté na dusíkový atóm kruhu môže byť nahradená atómom N alebo v takto vytvorenej 5- až 7-člennej azacykloalkylskupine -CH2-CH< jednotka môže byť nahradená -CH=C jednotkou a v takto vytvorenom pipeŕazinyl- alebo homopiperazinylkruhu môže byť metylénová skupina, ktorá susedí s atómom dusíka v polohe 4 byť nahradená karbonylskupinou, chinuklidinylovú alebo pyridylskupinu,Rg represents a hydrogen atom, an alkyl or phenylalkyl group having from 1 to 3 carbon atoms in the alkyl part, as well as in the 6- or 7-membered azacycloalkyl group thus formed, one unit> CH- in the 4-position relative to the ring nitrogen atom the N atom or the 5- to 7-membered azacycloalkyl group -CH2-CH <thus formed may be replaced by a -CH = C unit and the piperazinyl- or homopiperazinyl ring thus formed may be a methylene group adjacent to the nitrogen atom in the 4-position to be replaced by carbonyl , quinuclidinyl or pyridyl, B znamená prípadne atómom fluóru, chlóru alebo brómu, trifluórmetylovou skupinou, alkylovou, alkoxylovou, alkylsulf enylovou , alkylsulfinylovou alebo alkylsulfonylovou skupinou vždy s 1 až 3 atómami uhlíka v alkylovej alebo alkoxylovej časti mono- alebo disubstituovanú fenylénovú skupinu, kde substituenty sú rovnaké alebo rozdielne a v ktorých ďalej môžu byť 1 alebo 2 nesubstituované metinové skupiny vždy nahradené N-atómom alebo piperidinylénovú skupinu,B is optionally fluorine, chlorine or bromine, trifluoromethyl, alkyl, alkoxy, alkylsulfenyl, alkylsulfinyl or alkylsulfonyl having from 1 to 3 carbon atoms in the alkyl or alkoxy moiety of a mono- or disubstituted phenylene group wherein the substituents are the same or different and furthermore, 1 or 2 unsubstituted meth groups may in each case be replaced by an N-atom or a piperidinylene group, C znamená karbonyl-, -CH2CH2-, -CH=CH-, -CH2-, -CH20-,C is carbonyl-, -CH 2 CH 2 -, -CH = CH-, -CH 2 -, -CH 2 O-, -och2-, -conr4-, -conr4-ch2-, -nr4co-, -nr4co-nr4-,-och 2 -, -con 4 -, -con 4 -ch 2 -, -nr 4 co-, -nr 4 co-nr 4 -, -CH2NR4-, -NR4CH2-, -SO2NR4-, -SO2NR4-CH2- alebo-CH 2 NR 4 -, -NR 4 CH 2 -, -SO 2 NR 4 -, -SO 2 NR 4 -CH 2 - or -NR4S02-skupinu, kde-NR 4 SO 2 - wherein R4 predstavuje atóm vodíka, alkylovú alebo fenylalkylovú skupinu vždy s 1 až 3 atómami uhlíka v alkylovej časti alebo tiež, ak C predstavuje cez karbonylovú skupinu na zvyšok B naviazanú skupinu -C0NR4-, R4 predstavuje metylénovú alebo 1, 2-etylénskupinu, ktoré sú vždy naviazané na atóm uhlíka v polohe orto atómu’ uhlíka zvyšku B k polohe pripojenia zvyšku -conr4D znamená prípadne atómom fluóru, chlóru alebo brómu, trifluórmetylovou skupinou, alkylovou, alkoxylovou, alkylsulfenylovou, alkylsulfinylovou alebo alkylsulfonylskupinou vždy s 1 až 3 atómami uhlíka v alkylovej a alkoxylovej časti mono alebo disubstituovanú fenylénovú skupinu, kde substituenty sú rovnaké alebo rozdielne a kde ďalej 1 alebo 2 nesubstituované metinové skupiny môžu byť nahradené vždy N-atómom, cyk’loalkylénovú skupinu s 5 až 7 atómami uhlíka, v ktorej jedna alebo dve >CH- jednotky môžu byť nahradené N-atómom, pričom naviac v takto vytvorenom aza- alebo diazacyklohexylénovom kruhu môže byť metylénová skupina, susediaca s atómom dusíka nahradená karbonylovou skupinou a väzba na zvyšky C a E tiež môže byť vykonaná cez atóm dusíka aza- alebo diazacyklohexylénového kruhu aR 4 is H, an alkyl or phenylalkyl group each having 1 to 3 carbon atoms in the alkyl moiety, or alternatively, where C is through a carbonyl group bonded to the rest of the B group -C0NR 4 -, R 4 is methylene or 1, 2-ethylene, which are in each case bonded to a carbon atom in the ortho position of the carbon of residue B to the position of attachment of the -conr 4 D radical, optionally with fluorine, chlorine or bromine, trifluoromethyl, alkyl, alkoxy, alkylsulfenyl, alkylsulfinyl or alkylsulfonyl of 1 to 3 atoms carbon in the alkyl and alkoxy moiety of a mono or disubstituted phenylene group, wherein the substituents are the same or different and wherein further 1 or 2 unsubstituted meth groups may each be replaced by an N-atom, a C 5 -C 7 cycloalkylene group in which one or two> CH- units can be replaced by an N-atom, in addition in the aza so formed - or the diazacyclohexylene ring, the methylene group adjacent to the nitrogen atom can be replaced by a carbonyl group and the bond to the C and E residues can also be carried out via the nitrogen atom of the aza- or diazacyclohexylene ring, and E znamená väzbu, alkylénoxyskupinu s 1 až 3 atómami uhlíka v alkylovej časti, pričom atóm kyslíka je naviazaný na zvyšok D, priamu alkylénovú skupinu s 1 až 5 atómami uhlíka, ktoré môžu byť substituované 1 alebo 2 alkylovými skupinami, hydroxylovou, alkoxylovou, R^NH-,E represents a bond, an alkyleneoxy group having 1 to 3 carbon atoms in the alkyl moiety, wherein the oxygen atom is attached to the radical D, a direct alkylene group having 1 to 5 carbon atoms which may be substituted by 1 or 2 alkyl groups, hydroxyl, alkoxy, R R; NH- R^NÍalkyl)- alebo R^N(fenylalkyl)-skupinou alebo alkenylénovovú skupinu s 2 až 5 atómami uhlíka, ktorá môže byť substituovaná jednou alebo dvoma alkylovými skupinami, pričom alkylová časť fenylalkylovej skupiny môže obsahovať 1 až 3 atómy uhlíka a ostatné alkylové, alkylénové a alkoxylové časti vždy 1 až 8 atómov uhlíka, kde znamená atóm vodíka, alkylovú skupinu s 1 až 8 atómami uhlíka, alkoxykarbonylovú skupinu s celkom 2 až 5 atómami uhlíka, fenylalkoxykarbonylovú skupinu alebo alkylovú skupinu s 1 až 8 atómami uhlíka, cykloalkyl- , fenylalkyl alebo fenylovou skupinou substituovanú karbonyl- alebo sulfonylskupinu, v ktorých alkylová a alkoxylová časť v uvedených fenylalkylových a fenylalkoxyskupinách môže obsahovať vždy 1 až 3 atómy uhlíka a cykloalkylová časť 3 až 7 atómov uhlíka, pričom v definícii zvyšku R$ skôr uvedené fenylové jadrá môžu byť naviac mono- alebo disubstituované atómom fluóru, chlóru alebo brómu, trifluórmetylskupinou, alkylovou, alkoxylovou, alkylsulfenylovou, alkylsulfinylovou alebo alkylsulfonylovou skupinou vždy s 1 až 3 atómami uhlíka v alkylovej a alkoxylovej časti a substituenty môžu byť rovnaké alebo rozdielne, pričom, keďR (N (alkyl)) - or R (N) (phenylalkyl) - or a C 2 -C 5 alkenylene group which may be substituted by one or two alkyl groups, the alkyl portion of the phenylalkyl group may contain 1 to 3 carbon atoms and other alkyl, alkylene and alkoxy moieties of from 1 to 8 carbon atoms in each case denoting a hydrogen atom, an alkyl group having from 1 to 8 carbon atoms, an alkoxycarbonyl group having a total of 2 to 5 carbon atoms, a phenylalkoxycarbonyl group or an alkyl group having 1 to 8 carbon atoms; phenylalkyl or phenyl-substituted carbonyl or sulfonyl, in which the alkyl and alkoxy moieties in said phenylalkyl and phenylalkoxy groups may each contain 1 to 3 carbon atoms and the cycloalkyl moiety 3 to 7 carbon atoms, wherein the phenyl radicals mentioned above may be phenyl groups in addition mono- or disubstituted by fluorine, chlorine u or bromo, trifluoromethyl, alkyl, alkoxy, alkylsulfenyl, alkylsulfinyl or alkylsulfonyl having in each case 1 to 3 carbon atoms in the alkyl and alkoxy moiety and the substituents may be the same or different, wherein, when i) A-B-skupina znamená v polohe 4 R^-NH-CH2-skupinou substituovanú fenylovú skupinu, v ktorej R^ predstavuje benzyloxykarbonylovú skupinu, RaOOC-E-D-C-skupina nemôže predstavovať 3-karboxy-fenylaminokarbonylovú skupinu (viď. EP-A-0372486 a J. Med. Chem. 35, 4393 až 4407 (1992)), alebo, keď ii) A-B-skupina znamená v polohe 4 Rj5-NH-CH2-skupinou substituovanú fenylovú skupinu, v ktorej predstavuje atóm vodíka alebo acetylovú skupinu,i) AB-group in the 4-position is R 1 -NH-CH 2 -substituted phenyl in which R 1 is benzyloxycarbonyl, R and OOC-EDC cannot be 3-carboxy-phenylaminocarbonyl (see EP- A-0372486 and J. Med. Chem., 35, 4393-4407 (1992)), or when (ii) the AB-group represents in the 4-position the R 5 -NH-CH 2 -substituted phenyl group in which it represents a hydrogen atom or an acetyl group, Ra-OOC-E-D-C-skupina nemôže predstavovať v polohe 4 karbometylovou, metoxykarbonylmetylovou, 2-karboxyetylovou, 2-metoxykarbonyletylovou alebo 2-etoxykarbonyletylovou skupinou substituovanú fenylkarbonylovú skupinu (viď. EP-A-0044541, JP-A-5813553, JP-A-5939866, JP-A-5846051 a Chem. Pharm. Bull. 33, 5059 až 5061 (1985)), alebo, keď iii) A-B-skupina znamená v polohe 4 NH2-CH2-CH2-skupinou substituovanú fenylovú skupinu, RaOOC-E-D-C-skupina nemôže znamenať 4-etoxykarbonylfenylkarbonylovú skupinu (viď. DE-A-3718638) alebo, keď iv) A-B-skupina znamená 4-aminofenylovú, 3-aminometylfenylovú, 4-aminometyl-3-metoxyfenylovú alebo 3-aminometyl-4metoxyfenylskupinu, RgOOC-E-D-C-skupina nemôže znamenať 4-'etoxykarbonylmetoxy-2,3-dichlórfenylkarbonylskupinu (viď J. Med. Chem. 27, 1579 až 1587 (1984) a Diuretics:The R and -OOC-EDC group cannot represent at the 4-position a carbomethyl, methoxycarbonylmethyl, 2-carboxyethyl, 2-methoxycarbonylethyl or 2-ethoxycarbonylethyl substituted phenylcarbonyl group (see EP-A-0044541, JP-A-5813553, JP-A -5939866, JP-A-5846051 and Chem Pharm. Bull., 33, 5059-5061 (1985)), or when (iii) the AB group represents a 4-substituted phenyl group at the 4-position of the NH2-CH2-CH2-group, R and The OOC-EDC group cannot be a 4-ethoxycarbonylphenylcarbonyl group (see DE-A-3718638) or when iv) the AB group is a 4-aminophenyl, 3-aminomethylphenyl, 4-aminomethyl-3-methoxyphenyl or 3-aminomethyl-4-methoxyphenyl group The RgOOC-EDC group cannot be 4-ethoxycarbonylmethoxy-2,3-dichlorophenylcarbonyl (see J. Med. Chem. 27, 1579-1587 (1984)) and Diuretics: Chem. Pharmacol., Clin. Appl., Proc.' Int. Conf. Diuretics, 1., 21 až 29 (1984) alebo, keďChem. Pharmacol., Clin. Appl., Proc. Int. Conf. Diuretics, 1, 21-29 (1984) or when v) A-B-skupina predstavuje v polohe 4 NH2-CH2- alebo (CH^)3CO-CO-NH-CH2-skupinou substituovanú fenylovú skupinu, RaOOC-E-D-C-skupina nemôže predstavovať 4-karboxyfenylmetoxyskupinu (viď. Int. J. Pept. Proteín Res. 18, 451 až 458 (1981)), alebo, keď vi) A-B-skupina predstavuje v polohe 4 NH2-CH2-skupinou substituovanú fenylovú skupinu, RaOOC-E-D-C-skupina nemôže predstavovať 4-karboxy-fenylaminosulfonylskupinu (viďv) AB group is at the 4-NH 2 CH 2 or (CH) 3 CO-CO-NH-CH 2 group joining substituted phenyl, R a OOC-EDC-group can not be a 4-karboxyfenylmetoxyskupinu (see., Int. J Pept. Protein Res., 18, 451-458 (1981)), or when vi) the AB group represents a phenyl group substituted at the 4-position of the NH 2 -CH 2 -group, the R and OOC-EDC group cannot represent a 4-carboxy- phenylaminosulfonyl (see Chem. Pharm. Bull (Tokio) 7, 734 až 739 (1959) a J.Chem. Pharm. Bull (Tokyo) 7, 734-739 (1959) and J. Chem. Phys. 32, 691 až 697 (1960)) alebo, keď vii) A-B-skupina predstavuje 4-(2-pyridyl)-fenylovú alebo 4(3-pyridyl)fenylovú skupinu, Ra00C-E-D-C-skupina nemôže predstavovať 4-karboxyfenylkarbonylamino-skupinu, 4benzyloxykarbonylfenylkarbonylamino-skupinu alebo 2-(4karboxy-fenyl)etylskupinu (viď. J. Med. Chem. 11, 295 (1968) a US-A-2837522) alebo, keď viii) A-B-skupina predstavuje 3-(4-pyridyl)fenylovú skupinu, RaOOC-E-D-C-skupina nemôže predstavovať 2-(karboxymetyl)fenylkarbonylaminoskupinu (viď Farmaco 44, 721 až 729 (1989)).Chem. Phys. 32, 691-697 (1960)) or when vii) the AB group represents a 4- (2-pyridyl) phenyl or 4- (3-pyridyl) phenyl group, the R and 00C-EDC groups cannot represent 4-carboxyphenylcarbonylamino- 4-benzyloxycarbonylphenylcarbonylamino or 2- (4-carboxyphenyl) ethyl (see J. Med. Chem. 11, 295 (1968) and US-A-2837522) or when viii) AB is 3- (4- pyridyl) phenyl, R and OOC-EDC cannot be 2- (carboxymethyl) phenylcarbonylamino (see Farmaco 44, 721-729 (1989)). ich tautoméry, ich stereoizoméry vrátane ich zmesí a ich solí.their tautomers, their stereoisomers, including mixtures thereof, and their salts. 2. Deriváty karboxylových kyselín všeobecného vzorca2. Carboxylic acid derivatives of the general formula I podlá nároku 1, kdeI according to claim 1, wherein Ra znamená atóm vodíka, alkylovú skupinu s 1 až 5 atómami uhlíka, fenylalkylovú skupinu s 1 až 3 atómami uhlíka v alkylovej časti alebo cykloalkylovú skupinu s 5 až 7 atómami uhlíka,R a represents a hydrogen atom, a C 1 -C 5 alkyl group, a C 1 -C 3 phenylalkyl group or a C 5 -C 7 cycloalkyl group, A znamená cez atóm uhlíka zvyšku A so zvyškom B spojenú aminoalkylovú skupinu s 2 až 5 atómami uhlíka alebo piperidinylovú skupinu, kde spojenie piperidinylovej skupiny so zvyškom B je vykonané cez atóm uhlíka piperidinylovej skupiny a atóm vodíka aminoskupiny vo vyššie uvedených aminoalkylových skupinách a atóm vodíka na atóme dusíka uvedených piperidinylových skupinách môže byť nahradený zvyškom a ďalej môžu byť atómy uhlíka piperidinylovej skupiny substituované metylovou, kyanovou, karboxylovou, metoxykarbonylovou alebo aminokarbonylovou skupinou, kdeA represents a C 2-5 aminoalkyl group or a piperidinyl group linked via the carbon atom of the residue A of the residue B, wherein the coupling of the piperidinyl group to the B group is carried out via the carbon atom of the piperidinyl group and the hydrogen atom of the amino group in the above aminoalkyl groups; the nitrogen atom of said piperidinyl groups may be replaced by a residue and furthermore, the carbon atoms of the piperidinyl group may be substituted by a methyl, cyano, carboxyl, methoxycarbonyl or aminocarbonyl group, wherein R^ predstavuje alkylovú skupinu s 1 až 3 atómami uhlíka, benzylovú skupinu, alkoxykarbonylovú skupinu s celkom 2 až 6 atómami uhlíka, benzyloxykarbonylovú skupinu alebo CH^-CO-O-(CH2)-O-CO-skupinu, ako aj v jednej takto vytvorenej piperidinylovej skupine >CH- jednotka- v polohe 4 môže byť nahradená atómom dusíka alebo v takto vytvorenej piperidinylovej skupine -CH2-CH< jednotka môže byť nahradená -CH=CH jednotkou, chinuklidinylovú alebo pyridylskupinu,R 1 represents a C 1 -C 3 alkyl, benzyl, C 2 -C 6 alkoxycarbonyl, benzyloxycarbonyl or CH 2 -CO-O- (CH 2 ) -O-CO-group as well as in one the piperidinyl> CH- unit thus formed in the 4-position may be replaced by a nitrogen atom or in the piperidinyl -CH 2 -CH <unit formed by the -CH = CH unit, a quinuclidinyl or pyridyl group thus formed, B znamená prípadne atómom fluóru, chlóru alebo brómu, alkylovou, alkoxylovou, alkylsulfenylovou, alkylsulfinylovou alebo alkylsulfonylovou skupinou vždy s 1 až 2 atómami uhlíka v alkylovej a alkoxylovej časti substituovanú fenylénovú skupinu, pyridinylénovú alebo piperidinylénovú skupinu,B is optionally a fluorine, chlorine or bromine atom, an alkyl, alkoxy, alkylsulfenyl, alkylsulfinyl or alkylsulfonyl group having from 1 to 2 carbon atoms in the alkyl and alkoxy moiety substituted by a phenylene, pyridinylene or piperidinylene group, C znamená -CO-, -CH2CH2-, -CH=CH-, -CH2-, -CH20-, -0CH2-,C is -CO-, -CH 2 CH 2 -, -CH = CH-, -CH 2 -, -CH 2 O-, -OCH 2 -, -conr4-, -nr4co-, -nr4co-nr4-, -ch2nr4-, -nr4ch2-,-conr 4 -, -nr 4 co-, -nr 4 co-nr 4 -, -ch 2 nr 4 -, -nr 4 ch 2 -, -SO2NR4~ alebo -NR4SO2~skupinu, kde-SO 2 NR 4 - or -NR 4 SO 2 - group wherein R4 predstavuje atóm vodíka, alkylovú alebo fenylalkylovú skupinu vždy s 1 až 2 atómami uhlíka v alkylovej časti alebo tiež, ak C predstavuje cez karbonylovú skupinu na zvyšok B naviazanú skupinu -CONR4~, R4 predstavuje metylénovú alebo 1, 2-etylénskupinu, ktoré sú vždy naviazané na atóm uhlíka zvyšku B v polohe orto k miestu pripojenia zvyšku -C0NR4D znamená prípadne atómom chlóru alebo brómu, alkylovou alebo alkoxylovou skupinou s 1 alebo 2 atómami uhlíka substituovanú fenylénovú skupinu alebo cyklohexylénovú skupinu, pričom v cyklohexylénovej skupine jedna alebo dve >CH- jednotky môžu byť nahradené N-atómom, pričom naviac v takto vytvorenom piperidinylénovom alebo piperazinylénovom kruhu môže byť metylénová skupina, susediaca s atómom dusíka nahradená karbonylovou skupinou a väzba na zvyšky C a E tiež môže byť vykonaná cez atóm dusíka piperidinylénového alebo piperazinylénového kruhu aR 4 represents a hydrogen atom, an alkyl or phenylalkyl radical having from 1 to 2 carbon atoms in the alkyl part, or also when C represents a -CONR 4 - group attached via a carbonyl group to the radical B, R 4 represents a methylene or 1,2-ethylene group, which are each attached to a carbon atom of B in the ortho position to the point of attachment of -C0NR 4 D is chlorine or bromine, alkyl or alkoxy having 1 or 2 carbon atoms substituted phenylene or cyclohexylene, in which one or cyclohexylene two> CH- units may be replaced by an N-atom, and in addition to the piperidinylene or piperazinylene ring thus formed, the methylene group adjacent to the nitrogen atom may be replaced by a carbonyl group and the bond to residues C and E may also be via the piperidinylene or piperazinylene circle and E znamená väzbu, metylénoxyskupinu, kde je atóm kyslíka naviazaný na zvyšok D, 1,2-etenylovú skupinu alebo priamu alkylénovú skupinu s 1 až 5 atómami uhlíka, ktorá môže byť substituovaná alkylovou skupinou s 1 až 7 atómami uhlíka alebo R^NH-skupinou, kde znamená atóm vodíka, alkylovú skupinu s 1 až 7 atómami uhlíka alebo benzylovou skupinou substituovanú karbonylovú skupinu alebo alkylovou skupinou s 1 až 5 atómami uhlíka alebo benzylovou skupinou substituovanú sulfonylovú skupinu, pričom, keď iii) A-B-skupina znamená v polohe 4 NH2-CH2-CH2-skupinou substituovanú fenylovú skupinu, RaOOC-E-D-C-skupinaE represents a bond, a methyleneoxy group wherein the oxygen atom is bonded to the radical D, a 1,2-ethenyl group or a straight alkylene group having 1 to 5 carbon atoms which may be substituted by an alkyl group having 1 to 7 carbon atoms or an R ^NH group wherein the hydrogen atom is an alkyl group having 1 to 7 carbon atoms or a benzyl group substituted by a carbonyl group or an alkyl group having 1 to 5 carbon atoms or a benzyl group substituted by a sulfonyl group, wherein when iii) the AB group is NH4- CH2-CH2-substituted phenyl, R and OOC-EDC I nemôže znamenať 4-etoxykarbonylfenylkarbonylovú skupinu , j alebo, keď vii) A-B-skupina predstavuje 4-(2-pyridyl)-fenylovú alebo 4(3-pyridyl)fenylovú skupinu, RaOOC-E-D-C-skupina nemôže predstavovať 4-karboxyfenylkarbonylamino-skupinu, 4benzyloxykarbonylfenylkarbonylämino-skupinu alebo 2-(4karboxy-fenyl)etylskupinu 1 alebo, keď viii) A-B-skupina predstavuje 3-(4-pyridyl)fenylovú skupinu, RaOOC-E-D-C-skupina nemôže predstavovať 2-(karboxymetyl)fenylkarbonylaminoskupinu, ich tautoméry, ich stereoizoméry vrátane ich zmesí a ich soli.I cannot be a 4-ethoxycarbonylphenylcarbonyl group, j or, when vii) the AB group is a 4- (2-pyridyl) phenyl or 4- (3-pyridyl) phenyl group, the R and OOC-EDC group cannot be 4-carboxyphenylcarbonylamino- 4-benzyloxycarbonylphenylcarbonylamino or 2- (4-carboxyphenyl) ethyl 1 or, when viii) AB-group is 3- (4-pyridyl) phenyl, R and OOC-EDC cannot be 2- (carboxymethyl) phenylcarbonylamino, their tautomers, their stereoisomers, including mixtures thereof, and their salts. 3. Deriváty karboxylových kyselín všeobecného vzorca3. Carboxylic acid derivatives of the general formula I podľa nároku 1, kdeI according to claim 1, wherein Ra znamená atóm vodíka, alkylovú skupinu s 1 až 4 atómami uhlíka, 2-fenyletylovú skupinu alebo cyklohexylovú skupinu, And R is H, alkyl of 1 to 4 carbon atoms, 2-phenylethyl or cyclohexyl, A znamená cez atóm uhlíka zvyšku A so zvyškom B spojenú aminoalkylovú skupinu s 3 až 5 atómami uhlíka alebo piperidinylovú skupinu, kde spojenie piperidinylovej skupiny so zvyškom B je vykonané cez atóm uhlíka piperidinylovej skupiny a atóm vodíka aminoskupiny vo vyššie uvedených aminoalkylových skupinách a atóm vodíka na atóme dusíka uvedených piperidinylových skupinách môže byť nahradený zvyškom R^ a ďalej môžu byť atómy uhlíka piperidinylovej skupiny substituované metylovou, kyanovou, karboxylovou, metoxykarbonylovou alebo aminokarbonylovou skupinou, kde predstavuje alkylovú skupinu s 1 až 3 atómami uhlíka, benzylovú skupinu, alkoxykarbonylovú skupinu s celkom 2 až 5 atómami uhlíka alebo CHj-CO-O-(CH2)-O-CO-skupinu, a v takto vytvorenej piperidinylovej skupine >CH- jednotka v polohe 4 môže byť nahradená atómom dusíka alebo v takto vytvorenej piperidinylovej skupine -CH2-CH< jednotka môže byť nahradená -CH=C< jednotkou, chinuklidinylovú aleboA is a C 3 -C 5 aminoalkyl group or a piperidinyl group linked via the carbon atom of the residue A of the residue B, wherein the coupling of the piperidinyl group to the B group is carried out via the carbon atom of the piperidinyl group and the hydrogen atom of the amino group in the above aminoalkyl groups; the nitrogen atom of said piperidinyl groups may be replaced by the radical R @ 1 and furthermore, the carbon atoms of the piperidinyl group may be substituted by a methyl, cyano, carboxyl, methoxycarbonyl or aminocarbonyl group wherein C1-3 alkyl, benzyl, alkoxycarbonyl having a total of 2 up to 5 carbon atoms or a CH 3 -CO-O- (CH 2 ) -O-CO-group, and in the piperidinyl group> CH- thus formed, the unit at the 4-position can be replaced by a nitrogen atom or in the piperidinyl group -CH 2 -CH <unit may be replaced by -CH = C <unit, c hinuclidinyl or - 93 4-pyridylovú skupinu,- 93 4-pyridyl, B znamená prípadne metylovou alebo metoxylovou substituovanú fenylénovú skupinu, 2,5-pyridiňylénovú alebo 1,4piperidinylénovú skupinu,B represents an optionally methyl or methoxy substituted phenylene, 2,5-pyridinylene or 1,4-piperidinylene group, C znamená -CO-, -CH2CH2-, -CH=CH-, -CH2-, -CH2O-, -0CH2-, -CONR4-, -NR4CO-, -NR4CO-NR4- alebo -CH2NR4-skupinu alebo -SO2NR4-, kde S02 skupina je spojená so zvyškom B a kdeC is -CO-, -CH 2 CH 2 -, -CH = CH-, -CH 2 -, -CH 2 O-, -OCH 2 -, -CONR 4 -, -NR 4 CO-, -NR 4 CO-NR 4 - or - CH 2 NR 4 - or -SO 2 NR 4 -, wherein the SO 2 group is linked to the residue B and wherein R4 predstavuje atóm vodíka, metylovú aleboR 4 represents a hydrogen atom, a methyl atom or a methyl group; 2-fenyletylovú skupinu alebo tiež, ak C predstavuje -CONR4-skupinu naviazanú na zvyšok B cez karbonylovú skupinu, predstavuje R4 metylénovú alebo 1, 2-etylénskupinu, ktoré sú vždy naviazané na atóm uhlíka zvyšku B v polohe orto k miestu pripojenia zvyšku -CONR4-,2-phenylethyl or, if C is -CONR4-linked to residue B via a carbonyl group, R4 is methylene or 1,2-ethylene, which are in each case attached to the carbon atom of residue B in the ortho position to the point of attachment of -CONR4 -. D predstavuje fenylénovú skupinu alebo cyklohexylénovú skupinu, pričom v cyklohexylénovej skupine jedna alebo dve >CH- jednotky môžu byť nahradené N-atómom, pričom väzba na zvyšky C a E môže tiež byť vykonaná cez atóm dusíka piperidinyIónového alebo piperazinylénového kruhu aD represents a phenylene group or a cyclohexylene group, wherein in the cyclohexylene group one or two> CH- units can be replaced by an N-atom, wherein the bond to the C and E residues can also be carried out via the nitrogen atom of the piperidinyl or piperazinylene ring; E znamená väzbu, metylénoxyskupinu, kde je atóm kyslíka naviazaný na zvyšok D, priamu alkylénovú skupinu s 1 až 5 atómami uhlíka, ktorá môže byť substituovaná R^NH-skupinou, kdeE represents a bond, a methyleneoxy group where the oxygen atom is bonded to the radical D, a direct alkylene group having 1 to 5 carbon atoms, which may be substituted by an R 4 NH group, wherein R^ znamená atóm vodíka, alkylovú skupinu s 1 až 5 atómami uhlíka, substituovanú karbonylovú skupinu alebo alkylovou skupinou s 1 až 4 atómami uhlíka alebo benzylovou skupinou substituovanú sulfonylovú skupinu , ich tautoméry, ich stereoizoméry vrátane ich zmesí a ich soli.R @ 1 represents a hydrogen atom, a C1 -C5 alkyl group, a substituted carbonyl or C1 -C4 alkyl group or a benzyl substituted sulfonyl group, their tautomers, their stereoisomers, including mixtures thereof, and their salts. 4. Deriváty karboxylových kyselín všeobecného vzorca I podľa nároku 1, kdeThe carboxylic acid derivatives of formula I according to claim 1, wherein Ra znamená atóm vodíka, alkylovú skupinu s 1 až 4 atómami uhlíka alebo cyklohexylovú skupinu,R a represents a hydrogen atom, a C 1 -C 4 alkyl group or a cyclohexyl group, A znamená cez atóm uhlíka zvyšku A so zvyškom B spojenú piperidinylovú skupinu alebo 3,4-dehydropiperidinylovú skupinu, kde vždy atóm vodíka na atóme dusíka môže byť nahradený zvyškom R^ aA represents a piperidinyl group or a 3,4-dehydropiperidinyl group linked via the carbon atom of the radical A to the radical B, in which the hydrogen atom on the nitrogen atom can in each case be replaced by the radical R @ a; R^j predstavuje alkoxykarbonylovú skupinu s celkom 2 až 5 atómami uhlíka, prípadne v polohe 1 zvyškom R^ substituovanú 4-piperazinylovú skupinu, kde R^ má skôr definovaný význam alebo chinuklidinylovú skupinu,R 1 is an alkoxycarbonyl group having a total of 2 to 5 carbon atoms, optionally substituted at the 1-position by R 1 with a substituted 4-piperazinyl group, wherein R 1 is as defined above or a quinuclidinyl group, B predstavuje fenylénovú skupinu,B represents a phenylene group, C predstavuje -CONR4-skupinu, kdeC represents a -CONR 4 -group wherein R4 predstavuje atóm vodíka, metylovú alebo tiež, ak C predstavuje cez karbonylovú skupinu na zvyšok B naviazanú CONR4-skupinu, predstavuje R 4 metylénovú alebo 1,2-etylénskupinu, ktoré sú vždy naviazané na atóm uhlíka zvyšku B v polohe orto k miestu pripojenia zvyšku -CONR4-,R 4 represents a hydrogen atom, a methyl atom or also, when C represents a CONR 4 group attached via a carbonyl group to a residue B, R 4 represents a methylene or 1,2-ethylene group, which are always bonded to the carbon atom of residue B ortho to the attachment point -CONR4-. D predstavuje 1,4-fenylénovú skupinu alebo 1,4-cyklohexylénovú skupinu aD is 1,4-phenylene or 1,4-cyclohexylene; and E predstavuje väzbu, 1,2-etylénovú skupinu, ktorá môže byť substituovaná R^NH-skupinou, kdeE represents a bond, a 1,2-ethylene group which may be substituted with an R 1 NH-group, wherein Rg znamená alkylovú skupinu s 1 až 5 atómami uhlíka, substituovanú karbonylovú skupinu alebo alkylovou skupinou s 1 až 4 atómami uhlíka substituovanú sulfonylovú skupinu, ich tautoméry, ich stereoizoméry vrátane ich zmesí a ich soli ,R 8 represents a C 1 -C 5 alkyl group, a substituted carbonyl group or a C 1 -C 4 alkyl group substituted with a sulfonyl group, their tautomers, their stereoisomers, including mixtures thereof, and their salts, 5. Deriváty karboxylových kyselín všeobecného vzorca I podľa nároku 1, ktorými súThe carboxylic acid derivatives of the formula I according to claim 1 which are 4-[4-[[trans-4-[2-(metoxykarbonyl)etyl]cyklohexyl]aminokarbonyl ]fenyl]piperidín,4- [4 - [[trans -4- [2- (methoxycarbonyl) ethyl] cyclohexyl] aminocarbonyl] phenyl] piperidine, 4-[4-[[4-[2-(n-butánsulfonylamino)-2-(metoxykarbonyl)etyl]fenyl]aminokarbonyl]fenyl]piperidín,4- [4 - [[4- [2- (n-butanesulfonylamino) -2- (methoxycarbonyl) ethyl] phenyl] aminocarbonyl] phenyl] piperidine, 4-[4-[[trans-4-(2-karboxy-etyl)cyklohexyl]aminokarbonyl]fenyl]piperidín,4- [4 - [[trans-4- (2-carboxy-ethyl) -cyclohexyl] aminocarbonyl] phenyl] piperidine, 4-[4-[[4-[2-(n-butánsulfonylamino)-2-karboxyetyl]fenyl]aminokarbonyl]fenyl]piperidín,4- [4 - [[4- [2- (n-butanesulfonylamino) -2-carboxyethyl] phenyl] aminocarbonyl] -phenyl] -piperidine, 4- [3-[[4-[2-(n-butánsulfonylamino)-2-karboxyetyl]fenyl]aminokarbonyl]fenyl]piperidín a4- [3 - [[4- [2- (n-butanesulfonylamino) -2-carboxyethyl] phenyl] aminocarbonyl] phenyl] piperidine and 4-[3-[[4-[2-(n-butánsulfonylamino)-2-(metoxykarbonyl)etyl]fenyl]aminokarbonyl]fenyl]piperidín, ich tautoméry, ich stereoizoméry vrátane ich zmesí a ich soli.4- [3 - [[4- [2- (n-butanesulfonylamino) -2- (methoxycarbonyl) ethyl] phenyl] aminocarbonyl] phenyl] piperidine, their tautomers, their stereoisomers, including mixtures thereof, and their salts. 6. Fyziologicky prijateľné adičné soli zlúčenín podľa aspoň jedného z nárokov 1 až 5 s anorganickými alebo organickými kyselinami alebo bázami.Physiologically acceptable addition salts of the compounds according to at least one of claims 1 to 5 with inorganic or organic acids or bases. 7. Liečivo, obsahujúce zlúčeninu podľa aspoň jedného z nárokov 1 až 5 alebo fyziologicky prijateľnú adičnú sol podľa nárokov 6 vedia prípadne jedného alebo viacerých inertných nosičov a/alebo riedidiel.A medicament comprising a compound according to at least one of claims 1 to 5 or a physiologically acceptable addition salt according to claims 6, optionally containing one or more inert carriers and / or diluents. 8. Použitie zlúčeniny podľa aspoň jedného z nárokov 2 až 6 na výrobu liečiva, ktoré je vhodné na liečenie prípadne prevenciu chorôb, pri ktorých vznikajú menšie alebo väčšie bunkové agregáty alebo hrajú úlohu interakcie bunka-matrica.Use of a compound according to at least one of claims 2 to 6 for the manufacture of a medicament which is suitable for the treatment or prevention of diseases in which smaller or larger cell aggregates arise or play a role of cell-matrix interaction. 9. Spôsob výroby liečiva podľa nároku 7, vyznačujúci satým, že sa nechemickým spôsobom zapracuje zlúčenina podľa aspoň jedného z nárokov 1 až 6 do jedného alebo viacerých inertných nosičov a/alebo riedidiel.A method for producing a medicament according to claim 7, characterized in that the compound according to at least one of claims 1 to 6 is incorporated in a non-chemical manner into one or more inert carriers and / or diluents. 10. Spôsob výroby derivátov karboxylových kyselín podľa nárokov 1 až 6, vyznačujúci sa tým, žeA process for the production of carboxylic acid derivatives according to claims 1 to 6, characterized in that a) na výrobu zlúčenín všeobecného vzorca I, kde Ra predstavuj e atóm vodíka, sa zlúčenina všeobecného vzorca II(a) for the preparation of compounds of the formula I, in which R a represents a hydrogen atom, a compound of the formula II A - B - C - D - E - COORa’ (II) kdeA - B - C - D - E - COOR and (II) where A až E majú vyššie definovaný význam tak, ako v nárokoch 1 až 5 a Ra’ s výnimkou atómu vodíka má významy uvedené už v nárokoch 1 až 5 pre R&.A-E are as defined as in claims 1 to 5, and R a 'with the exception of hydrogen has the meaning given in claims 1 to 5 for R &. pomocou hydrolýzy, pyrolýzy alebo hydrogenolýzy prevedie na zlúčeninu všeobecného vzorca 1, kde R& predstavuje atóm vodíka aleboconverted by hydrolysis, pyrolysis or hydrogenolysis to a compound of formula 1 wherein R & lt ; 6 &gt; is hydrogen or b) Na výrobu zlúčenín všeobecného vzorca I, kde A je substituovaný zvyškom R^, sa zlúčenina vzorca IIIb) For the preparation of compounds of formula I, wherein A is substituted with R ^, a compound of formula III is used Αχ - B - C - D - E - COORa (III) kdeΑ χ - B - C - D - E - COOR and (III) where B až E a Ra majú definovaný význam v nárokoch 1 až 5 aB to E and R a are as defined in claims 1 to 5 a A-£ znamená cez atóm uhlíka so zvyškom B spojenú aminoalkylovú skupinu s 1 až 5 atómami uhlíka alebo cez atóm uhlíka so zvyškom B spojenú 5-, 6- alebo 7-člennú azacykloalkylovú skupinu, kde atómy uhlíka azacykloalkylovej skupiny môžu byť substituovanú jednou až tromi alkylový. mi skupinami vždy s 1 až 3 atómami uhlíka, aminokarbonylovou, kyanovou, R^O- alebo R^O-CO-skupinou, kde R^ má ♦ už vyššie uvedený význam, nechá reagovať so zlúčeninou všeobecného vzorca IVA-? Represents a C 1-5 aminoalkyl linked via a carbon atom of the B moiety or a 5-, 6- or 7-membered azacycloalkyl group attached to the B-linked carbon moiety, wherein the azacycloalkyl carbon atoms may be substituted with one to three alkyl. In each case, the radicals are each of 1 to 3 carbon atoms, aminocarbonyl, cyano, R (O) O or R (O) O-CO, in which R (R) is as defined above, and reacted with a compound of formula (IV). Rb - Z-l (IV) kdeR b - Z 1 (IV) where R^ má už definovaný význam v nárokoch 1 až 5 a Z^ predstavuje nukleofilnú odštiepitelnú skupinu alebo tiež, ak je Z^ naviazaný na karbonýlovú skupinu, predstavuje hydroxyskupinu, alkanoyloxyskupinu alebo alkoxykarbonyloxyskupinu alebo tiež za prítomnosti redukčného činidla, akR 1 is as defined in claims 1 to 5 and Z 2 is a nucleophilic leaving group or, when Z 2 is attached to a carbonyl group, is hydroxy, alkanoyloxy or alkoxycarbonyloxy, or else in the presence of a reducing agent, if Z^ znamená spolu so susedným atómom vodíka zvyšku R^ atóm kyslíka alebo kTogether with the adjacent hydrogen atom of the radical R @ 1 represents an oxygen atom or k c) Na výrobu zlúčenín všeobecného vzorca I, kde Ra s výnimkou vodíka má vyššie definovaný význam v nárokoch 1 až 5, sa nechá reagovať zlúčenina všeobecného vzorca Vc) For the preparation of the compounds of the formula I wherein R and with the exception of hydrogen as defined in claims 1 to 5, a compound of the formula V is reacted A-B-C-D-E - COOH (V) kdeA - B - C - D - E - COOH (V) where A až E majú už definovaný význam v nárokoch 1 až 5, so zlúčeninou všeobecného vzorca VI (VI) kdeA to E are as previously defined in claims 1 to 5, with a compound of formula VI (VI) wherein Ra’ s výnimkou vodíka majú významy uvedené vyššie pre Ra v nárokoch 1 až 5 aR a 'with the exception of hydrogen have the meanings given above for R a in claims 1 to 5 a Z2 predstavuje nukleofilnú odštiepiteľnú skupinu aleboZ 2 represents a nucleophilic leaving group or d) Na výrobu zlúčenín všeobecného vzorca I, kde C znamená -CH2-NH-skupinu, sa zlúčenina všeobecného vzorca VII *d) For the preparation of compounds of formula I wherein C is -CH2-NH-, a compound of formula VII * A - B - CH = N - D - E - COORa (VII) e kdeA - B - CH = N - D - E - COOR and (VII) e where A, B, D, E a Ra majú už definovaný význam v nárokoch 1 až 5, redukuje aleboA, B, D, E and R and are as previously defined in claims 1 to 5, reduce or e) Na výrobu zlúčenín všeobecného vzorca I, kde C predstavuje -CO-NR4-skupinu, sa zlúčenina všeobecného vzorca VIIIe) For the preparation of compounds of formula I wherein C represents a -CO-NR4-group, a compound of formula VIII is prepared A2 - B - COOH (VIII) kdeA 2 - B - COOH (VIII) where B má už definovaný význam v nárokoch 1 až 5 a A2 predstavuje na atóme dusíka alkyl-, aralkyl-, alkanoyl-, trifluóracetyl- alebo alkoxykarbonylovým zvyškom substituovanú skupinu A, nechá reagovať s amínom všeobecného vzorca IXB is as defined in claims 1 to 5 and A 2 is an alkyl, aralkyl, alkanoyl, trifluoroacetyl or alkoxycarbonyl radical substituted with A, reacted with an amine of formula IX XX R4 - NH - D - E - COORa’ (IX) kdeR 4 - NH - D - E - COOR a '(IX) where D, E a R4 majú už definovaný význam v nárokoch 1 až 5 a R ’ s výnimkou atómu vodíka má významy už uvedené pre R& v nárokoch 1 až 5 aleboD, E and R 4 are as defined in claims 1 to 5 and R 1, with the exception of a hydrogen atom, has the meanings already indicated for R & apos ; in claims 1 to 5, or f) Na výrobu zlúčenín všeobecného vzorca I, kde C predstavuje -NR4CO-skupinu, sa zlúčenina všeobecného vzorca Xf) To produce compounds of formula I wherein C is -NR 4 CO-, a compound of formula X is prepared A2 - B - NH-R4 (X) kdeA 2 - B - NH - R 4 (X) wherein R4 a B majú už definovaný význam v nárokoch 1 až 5 aR 4 and B are as defined in claims 1 to 5 a A2 predstavuje na atóme dusíka alkyl-, aralkyl-, alkanoyl-, trifluóracetyl- alebo alkoxykarbonylovým zvyškom substituovanú skupinu A, nechá reagovať s karboxylovou kyselinou všeobecného vzorcaA2 represents an alkyl-, aralkyl-, alkanoyl-, trifluoroacetyl- or alkoxycarbonyl-substituted group A on the nitrogen atom, reacted with a carboxylic acid of the formula XIXI HOOC - D - E - COOR ’ (XI) cL kdeHOOC - D - E - COOR '(XI) cL where D a E majú definovaný význam v nárokoch 1 až 5 aD and E are as defined in claims 1 to 5 and Ra’ s výnimkou atómu vodíka má významy uvedené v nárokoch 1 až 5 pre Ra aleboR a ', with the exception of a hydrogen atom, has the meanings given in claims 1 to 5 for R a or g) Na výrobu zlúčenín všeobecného vzorca I, kde A predstavuje cez atóm uhlíka so zvyškom B spojenú aminoalkylovú skupinu s 1 až 5 atómami uhlíka, sa zlúčenina všeobecného vzorca(g) For the preparation of compounds of the formula I in which A represents a C 1 -C 5 aminoalkyl group linked via a carbon atom of the radical B, a compound of the formula XIIXII Ag-B-C-D-E- COORa (XII) kdeAg-BCDE-COOR and (XII) wherein B až E a Ra má významy definované v nárokoch 1 až 5 a Ag predstavuje kyanoskupinu alebo kyanoalkylovú skupinu s 1 až 4 atómami uhlíka v alkylovej časti a v prípade potreby sa počas reakcie na chránenie reaktívnych skupín použité chrániace zvyšky odštiepia a/alebo sa prípadne takto získaná zlúčenina všeobecného vzorca I, kde R4 znamená atóm vodíka, pomocou alkylácie prevedie na zodpovedajúcu zlúčeninu všeobecného vzorca I, kde R4 predstavuje prípadne fenylskupinou substituovanú alkylovú skupinu s 1 alebo 2 atómami uhlíka a/alebo sa takto získaná zlúčenina všeobecného vzorca I rozdelí na svoje enantioméry a/alebo diastereoméry a/aleboB and E, and R a is as defined in claims 1 to 5, and Ag is cyano or cyanoalkyl group having 1 to 4 carbon atoms in the alkyl moiety and, if necessary, during the reaction for the protection of reactive groups may use protecting moieties are cleaved and / or optionally the following the resulting compound of formula I wherein R 4 is hydrogen is converted to the corresponding compound of formula I wherein R 4 is an optionally substituted phenyl group having 1 or 2 carbon atoms by alkylation and / or the compound of formula I thus obtained is separated into its enantiomers and / or diastereomers and / or 100 sa takto získaná zlúčenina všeobecného vzorca I prevedie na svoje soli, najmä pre farmaceutické použitie na svoje fyziologicky prijateľné soli s anorganickými alebo organickými kyselinami a/alebo sa takto získaná zlúčenina všeobecného vzorca I, ak obsahuje karboxylovú skupinu, prípadne prevedie na svoje adičné soli s anorganickými alebo organickými bázami, najmä na farmaceutické použitie na svoje fyziologicky prijateľné adičné soli.100, the compound of the formula I thus obtained is converted into its salts, in particular for pharmaceutical use, into its physiologically acceptable salts with inorganic or organic acids and / or the compound of the formula I thus obtained, if it contains a carboxyl group, inorganic or organic bases, in particular for pharmaceutical use for their physiologically acceptable addition salts.
SK1281-93A 1992-12-10 1993-11-17 Carboxylic acids derivatives, medicaments containing these compounds and method of their production SK128193A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4241632A DE4241632A1 (en) 1992-12-10 1992-12-10 New (aza)aromatic or alicyclic carboxylic acid cpds. - used e.g. for treating thrombosis, inflammation, osteoporosis, cardiac infarct or tumour metastasis

Publications (1)

Publication Number Publication Date
SK128193A3 true SK128193A3 (en) 1995-02-08

Family

ID=6474905

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1281-93A SK128193A3 (en) 1992-12-10 1993-11-17 Carboxylic acids derivatives, medicaments containing these compounds and method of their production

Country Status (17)

Country Link
EP (1) EP0604800A1 (en)
JP (1) JPH06239817A (en)
KR (1) KR940014330A (en)
CN (1) CN1094035A (en)
AU (1) AU5230693A (en)
CA (1) CA2111035A1 (en)
CZ (1) CZ270593A3 (en)
DE (1) DE4241632A1 (en)
FI (1) FI935513A (en)
HU (1) HU9303521D0 (en)
IL (1) IL107956A0 (en)
MX (1) MX9307781A (en)
NO (2) NO934501D0 (en)
NZ (1) NZ250391A (en)
PL (1) PL301396A1 (en)
SK (1) SK128193A3 (en)
ZA (1) ZA939230B (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4326344A1 (en) * 1993-08-05 1995-02-09 Thomae Gmbh Dr K Carbonamides, pharmaceutical compositions containing these compounds and process for their preparation
TW397831B (en) * 1994-07-15 2000-07-11 Meiji Seika Kaisha The anti-platelet-agglutination hexahydrogenated pyridine and its derivatives
GB9514160D0 (en) * 1994-07-25 1995-09-13 Zeneca Ltd Aromatic compounds
GB9417532D0 (en) * 1994-08-31 1994-10-19 Zeneca Ltd Aromatic compounds
GB9420557D0 (en) * 1994-10-12 1994-11-30 Zeneca Ltd Aromatic compounds
US6069143A (en) * 1994-12-20 2000-05-30 Smithkline Beecham Corporation Fibrinogen receptor antagonists
TW434240B (en) * 1995-06-20 2001-05-16 Zeneca Ltd Aromatic compounds, preparation thereof and pharmaceutical composition comprising same
TW502026B (en) * 1995-06-20 2002-09-11 Zeneca Ltd Aromatic compounds useful as antagonists of e-type prostaglandins, processes for the preparation thereof, pharmaceutical compositions comprising the compounds, and intermediates
DE69635254T2 (en) * 1995-07-07 2006-07-13 Astrazeneca Ab Ortho-substituted aromatic compounds containing three (het) aryl rings, their preparation and their use as prostaglandin E2 (PGE2) antagonists
DE19614204A1 (en) * 1996-04-10 1997-10-16 Thomae Gmbh Dr K Carboxylic acid derivatives, medicaments containing these compounds, their use and processes for their preparation
US5854245A (en) * 1996-06-28 1998-12-29 Merck & Co., Inc. Fibrinogen receptor antagonists
AU6320998A (en) * 1997-02-21 1998-09-09 Bristol-Myers Squibb Company Benzoic acid derivatives and related compounds as antiarrhythmic agents
SI1379520T1 (en) 2001-02-23 2006-08-31 Merck & Co Inc N-substituted nonaryl-heterocyclic nmda/nr2b antagonists
KR20110010824A (en) 2003-01-14 2011-02-07 아레나 파마슈티칼스, 인크. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
PL378295A1 (en) * 2003-02-24 2006-03-20 Arena Pharmaceuticals, Inc. Substituted aryl and heteroaryl derivatives as modulators of glucose metabolism and the prophylaxis and treatment of disorders thereof
US7592360B2 (en) 2003-06-04 2009-09-22 Merck & Co., Inc. 3-fluoro-piperidines as NMDA/NR2B antagonists
AR045047A1 (en) 2003-07-11 2005-10-12 Arena Pharm Inc ARILO AND HETEROARILO DERIVATIVES TRISUSTITUIDOS AS MODULATORS OF METABOLISM AND PROFILAXIS AND TREATMENT OF DISORDERS RELATED TO THEMSELVES
CA2558585C (en) 2004-02-27 2010-10-12 Amgen Inc. Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
EP1726580A4 (en) * 2004-03-15 2008-02-13 Takeda Pharmaceutical Aminophenylpropanoic acid derivative
DOP2006000010A (en) 2005-01-10 2006-07-31 Arena Pharm Inc PROCEDURE TO PREPARE AROMATIC ETERES
MY148521A (en) 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
US7465804B2 (en) 2005-05-20 2008-12-16 Amgen Inc. Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
US7582803B2 (en) 2005-09-14 2009-09-01 Amgen Inc. Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders
WO2008030618A1 (en) 2006-09-07 2008-03-13 Amgen Inc. Benzo-fused compounds for use in treating metabolic disorders
EP2064193A1 (en) 2006-09-07 2009-06-03 Amgen, Inc Heterocyclic gpr40 modulators
US7572934B2 (en) 2007-04-16 2009-08-11 Amgen Inc. Substituted biphenyl GPR40 modulators
BRPI0818253A2 (en) 2007-10-10 2015-04-07 Amgen Inc Substituted biphenyl gpr40 modulators
JP2011515341A (en) 2008-03-06 2011-05-19 アムジエン・インコーポレーテツド Conformationally restricted carboxylic acid derivatives useful for the treatment of metabolic disorders
CA2739888C (en) 2008-10-15 2013-11-19 Amgen Inc. Spirocyclic gpr40 modulators
US10894787B2 (en) 2010-09-22 2021-01-19 Arena Pharmaceuticals, Inc. Modulators of the GPR119 receptor and the treatment of disorders related thereto
TW201329025A (en) 2011-11-01 2013-07-16 Astex Therapeutics Ltd Pharmaceutical compounds
MX2021011472A (en) 2015-01-06 2022-08-17 Arena Pharm Inc Methods of treating conditions related to the s1p1 receptor.
KR102603199B1 (en) 2015-06-22 2023-11-16 아레나 파마슈티칼스, 인크. (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta for use in S1P1 receptor-related disorders [B]Indole-3-yl)crystalline L-arginine salt of acetic acid (Compound 1)
WO2018151873A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4402975A (en) * 1980-07-21 1983-09-06 Teijin Limited Aminocarboxylic acids, amino alcohols, or the derivatives thereof, processes for production thereof, and pharmaceutical uses thereof
DE3718638A1 (en) * 1987-06-04 1988-12-22 Thomae Gmbh Dr K NEW PHENYLETHANOLAMINE, MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF
US5039805A (en) * 1988-12-08 1991-08-13 Hoffmann-La Roche Inc. Novel benzoic and phenylacetic acid derivatives
NZ239876A (en) * 1990-09-27 1993-12-23 Merck & Co Inc Glycyl-b-alanine derivatives and pharmaceutical compositions thereof.
DE4035961A1 (en) * 1990-11-02 1992-05-07 Thomae Gmbh Dr K CYCLIC IMINODERIVATES, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF
DE4102024A1 (en) * 1991-01-24 1992-07-30 Thomae Gmbh Dr K BIPHENYL DERIVATIVES, MEDICAMENTS CONTAINING THESE COMPOUNDS, AND METHOD FOR THE PRODUCTION THEREOF
DE4127404A1 (en) * 1991-08-19 1993-02-25 Thomae Gmbh Dr K CYCLIC IMINODERIVATES, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF
DE4213931A1 (en) * 1992-04-28 1993-11-04 Thomae Gmbh Dr K CYCLIC IMINODERIVATES, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF
DE4213919A1 (en) * 1992-04-28 1993-11-04 Thomae Gmbh Dr K CYCLIC IMINODERIVATES, METHOD FOR THE PRODUCTION THEREOF AND MEDICAMENTS CONTAINING SUCH COMPOUNDS

Also Published As

Publication number Publication date
PL301396A1 (en) 1994-07-25
MX9307781A (en) 1994-06-30
NO934501D0 (en) 1993-12-09
CZ270593A3 (en) 1994-11-16
CN1094035A (en) 1994-10-26
HU9303521D0 (en) 1994-04-28
FI935513A0 (en) 1993-12-09
NZ250391A (en) 1996-06-25
DE4241632A1 (en) 1994-06-16
IL107956A0 (en) 1994-04-12
AU5230693A (en) 1994-06-23
NO934501L (en) 1994-06-13
JPH06239817A (en) 1994-08-30
ZA939230B (en) 1995-06-09
KR940014330A (en) 1994-07-18
FI935513A (en) 1994-06-11
EP0604800A1 (en) 1994-07-06
CA2111035A1 (en) 1994-06-11

Similar Documents

Publication Publication Date Title
SK128193A3 (en) Carboxylic acids derivatives, medicaments containing these compounds and method of their production
US5994356A (en) Carboxylic acid derivatives, medicaments comprising these compounds, their use and processes for their production
SK107293A3 (en) Carboxylic acid derivatives, drugs containing these compounds and method of their production
EP0528369B1 (en) Cyclic imino derivatives, pharmaceutical compositions containing them and process for their preparation
US8193207B2 (en) Lactam compounds and methods of using the same
US5700801A (en) Piperazine derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them
EP2616447B1 (en) Pyrazine derivatives as enac blockers
US7951818B2 (en) Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases
US20070293529A1 (en) Tetrasubstituted ureas as modulators of 11-beta hydroxyl steroid dehydrogenase type 1
SK94393A3 (en) Cyclic derivatives of urea, process for their production and their pharmaceutical agents with the content of those
SK8394A3 (en) Fivemembers heterocyclecs method of their production and medicine containing these matters
US7399779B2 (en) 3,6-disubstituted azabicyclo [3.1.0] hexane derivatives useful as muscarinic receptor antagonists
DE19834751A1 (en) Disubstituted bicyclic heterocycles, their preparation and their use as medicines
CA2129374A1 (en) Carbonamides, pharmaceutical compositions containing these compounds and processes for their preparation
DE4304650A1 (en) Condensed 5-membered heterocycles, processes for their preparation and pharmaceutical compositions containing them
US5607944A (en) Bicyclic heterocyclic compounds, pharmaceutical preparations containing these compounds and processes for their preparations
US5489693A (en) Cyclic imino derivatives, pharmaceutical compositions containing these compounds and processes preparing them
DE4427838A1 (en) Condensed azepine derivatives, pharmaceutical compositions containing them and methods for their preparation
US5641772A (en) Condensed diazepinones, processes for preparing them and agents containing these compounds for treating diseases of the central nervous system and for promoting cerebral blood circulation
DE19754490A1 (en) By an aminocarbonyl substituted bicyclic, their preparation and their use as medicaments
AU703946B2 (en) Substituted phenylamidines, pharmaceutical compositions containing these compounds and processes for preparing them
EP0333026A1 (en) 3-(2,3,4,5,6-Pentafluorophenoxy)-8-azabicyclo[3.2.1]octanes, a process for their preparation and their use as medicaments
US5610155A (en) Condensed diazepinones, processes for preparing them and agents containing these compounds for treating diseases of the central nervous system and for promoting cerebral blood circulation
WO2001017990A1 (en) Heterocyclic derivatives as inhibitors of factor xa